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The treatment of late-iife 
A 
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anxiety disorders: 
general introduction 
u J^ JE 
This chapter is based on: 
- Hendriks, G.J., Keijsers, G.PJ. & Hoogduin, C.A.L. (1999). Cognitieve gedragstherapie 
bij ouderen met angststoornissen - casusbeschrijving [Cognitive behavioural therapy 
in late-life anxiety - case study). Tijdschrift voor Psychiatrie, 41, 677-681. 
- Hendriks, G.J. & Weijnen, I. van (2001). Angststoornissen [Anxiety disorders] In: 
T.J. Heeren, M.G Kat &r M.L. Stek (red.), Handboek Ouderenpsychiatrie (pp. 97-107). 
Maarssen: De Tijdstroom. 
- Hendriks, G.J., Allart-van Dam, E. & Balkom, A.J.L.M. van (2004). Waarom is kennis 
over therapieresistentie bij angststoornissen belangrijk? [Why is knowledge 
about treatment failure in anxiety disorders important?]. In: G.J. Hendriks & J.L. 
Klompenhouwer (red.). Angststoornissen: behandeling en therapieresistentie (pp. 1-23). 
Nijmegen: Cure & Care Publishers. 
- Hendriks, G.J., Rees, M.M. van, Keijsers G.P.J., Verbraak, M.J.P.M. & Hoogduin, 
C.A.L. (2008). Behandeling van ouderen met een obsessieve compulsieve stoornis 
[Treatment of obsessive-compulsive disorder in older patients - case studies]. 
Tijdschrift voor Psychiatrie, 50(9), 617-621. 
- Multidisciplinaire Richtlijn Angststoornissen Addendum Ouderen' [Guideline anxiety 
disorders - addendum elderly] (2008). Landelijke Stuurgroep Multidisciplinaire 
Richtlijnontwikkeling in de GGZ (auteurs: J. Schuurmans, M. Veerbeek & GJ. 
Hendriks). Utrecht: Trimbos-instituut. 
General introduction 
1.1 Introduction 
For young and middle-aged adults powerful, evidence-based and guideline-recommended 
treatments are available for panic disorder with (PDA) or without agoraphobia (PD), social 
phobia, obsessive-compulsive disorder, posttraumatic stress disorder, and generalized 
anxiety disorder (Abramowitz, 1997; Bakker, Van Balkom & Spinhoven, 2002; Bisson 
&r Andrew, 2007; Bradley, Green, Russ, Dutra & Westen, 2005; Fedoroff & Taylor, 
2001; Mitte, 2005a, Mitte, 2005b; Norton & Price, 2007; Seidler & Wagner, 2006; Stein, 
Seedat, Van der Linden &r Zungu-Dirwayi, 2000; Taylor, 1996; Van Balkom, Bakker, 
Spinhoven, Blaauw, Smeenk & Ruesink, 1997; Van der Linden, Stein & Van Balkom, 
2000). Cognitive-behavioural therapy (CBT) and pharmacotherapy with selective 
serotonin reuptake inhibitors (SSRIs) are the treatments of choice for these disorders. 
CBT and SSRIs are also assumed to be effective in older adults diagnosed with anxiety 
disorders (Pinquart & Duberstein, 2007). However, to date empirical evidence on the 
efficacy of these two treatments in adults aged 60-plus years is scarce since randomized 
controlled trials (RCTs) testing both CBT and SSRIs and direct comparisons of the two 
treatment arms in older and younger adults are lacking. Inspired by successful outcomes 
following CBT as well as SSRIs in case studies of 60-plus patients suffering from anxiety 
disorders (Hendriks, Keijsers & Hoogduin, 1999; Hendriks, Van Rees, Verbraak, Keijsers 
&r Hoogduin, 2008b), the main purpose of this thesis was to gather empirical evidence 
for the effectiveness of these two treatments in this specific population. 
In this chapter the available evidence on the prevalence, onset and course of late-
life anxiety disorders, the phenomenology and impact of anxiety in later life, and the 
effectiveness of CBT and antidepressants in the management of the various disorders 
is described. If available, for each of these aspects data on differences and similarities 
between older and younger adults diagnosed with the same anxiety disorder are also 
summarized. 
The following case history illustrates the effectiveness of CBT in an older adult who 
had been suffering from nervousness, panic attacks and avoidance behaviour for several 
decades. 
Mr. Ρ was 69 years old when he was referred to our outpatient anxiety clinic. For over 
40 jyears he had been suffering from stomach aches, tension headaches, palpitations, 
tremors, dizziness, nervousness, fear of fainting and heart disease, constant worries 
about his health and finances, and had avoided numerous circumstances and activities 
(e.g. crossing bridges, visiting crowded places, and iravelling long distances). On occasions 
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he used oxazepam PRN' to alleviate his fears and tension; when he had to visit friends 
or family living in another town, for example, he took oxazepam in advance to dampen 
the symptoms of anxiety and worrying during travelling. He had consulted his general 
practitioner (GP) almost monthly for years requesting a physical examination. Each visit 
his GP reassured him that he was healthy and that his complaints were attributable to 
nervousness and tension, for which he prescribed benzodiazepines. Eventually, Mr. Ρ was 
referred to our outpatient clinic on account of his chronic worries and nervousness. 
Using the Anxiety Disorders Interview Schedu!e-iV (Bouman, De Ruiter & Hoogduin, 
1997; DiNardo, Brown & Bariow, 1994) Mr. Ρ was found to meet all criteria for panic 
disorder with agoraphobia (PDA), for which he had never received treatment. He was 
subsequently referred to protocolized, PDA-specific CBT. After having concluded the 
14-week programme, oxazepam PRN was tapered off and then stopped consistent with 
the last exposure step. Following treatment Mr. Ρ was considerably better able to control 
his panic symptoms and his agoraphobic avoidance was reduced to almost zero. 
This case history of an older man with PDA illustrates the effectiveness of CBT in spite of 
the 40-year chronicity. However, in elderly people reporting anxiety-related complaints 
the symptoms may often not be recognized as serious and the possibility of a psychological 
disorder is hence most often overlooked, leaving many patients un(der)diagnosed and 
un(der)treated. The diagnostic focus often primarily concerns the patient's physical 
problems and the reassurance that no physical abnormalities have been found. Even if 
diagnosed adequately, the elderly patient is seldom offered a targeted and evidence-based 
treatment. Thus, rather than antidepressants and/or CBT, the treatments of choice for 
anxiety disorders, benzodiazepines are prescribed. 
In contrast to the abundance of empirical research on depression and dementia in the 
elderly and even though research into the treatment of late-life anxiety disorders has 
stepped up in recent years, it is still in its infancy and there still is a large gap to bridge 
(Flint, 2005a; Flint, 2007) Studies on age-related differences in anxiety phenomenology 
are limited and well-conducted RCTs in elderly patients are still scarce. In their 
multidisciplinary guidelines for the treatment of anxiety disorders, the National Institute 
for Mental Health (i.e. Trimbos-instituut) proposes in the appendix on the elderly 
(Addendum Ouderen', 2008)2 several possible reasons explaining this lack of research. 
First, depression and dementia are both considered 'pure' geriatric psychiatric disorders. 
1 PRN = pro re nata ('when it occurs' or 'if necessary') 
2 http//www ggzrichtlijnen.nl/ 
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The age at onset of both depression and dementia is usually considerably higher and may 
therefore be more easily recognized than late-life anxiety disorders. In contrast, anxiety 
disorders generally have an earlier onset and a more chronic and fluctuating course into 
late adulthood. Second, in later life comorbidity with depression may mask the existing 
anxiety symptoms, increasing the likelihood that the anxiety disorder goes unrecognized. 
Also by virtue of focusing on somatic symptoms, especially chronic conditions like 
pulmonary or cardiovascular diseases, clinicians may miss an underlying or comorbid 
anxiety disorder in elderly patients. In addition, 'ageism', which in this context refers 
to the misinterpretation of deviant behaviours as age-appropriate, may hinder the 
diagnosis and thus proper treatment of late-life anxiety disorders. Avoidance behaviour 
after a myocardial infarct is, for instance, often deemed understandable and an adequate, 
adaptive response. Finally, being retired and often receiving support in and around 
the home, elderly people may increasingly and successfully avoid anxiety-provoking 
situations, like travelling by car or visiting crowded shopping malls unattended, without 
raising suspicions of a more serious affliction. 
With the proportion of young and middle-aged adults with anxiety disorders receiving 
adequate treatment generally varying between 15 to 50% (Wang, Lane, Olfson, Pincus, 
Wells & Kessler, 2005b), undertreatment of this type of disorders can be said to be 
rather common. Belonging to an older age group, however, is an additional risk factor 
for not receiving adequate treatment (Wang, Berglund, Olfson, Pincus, Wells & Kessler, 
2005a). Thus, the scarcity of empirical research in this age group may partly also be 
attributable to the fact that we are dealing with a population that tends to go largely 
underdiagnosed and hence un(der)treated. Both from an economic and a mental health-
perspective the cost of this unmet need is substantial. Recent studies estimate that 'years 
lived with disability' would decrease with 49% and treatment costs with 40% if every 
person suffering from an anxiety disorder would be offered timely and optimal treatment 
(Andrews, Issakidis, Sanderson, Corry 6r Lapsley, 2004; Issakidis, Sanderson, Corry, 
Andrews & Lapsley, 2004). Although it is not realistic to expect every person suffering 
from an anxiety disorder to be offered such adequate treatment, these figures should 
make us think given that our life expectancy is increasing and thus also the number of 
and the time elderly patients are left untreated. The few figures and recommendations we 
do have all suggest that both at the diagnostic and the therapeutic level as well as from 
a scientific point of view our elderly citizens that suffer from anxiety symptoms merit 
more attention and care. 
One may believe that because older people that suffer from anxiety are generally 
underdiagnosed and hence not referred for targeted treatment, anxiety disorders 
are a minor health problem in later life. With the work presented in this thesis this 
13 
Chapter 1 
presumption is challenged and the need for more empirical research in this specific field 
substantiated. The following sections provide an overview of the empirical status of late-
life anxiety disorders and various prejudices are refuted. Several of the many questions 
that have so far remained unanswered are tackled in the eight studies that follow and that 
form the body of the present dissertation. These eight studies are introduced at the end 
of this chapter. Two investigated late-life anxiety disorders in general. Four studies were 
specifically aimed at establishing the efficacy and feasibility of guideline-recommended 
treatments for late-life panic disorder and two studies were aimed at differences in CBT 
efficacy and agoraphobic cognitions between older and younger patients. Therefore the 
empirical findings on the specific domain of late-life panic disorder are highlighted. 
1.2 Late-life anxiety disorders remain largely underdiagnosed 
and un (der)treated despite their high prevalence 
Recent epidemiological studies identified anxiety disorders as the most prevalent of all 
mental disorders in later life. Comprising more than 3,000 participants aged between 55 
and 85 years, the Longitudinal Aging Study Amsterdam (LASA; see http://www.lasa-vu. 
nl/ for more detailed information) found a six-month prevalence of approximately 10% 
for late-life anxiety disorders (Beekman, Bremmer, Deeg, Van Balkom, Smit, De Beurs 
et al., 1998; Van Zeist, De Beurs, Beekman, Deeg & Van Dyck, 2003). Additionally, the 
National Comorbidity Survey Replication (NCS-R), carried out in 9,000 adults (over 
18 years) in the United States, estimated the overall life-time prevalence of anxiety 
disorders in later life at more than 15% (Kessler, Berglund, Dernier, Jin, Merikangas & 
Walters, 2005a). Although data from the NCS-R conducted in the United States reported 
a declining life-time prevalence of anxiety disorders in adults aged over 60 years relative 
to the younger adults, in both age groups anxiety disorders were the most prevalent 
mental disorders. In contrast, underdiagnosing and undertreatment are reflected in the 
available epidemiological data The LASA data showed that a mere 2.6% of elderly patients 
reporting anxiety symptoms consulted a psychiatrist and only 3.8% were seen by health 
professionals at a mental health outpatient clinic. The use of antidepressants was also 
deplorably low (3 8%), while 25% were prescribed benzodiazepines (De Beurs, Beekman, 
van Balkom, Deeg, Van Dyck & Van Tilburg, 1999). Although six years later the use of 
benzodiazepines had increased to 43%, the other figures had only marginally changed. 
The prescription of antidepressants had doubled to 7% and referral to mental health 
facilities risen to 14% (Schuurmans, Comijs, Beekman, De Beurs, Deeg, Emmelkamp 
et al., 2005). Compared to depression, the referral rate to specialized mental health 
care for late-life anxiety disorders was three times lower, i.e. 55% versus 17% (Ettner & 
Hermann, 1997). 
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The NCS-R confirmed the increased overall risk of elderly people (aged over 60 years) 
going untreated for mental disorders relative to their younger counterparts: the odds 
ratios for receiving specialized mental health care were 2.4 to 4 8 larger in the younger 
adults (Wang et al., 2005b). 
1.3 Although partially overlapping, later-life anxiety disorders 
and depression need to be distinguished 
That in the elderly, although prevalent, anxiety disorders are generally un(der)treated 
may strengthen mental health professionals and researchers in their assumption that 
in later life depression is much more common than anxiety. This conclusion does not 
hold. However, LASA reported a one-month prevalence of 2% for major depression and 
a rate of 12.9% for minor depression (Beekman, Deeg, Van Tilburg, Smit, Hooijer & Van 
Tilburg, 1995). The NCS-R mentioned life-time prevalence rates of 10 6% and 1.3% for 
major depression and dysthymia, respectively (Kessler et al., 2005a). With a six-month 
prevalence of approximately 10% in LASA and a life-time prevalence of approximately 
15% in the NCS-R it is concluded that the two classes of disorders are equally prevalent 
in the elderly. 
In addition, the widespread assumption that anxiety accompanies depression at an 
older age and that for late-life anxiety a diagnosis of a mixed anxiety-depression syndrome 
is to be preferred to a diagnosis of distinct anxiety disorders (Flint, 1994, Flint, 2005a), 
may not be warranted. The LASA also revealed that with 1.8% the prevalence of a mixed 
anxiety-depression syndrome was lower than previously assumed (Schoevers, Beekman, 
Deeg, Geerlings, Jonker & Van Tilburg, 2000). Instead, and although there was clear 
evidence of a large overlap, the study uncovered more differences than similarities 
between late-life anxiety and depression (Beekman, De Beurs, Van Balkom, Deeg, Van 
Dyck & Van Tilburg, 2000). Whereas a quarter of the elderly participants diagnosed 
with an anxiety disorder also met the DSM-IV criteria for a comorbid major depression, 
approximately half of those diagnosed with major depression satisfied the criteria for 
a comorbid anxiety disorder. Although anxiety and depressive symptoms partially 
overlapped, they could also be distinguished from each other, while the risk factors 
for the two syndromes were also distinct. Whereas late-life depression was associated 
with an older age of onset and an external locus of control, the risk profile for late-life 
anxiety disorders was more complex and consisted of a combination of vulnerability 
factors, actual stress and social aspects. These differences in comorbidity patterns and 
risk factors suggest that also in later life anxiety and depression are distinguishable 
diagnostic entities meriting separate investigation. 
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1.4 Late-life anxiety disorders characteristically have an onset at 
a relatively young age and run a chronic course 
The NCS-R data showed that, when compared to mood disorders, anxiety disorders 
generally have the youngest age at onset (Kessler et al., 2005a). The median age of onset 
was 11 years, with 75% of all anxiety disorders starting before the age of 21 years and 
only 1% starting after the age of 65 years, whereas for mood disorders the median age at 
onset was 30 years with 75% starting before the age of 43 years. Although prospective 
post-treatment follow-up studies in adult populations (18 to 65 years) gauging the 
clinical course of anxiety disorders for more than ten years are scarce, evidence has been 
gathered revealing the chronicity of symptoms and relative high relapse risk for anxiety 
disorders in general and for panic disorder in particular (Andersch & Hetta, 2003; Bruce, 
Yonkers, Otto, Eisen, Weisberg, Pagano et al., 2005; O'Rourke, Fahy, Brophy, Prescott, 
1996; Rubio & Lopez-lbor, 2007; Rublo & Lopez-Ibor, Jr., 2007; Swoboda, Amering, 
Windhaber & Katschnig, 2003; Tyrer, Seivewright &r Johnson, 2004; Yonkers, Bruce, 
Dyck & Keller, 2003). The recovery rate for anxiety disorders following treatment varied 
from 40 to 60%, but with the same proportions the relapse rates during follow-up periods 
of several years remained high. More specifically, with 0.82 versus 0.48 the probability of 
recovery of PD was higher than that of agoraphobic PD, while the probabilities of relapse 
were similar (0.56 and 0.58, respectively; Bruce et al., 2005). 
Given that the greater majority of adults suffering from anxiety disorders do not 
receive adequate treatment (Wang et al., 2005b) and that for those that do the chance 
of relapse is still as high as 0.4 to 0.6, we can safely conclude that anxiety disorders 
tend to start at a young age and are highly likely to be chronic, running a fluctuating 
course into late adulthood, thus contributing to a relatively high prevalence in later life. 
Nevertheless, some critical remarks are warranted here. With regard to the clinical course 
of the disorders, empirical findings on recovery and relapse were, to date, naturalistic 
and observational, and not obtained using guideline-recommended treatments. More 
importantly, treatment was mainly limited to pharmacotherapeutic interventions 
with benzodiazepines, SSRIs or tricyclic antidepressants (TCAs), or combinations of 
these agents. In only one study (Tyrer et al., 2004) psychological and pharmacological 
treatments were delivered concurrently. Moreover, as most studies reported data on 
adherence to treatment, lack in adherence may also contribute to the chronic course of 
many anxiety disorders. 
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1.5 Late-life anxiety disorders should not be regarded as a minor 
health problem 
Clinicians and researchers are inclined to consider anxiety disorders in older adults 
a minor health problem that does not seriously impair their quality of life, but the 
reverse is true (Wetherell, Thorp, Patterson, Golshan, Jeste & Gatz, 2004a) Firstly, 
as mentioned earlier, empirical findings showed serious comorbidity late-life anxiety 
disorders are frequently associated with major depression and other anxiety disorders 
(Beekman et al, 2000, Van Balkom, Beekman, De Beurs, Deeg, Van Dyck & Van Tilburg, 
2000) Secondly, the quality of life is clearly affected in anxiety-ridden elderly people 
to a comparable level as observed in elderly adults suffering from major depression 
they experience significantly more decline in physical health, general well-being, and 
social and overall functioning compared to asymptomatic elderly (Wetherell et al, 
2004a) Thirdly, although hardly effective in reducing anxiety symptoms, the LASA 
data showed a frequent and increasing (from 25% to 43% in six years) prescription of 
benzodiazepines in older adults with serious anxiety complaints (Van Balkom et al , 
2000, De Beurs et al , 1999, Schuurmans et al , 2005) Finally, even though a multitude 
of confounding variables among which age, depression, somatic diseases, smoking and 
drinking, physical activity, and overweight were controlled for, a recent study showed 
that in men suffering from late-life anxiety disorders the risk of mortality had increased 
with 78% relative to asymptomatic controls (Van Hout, Beekman, De Beurs, Comijs, Van 
Marwijk, De Haan et al , 2004) 
In summary, anxiety disorders are highly prevalent in later life, are characterized by a 
chronic course, and are associated with substantial physical and mental comorbidity, a 
decline in (social) functioning and hence a substantially reduced quality of life 
1.6 The diagnosis of late-life anxiety disorders may be compli-
cated by age-related variables 
Given the high prevalence of late-life anxiety disorders it is remarkable as well as 
undesirable that so few sufferers are properly referred to and thus adequately treated by 
specialized mental health-care providers Apparently, primary care professionals have 
great difficulty recognizing the condition and are thus also unfamiliar with the available 
treatment options Several reasons underpin this assumption Most elderly people with 
anxiety problems tend to attribute their symptoms to physical causes (Gunan &r Miner, 
1991, Sheehan, Philpot & Banerjee, 2002) Moreover, the process of ageing is often 
associated with more physical illness and other (un)explained physical symptoms As 
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in the elderly symptoms of anxiety and depression often coincide with serious somatic 
conditions, especially cardiovascular involvement and chronic obstructive pulmonary 
diseases (COPD), separating anxiety disorders from 'normal' anxiety induced by 
medical problems and procedures may be difficult (Seung Kim, Braun & Kunik, 2002) 
As physicians will likely be targeting diagnostic procedures for the somatic symptoms, 
which may also cover specific physical anxiety symptomatology, the diagnosis of a 
comorbid anxiety disorder may easily be missed (Wetherell, Maser & Van Balkom, 
2005a) This is illustrated by earlier findings after having been referred to a hospital 
under suspicion of a coronary artery disease and following negative cardiovascular 
screening, 40 to 60% of the elderly patients were diagnosed with a panic disorder (Katon, 
Hall, Russo, Cormier, Holhfield, Vitaliano, 1988, Wulsin, Hillard, Geier, Hissa & Rouan, 
1988) If screened properly, an accompanying panic disorder may also often be diagnosed 
in COPD patients (Cassem, 1995, Karajgi, Rifkin, Doddi & Kolli, 1990) Additionally, 
the current generation of elderly may be less open in sharing psychological problems 
than the younger generations and may therefore have been struggling with anxiety 
symptoms for many years without ever receiving adequate treatment (Weijnen & De 
Beurs, 2001, Weijnen, Schuurman, Comijs, Emmelkamp, Van Dyck & Van Hout, 2006) 
A prospective cohort study showed that less than 5% of the elderly patients confronted 
with psychological problems consulted their GPs (Shah, McNiece & Majeed, 2001) 
The question whether they are reluctant in communicating their personal problems or 
whether they lack the necessary verbalizing skills to do so remains Also, the level of 
agreement between targeted screening for anxiety and depression in older patients and 
the diagnostic findings of GPs is low (Volkers, Nuyen, Verhaak & Schellevis, 2004, Watts, 
Bhutani, Stout, Ducker, Cleator, McGarry et al , 2002) Chronic somatic comorbidity and 
the absence of earlier mental problems also decreased the chance of a proper diagnosis 
(Nuyen, Volkers, Verhaak, Schellevis, Groenewegen & Van den Bos, 2005) Finally, it 
is plausible that ageing may lead to phenomenological differences with younger adults 
suffering from similar anxiety disorders and therefore possibly making an adequate 
diagnosis more difficult (Tnmbos-instituut, 2008) 
1.7 Phenomenological differences between older and younger 
adults suffering from anxiety 
Several authors have stressed the necessity of differentiating between anxiety disorders 
in young and middle-aged individuals and older adults The main arguments are the 
supposed differences in phenomenology and outcome between the two age bands 
(Fuentes & Cox, 2000, Jeste, Blazer & First, 2005, Stanley & Beck, 2000) It may also 
be important to differentiate between an early and a late onset of the complaints in older 
18 
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patients as age at onset may likewise have a differential impact on these parameters 
(Grant, Mancebo, Pinto, Williams, Eisen & Rasmussen, 2007; Sheikh, Swales, Carlson 
& Lindley, 2004a; Wetherell, Hopko, Diefenbach, Avenll, Beck, Craske et al , 2005b). 
However, the criteria for the differentiation of early and late-onset anxiety seem fairly 
arbitrary and the threshold age range in previous studies varied from 30 to 60 years, with 
several retrospective and explorative studies using a threshold age of 55 to 60 years (Depp, 
Woodruff-Borden, Meeks, Gretarsdottir & de Kryger, 2005; Lenze, Mulsant, Mohlman, 
Shear, Dew, Schulz et al., 2005a; Le Roux, Gatz & Wetherell, 2005; Segui, Salvador-
Carulla, Marquez, Garcia, Canet & Ortiz, 2000, Sheikh, King & Taylor, 1991). Other 
studies based their differentiation on epidemiological data (Katerndahl & Talamantes, 
2000; Sheikh et al., 2004a). Unfortunately, a proper and valid definition of early- and 
late-onset anxiety disorders is as yet not available 
Until now, differences in cognitive, emotional, and physical symptoms between 
younger and older adults with anxiety problems have mainly been studied in undiagnosed 
or outpatient populations with mixed symptoms. Taken together, the studies showed 
that in all three categories older adults reported less severe symptoms (Brenes, 2006; 
Crittendon & Hopko, 2006; Goldberg, Breckenridge & Sheikh, 2003; Hunt, Wisocki 
&r Yanko, 2003; Klapow, Kroenke, Horton, Schmidt, Spitzer & Williams, 2002; Lau, 
Edelstein & Larkin, 2001). Other findings indicated that, in general, the experience of 
negative feelings and the intensity of emotional responses appeared to decrease with 
progressing age. This may possibly be attributable to a natural, age-related decrease in 
emotional responsiveness, i.e. a dampening of affective reactivity. Additionally, elderly 
people tend to be more in control of their emotional life and better able to cope with 
stressful life-events (Gross, Carstensen, Pasuphati, Tsai, Skorpen ir Hsu, 1997; Jorm, 
2000). So far, however, these factors have never been systematically examined and 
mentioned assumptions are hence not based on consistent findings. Moreover, most 
studies in this area suffered from methcdological shortcomings (Jorm, 2000). Thus, 
fundamental research on these issues, also in relation to medical problems, psychiatric 
comorbidity (e.g. depression), and the nature of anxiety in elderly people, is still in its 
infancy (Bryant, Jackson oar Ames, 2008). 
Age-related differences in the phenomei'ology of late-life anxiety disorders have, so 
far, only been explicitly studied in patients diagnosed with PD(A). Furthermore, the 
phenomenology of panic attacks in younger and older adults have also been investigated 
in non-clinical populations and populations with mixed anxiety disorders. The following 
paragraph therefore focuses on these age-dependent phenomenological differences 
in confirmed PD(A) patients and individuals experiencing panic attacks that are not 
directly related to PD(A). 
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Empirical findings of age-related differences in cognitive, affective, behavioural, 
and physiological symptoms in panic disorder 
Several studies demonstrated that, relative to the values obtained in younger individuals, 
ageing and onset at an older age is associated with a decrease in both cognitive and 
affective anxiety, as well as in physiological arousal. It is suggested that normal age-
related psychophysiological changes and the later symptom onset are responsible for 
these differences, which would explain why PD(A) has been considered to be a less 
severe disorder later in life (Sheikh et al., 2004a). Next, the various findings are discussed 
in more detail. 
In non-clinical individuals in a first study, the severity scores for panic attacks and 
phobic avoidance of the older adults were lower than those of their younger peers. When 
the onset of their panic attacks had occurred at an older age, their symptoms were even 
more reduced compared to those reported by their age peers whose symptoms had started 
at a younger age (Sheikh et al., 1991). A second study in a non-clinical cohort revealed a 
43% decrease in the prevalence of panic attacks in the older adults compared to a 26% 
reduction in the younger participants. Additionally, after controlling for physical health, 
cognitive anxiety was found to be a stronger predictor of non-clinical panic attacks in the 
older adults than self-reported physiological symptoms, whereas in the younger adults 
the latter symptoms were more predictive. Cognitive anxiety was accordingly proposed 
as the more relevant phenomenon for the assessment of panic in elderly people (Depp et 
al., 2005). Using a carbon dioxide challenge in non-clinical subjects aged between 18 and 
62 years, a third study (Griez, Colasanti, Van Diest, Salamon & Schruers, 2007) showed 
an age-related decline in the emotional anxiety response. Although in older adults a 
decline in the physiological arousal of anxiety is also plausible, empirical studies in this 
particular age group are scarce and often hampered by methodological limitations (Lau et 
al., 2001). In this context, the study of Flint and colleagues (1998) warrants mentioning. 
They found the responsiveness of cholecystokinin-4 (CCK-4) to be challenged in both 
younger (20-35 years) and older non-clinical adults (65-plus years), but also observed 
a waning of panic symptoms and physiological arousal in the older participants. These 
non-clinical findings may support the widely held clinical view that anxiety and panic 
symptoms decline in later life. Age-related empirical findings in clinical populations with 
PD(A) are scarce. Katerndahl and Talamantes (2000) confirmed the notion that an onset 
of panic attacks in later life is associated with less symptomatology and less psychiatric 
morbidity. However, their findings were limited by their cross-sectional design and 
the mixed psychiatric morbidity of their study sample. Only two research reports are 
available that specifically evaluated age-related differences in PD(A) phenomenology. 
Segui and colleagues (2000) recorded less frequent and less severe panic symptoms and 
lower scores on both observer-rated and self-report scales for their older respondents 
who had a PDA onset after age 60 than they did for the respondents with an onset at a 
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younger age However, phobic avoidance, a core symptom of PDA, did not differ in the 
two age groups Sheikh and colleagues (2004) later partially confirmed these findings 
compared to the younger respondents, their 60-plus PD patients reported less severe 
physical, affective, and cognitive anxiety symptoms They further divided their over-
60s group into an early- and a late-onset subgroup, setting the age at onset of the latter 
subgroup at 35-plus years in accordance with the available epidemiological findings 
Although compared to the early-onset group the self-reported physical symptoms 
were lower in the late-onset patients, no such onset-related differences were found for 
subjective PD severity or the scores for affective and cognitive anxiety These findings 
seem to underpin a declining severity of symptoms in later life However, the report 
suffered from a major limitation, viz the absence of phobic avoidance scores, rendering 
the evidence somewhat inconclusive and not applicable to older adults suffering from 
PDA 
In sum, anxiety disorders remain among the most common psychiatric syndromes in 
older adults substantially reducing their quality of life However, most elderly patients 
suffering from serious anxiety remain undiagnosed and therefore untreated, which may 
partially account for the scarcity in empirical research into the management of late-life 
anxiety and panic disorder in particular 
Next, barriers in the research into the treatment of late-life anxiety disorders are 
summarized, followed by an overview of the available empirical findings 
1.8 Older age does not hinder adequate management of anxiety 
disorders 
Until now, the recruitment and inclusion of a sufficient number of eligible patients 
proved a major obstacle to clinical trials evaluating the treatment of late-life anxiety 
disorders (see e g Cassidy, Baird & Sheikh, 2001 and Wetherell & Gatz, 2001) This lack 
of participants first and perhaps foremost arises from the problem of underdiagnosing 
and undertreatment, as well as an inability or reluctance in elderly patients to seek help 
for their anxiety complaints Also problems with transportation (in terms of options, 
time and costs) to and from outpatient clinics and research facilities, comorbid somatic 
diseases, as well as polypharmacy in the elderly (of prescribed and over-the-counter 
medication) contribute to the scarcity of RCTs in this field (Cassidy et al , 2001) As 
decreasing the age for inclusion is a viable strategy to recruit more participants (Macias, 
Ramsey & Rowan, 2007), many RCTs into late-life anxiety disorders included patients 
as 'young' as 55 or 60 years Although thus preventing problems in recruitment, most 
studies did not adequately differentiate between age bands, say respondents of 55-75 
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years and those over 75 years, despite the substantial variability in physical and mental 
health status and scale of societal activities. Accordingly, differences in recruitment 
strategies and the variability in ageing effects have limited the generalizability of the 
findings from the RCTs conducted so far (Izal, Nuevo, Montorio & Perez-Rojo, 2007). 
However, there has been extensive research into the management of anxiety disorders 
in populations aged between 18 and 65 years, as is reflected in several systematic and 
meta-analytic reviews, which has led to international and national guidelines stipulating 
CBT and antidepressants as the two treatments of choice'. In addition, the few findings 
from RCTs focusing exclusively on elderly patients (60-plus and 65-plus) also tentatively 
indicated that both regimens may also be the optimal treatments for the management 
of late-life anxiety disorders (Hendriks, Oude Voshaar, Keijsers, Hoogduin & Van 
Balkom, 2008a; Pinquart & Duberstein, 2007). These early findings thus support 
the multidisciplinary guidelines the National Institute for Mental Health (Trimbos-
instituut) had also adopted for the treatment of anxiety disorders in the elderly (http:// 
www.ggzrichtlijnen.nl/ 'Addendum ouderen')· In the next two sections the empirical 
findings for the psychological and the pharmacological treatment of anxiety disorders 
are described separately. 
Psychological treatment 
Although anxiety disorders are highly prevalent in later life causing a serious decline in 
quality of life, many health professionals and researchers seem to entertain a persistent 
but unexpressed idea that targeted psychological treatment is unsuited in the elderly. 
Prompted by this therapeutic nihilism studies into the psychological treatment of late-
life anxiety disorders were initiated during the 1990s. The main objective was to prove 
that well-established manualized CBT for the treatment of anxiety disorders was also 
effective in older populations, i.e. in patients over the age of 60 years. Although it was 
believed that the CBT programme should be adapted to the specific needs of the elderly 
and should be offered in a group format (Stanley & Averill, 1999; Stanley & Beck, 2000), 
there is no or very little actual evidence for these assumptions. Two trials did study age-
specific adaptations in manualized CBT for generalized anxiety disorder (GAD) in older 
adults (Mohlman, Gorenstein, Kleber, de Jesus, Gorman & Papp, 2003; Stanley, Beck, 
Novy, Averill, Swann, Diefenbach et al., 2003a). The adaptations in essence referred to a 
distinct focus on education, a frequent use of reminders and repetition of the treatment 
rationale, offering frequent help with the homework assignments, and the exploitation 
of adherence enhancement strategies. In the Mohlman study the adapted CBT showed on 
more outcome measures improvement compared to the standard CBT and in the Stanley 
3 hup //www nice org uk/guidance/index jsp 
http //www psych org/MainMenu/PsychiamcPractice/PracticeGuidelines_l aspx 
http //wwwggzrichllijnen nl/ 
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study participants in the adapted CBT responded more compared to a minimal contact 
control condition However, as both trials were small and the adapted protocohzed CBT 
was not directly compared to standard CBT, it is premature to conclude that age-specific 
adaptations indeed enhance the efficacy of CBT To date, there is no systematic research 
that has investigated which adaptations are needed to improve the effects of CBT for 
late-life anxiety disorders nor studies that determined the extent to which modifications 
improve efficacy 
The results of RCTs into the effectiveness of protocohzed CBTs for late-life anxiety 
disorders reported so far are promising However, evidence is predominantly limned 
to GAD or mixed anxiety disorders Until now, six RCTs showed evidence of CBT 
effectiveness in older adults suffering from GAD (Mohlman et al , 2003, Stanley et al , 
2003a, Stanley, Hopko, Diefenbach, Bourland, Rodriguez 61 Wagener, 2003b, Stanley, 
Beck & De Witt Glasco, 1996, Wetherell, Gatz & Craske, 2003) In the studies CBT 
consisted of progressive muscle relaxation training, cognitive restructuring, worry 
exposure, and worry behaviour prevention according to manuals specifically developed 
for the management of GAD (Borkovec & Costello, 1993, Craske, Barlow & O'Leary, 
1992) Outcome measures showed large effect sizes for worry, anxiety, and depression, 
both at post-treatment and at follow-up, and CBT showed unequivocal effects relative 
to waiting-list control conditions Four trials compared CBT with an active control 
condition consisting of other psychological treatments such as supportive counselling 
or a discussion group (Stanley et al, 1996, Stanley et al , 2003a, Stanley et al , 2003b, 
Wetherell et al , 2003), but here superiority of CBT was not unambiguous (Stanley et al , 
1996, Wetherell et al, 2003) 
In two other RCTs the effectiveness of CBT was confirmed in elderly populations 
with mixed anxiety disorders (Barrowclough, King, Colville, Russell, Burns 61 Tamer, 
2001, Schuurmans, Comijs, Emmelkamp, Gundy, Weijnen, Van den Hout et al, 2006) 
In both studies PD and GAD were the two most frequent disorders (70% or more) and 
CBT was conducted in accordance with evidence-based manuals (Borkovec & Costello, 
1993, Clarke et al, 1993, Wells, 1997) With large post-treatment and follow-up effect 
sizes (up to 12-months) for anxiety and depression, Barrowclough and colleagues 
(2001) demonstrated the superiority of CBT in comparison to supportive counselling 
Schuurmans and colleagues (2006) compared CBT to sertraline and found both post-
treatment and follow-up (3-month and 1-year) effects to show sertraline superior to CBT, 
with large effect sizes for anxiety and depression 
Although promising, some critical remarks have to be made in connection with the 
reported results Most of the mentioned CBT studies of elderly patients (Barrowclough 
et al , 2001, Schuurmans et al, 2006, Stanley et al , 2003, Wetherell et al, 2003) were 
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hampered by recruitment difficulties and high attrition rates (in excess of 25%) and 
concerned community-dwelling, relatively younger and relatively healthy participants. 
And, as mentioned above, the greater majority of the published RCTs into the psychological 
treatment of late-life anxiety disorders focused on populations diagnosed with GAD or 
mixed anxiety disorders, leaving most other anxiety syndromes undennvestigated and 
thus preventing generalization of the results to 'older' (e.g. 75-plus) elderly patients and 
populations suffering from specific anxiety disorders. 
Pharmacological treatment 
In stark contrast to the volume of RCTs testing pharmacological agents for major 
depression in later life, psychopharmacological interventions for late-life anxiety 
disorders have hardly been systematically studied (Mottram, Wilson & Strobl, 2006; 
Pinquart, Duberstein & Lyness, 2006). The data on late-life depression showed SSRls and 
TCAs to be comparably effective. Although the tolerability of both groups of agents was 
satisfactory, the classical TCAs (e.g. amitriptylme and clomipramine) were associated 
with significantly more side effects and dropout than the SSRIs (24% vs. 18%; Mottram 
et al., 2006; Wilson & Mottram, 2004). As to the pharmacological treatment of late-life 
anxiety disorders, Pinquart and Duberstein (2007) conducted a meta-analytic review 
of all available naturalistic studies and RCTs. With 0.81 and 1.76, respectively, the pre-
post effect sizes for CBT and pharmacological treatment were large. The effect sizes for 
benzodiazepines (1.76) and SSRIs (1.68) were comparable, while they were 1.14 for TCAs. 
Based on these data, pharmacological treatment was recommended as the treatment of 
choice for late-life anxiety. The findings warrant a more balanced interpretation, however. 
Although all 23 reviewed studies tested pharmacological treatments, only four were 
RCTs evaluating specific late-life anxiety disorders. One of these showed venlafaxine to 
be superior to placebo in the treatment of late-life GAD (Katz, Reynolds III, Alexopoulos 
& Hackett, 2002), while two reported large effect sizes for SSRIs in the management 
of mixed anxiety disorders (Lenze, Mulsant, Shear, Dew, Miller, Pollock et al., 2005b; 
Schuurmans et al., 2006) with the distinction that in these latter two trials over 70% of 
the patients were diagnosed with GAD. And lastly, in the fourth study both alprazolam 
and Imipramine showed large effect sizes compared to placebo in the treatment of late-
life PD. This was however a small-scale pilot study (Sheikh &r Swales, 1999). With a total 
number of 324 participants and cohorts ranging from 25 to 184 patients, the majority of 
these four RCTs were too small-scale to found the recommendations on. 
In contrast to guidelines 25% of all elderly patients are prescribed benzodiazepines, 
i.e. six times more often than antidepressants, as first-line agents in the management of 
late-life anxiety disorders (De Beurs et al., 1999). Six years later in the same population, 
this percentage was increased to 43%, which was still three times more often than 
antidepressants (Schuurmans et al., 2005). Frequent use of prescription benzodiazepines 
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is, however, associated with serious drug-related hazards such as an increased risk of 
falls and fractures and possible aggravation of cognitive difficulties (Paterniti, Dufouil 
& Alperovitch, 2002; Wang, Bohn, Glynn, Mogun & Avorn, 2001a; Wang, Bohn, 
Glynn, Mogun & Avorn, 2001b). But what are the underlying reasons for prescribing 
benzodiazepines, then? First of all, the agents are highly effective in the management of 
late-life anxiety (Pinquart & Duberstein, 2007). Furthermore, many older adults resist 
the use of antidepressants based on a fear of dependence, prior negative experiences, a 
resistance to viewing their symptoms as a medical illness, and concern that antidepressants 
will prevent natural feelings (Givens, Datto, Ruckdeschel, Knott, Zubntsky, Oslin et al., 
2006). Moreover, especially in older adults the use of both SSRIs and TCAs is not without 
risk. The high prevalence of somatic syndromes such as cardiovascular diseases and 
arthrosis, and the subsequent use of medications in this population increase the risk of 
interaction with SSRIs. The concurrent use of SSRIs and aspirin or NSAlDs, for example, 
raises the risk of gastrointestinal bleeding (Weinneb, Auraicombe, Lynch &: Lewis, 
2005, Yuan, Tsoi & Hunt, 2006). Furthermore, previous findings showed that in elderly 
patients using either benzodiazepines or antidepressants the risk of falls and fractures 
was comparable, even for the preferred SSRIs (Ensrud, Blackwell, Mangione, Bowman, 
Whooley, Bauer et al., 2002; Ensrud, Blackwell, Mangione, Bowman, Bauer, Schwartz 
et al., 2003; Hartikainen, Lonnroos & Louhivuori, 2007; Liu, Anderson, Mittmann, To, 
Axcell 61 Shear, 1998). 
In conclusion, research into the available psychopharmacological approaches to 
anxiety disorders to date indicates that the tolerability and effectiveness of antidepressants 
is comparable in younger and elderly adults. However, the benefits should be weighed 
carefully against the preferences of the elderly patients themselves, the relative risks of 
antidepressants, the severity of the anxiety symptoms as well as the available alternative, 
behavioural approaches like CBT. 
1.9 Aims and outline of this thesis 
Prompted by all the conflicting evidence and the considerable gaps in our knowledge, 
the work presented in this thesis was aimed at expanding the empirical data concerning 
the efficacy of antidepressants and CBT in older adults, that is, patients over 60 years 
of age that have been diagnosed with anxiety disorders in general, and finding the first 
empirical evidence for elderly patients with confirmed PD(A). Although RCTs and meta-
analyses have amply confirmed the effectiveness of both treatments in younger adults, 
RCTs directly comparing the two approaches in elderly patients suffering from anxiety in 
general are scarce, and, trials evaluating late-life PD(A) are absent, leaving the question 
whether CBT is to be preferred over specific pharmacological or other psychological 
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treatments unanswered. In the case of PD(A), it has never been tested whether the 
guideline-recommended treatments with antidepressants or CBT are effective or even 
feasible in elderly populations. Accordingly, the main research questions posed were: 
1. Are both CBT and antidepressants efficacious in the treatment of late-life anxiety 
disorders? 
2. Is CBT more effective than an active control comparison in the treatment of late-life 
anxiety disorders? 
3. Are both paroxetine and CBT effective and well-tolerated treatments for PD(A) in 
older adults? 
4. Does the content of agoraphobic cognitions differ between younger and older adults 
suffering from PDA? 
5. Is CBT as effective and as well-tolerated in older adults diagnosed with PDA as it 
has been found to be in younger adults? 
6. Are age, age at onset and duration of illness related to outcome in CBT for PDA? 
7. Are age and duration of illness related to paroxetine and CBT outcome in late-life 
PDA? 
First, in Chapter 2 the available RCTs of treatment approaches for late-life anxiety 
disorders are systematically reviewed, after which in Chapter 3 a meta-analysis is made 
of the efficacy of CBT in particular. 
Chapter 4 subsequently describes an RCT comparing the effects of paroxetine and 
CBT to a waiting-list control in the treatment of late-life PD(A) and in Chapter 5 the 
content of agoraphobic cognitions is compared between younger and older adults with 
PDA. Chapter 6 comprises a direct comparison of the effects and tolerability of CBT in a 
cohort of older and a cohort of younger adults diagnosed with PDA. 
In Chapter 7 is investigated whether and to what extent age, age of onset, and 
duration of illness predict the outcome of CBT for PDA in both younger and older adults, 
while Chapter 8 explores possible differential effects of age and duration of illness on 
predicting outcome following treatment with paroxetine or CBT in elderly patients with 
PD(A). 
Finally, in Chapter 9 the overall results of the studies reported are summarized and 
put into context. 
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Efficacy of psychological and 
pharmacological treatment 
approaches of late-life 
anxiety disorders: 
A systematic review 
* * * 
This chapter has been submitted for publication: 
Hendriks, G.J, Keijsers, G.PJ, Verbraak, MJPM & Hoogduin, C.A.L. Efficacy of 
psychological and pharmacological treatment approaches of late-life anxiety disorders 
A systematic review 
A systemalic review 
2.1 Introduction 
With prevalence rates up to 10 to 15% (Beekman et al., 1998; Flint, 1994) anxiety disorders 
can be said to be widespread in later life. The Longitudinal Aging Study Amsterdam 
(LASA) reported generalized anxiety disorders (GAD) and phobias as the most common, 
with a 6-month prevalence of 7.3% and 3.1%, respectively, and considerably lower rates 
for panic and obsessive-compulsive disorders (1.0% and 0.6%, respectively; Beekman 
et al., 1998). And yet, although the number of reports on late-life anxiety disorders has 
risen since the end of the previous millennium, research on this topic is still scarce 
when compared to the volume of studies on other common mental disorders manifesting 
themselves at older age. Several biases he at the root of this lack in scientific attention. 
Late-life anxiety is generally viewed as a minor health problem not warranting specific 
treatment. Recent findings, however, show that, if left untreated, late-life anxiety has a 
tendency to become chronic and is associated with a substantial risk of major depression, 
increases in health-care consumption, reduced quality of life, more disability, and 
increased relative mortality risk (Beekman et al., 2000; Brenes, Kritchevesky, Mehta, 
Yaffe, Simonsick, Ayonayon et al., 2007; De Beurs et al., 1999; Schuurmans et al., 2005, 
Van Hout et al., 2004; Wetherell et al., 2004a; Wetherell et al., 2005a). Nevertheless, 
despite the high prevalence of anxiety disorders and the substantial health loss, the 
majority of elderly people suffering from the symptoms does not receive appropriate 
treatment: only 5.1% is offered psychological treatment and 3.8% is prescribed an 
antidepressant. In contrast, benzodiazepine consumption is as high as 25-43% (De Beurs 
et al, 1999; Schuurmans et al., 2005). The undertreatment of late-life anxiety disorders 
is, among other causes, explained by the fact that few older adults are being referred 
for targeted treatment: the referral rate from primary care to a mental-health specialist 
(17%) is three times lower than it is for late-life depression (55%, Ettner & Hermann, 
1997). This would also explain the low number of randomized controlled clinical trials 
(RCTs) for late-life anxiety. 
In the guidelines (e.g. ΑΡΑ, 2002) cognitive-behavioural therapy (CBT) and anti­
depressants are recommended as evidence-based treatments for anxiety disorders 
in the general, middle-aged population. Recent meta-analyses of psychological and 
pharmacological treatments of anxiety in older adults, however, included both studies 
on anxiety symptoms and anxiety disorders and in their analyses the authors did 
not differentiate between type of psychological intervention (Nordhus & Pallesen, 
2003, Pinquart & Duberstein, 2007). The positive results of CBT and antidepressants 
for anxiety disorders in the general population prompted the present overview of all 
controlled clinical trials of psychological treatments and antidepressants that have been 
conducted thus far in elderly patients suffering from anxiety disorders. 
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2.2 Method 
We based our review on a literature search of the databases of PubMed and PsyclNFO, and 
the Cochrane Central Register of Controlled Trials for the period 1977 through July 2007 
using the keywords late-life, elderly, aged or old age combined with the keywords anxiety, 
anxiety disorder, panic disorder, obsessiveC-jcompulsive disorder, generaliz(s)ed anxiety 
disorder, social anxiety disorder, social phobia, post(-)traumatic stress disorder, spécifie 
phobia and the keywords therapy, psychotherapy, treatment, psychological treatment, 
cognitive treatment, behavio(u)r(a!) treatment, pharmacotherapy and medical treatment. We 
subsequently manually inspected the reference lists for any additional RCTs evaluating 
pharmacotherapeutic and psychological treatments for late-life anxiety disorders. 
Inclusion criteria 
The first and third author (GJ.H. and MJ.P.M.V.) independently checked all inclusion 
and exclusion criteria for all identified studies. To be included in the review studies 
needed to meet the following criteria: 
a A diagnosis of anxiety disorder according to ICD-10, DSM-III, DSM-I1I-R, or 
DSM-1V as verified by a (semi-)structured clinical interview; 
b The use of valid outcome measures (self-report questionnaires or clinical inter-
views); 
c Pre- and post-treatment results presented for each treatment condition; 
d A mean or median age of 60 years and older; and 
e A randomized controlled research design. 
Selection procedure, data extraction and quality assessment 
The coding form listed the following items: year of publication, diagnosis, diagnostic 
criteria, duration of the disorder, age and sex of the patients, type and duration of the 
treatment, presence and duration of the follow-up assessment(s), outcome measures and 
the results on the post-treatment outcome measures and finally type of control condition. 
Type of control condition was classified as either a waiting-list (WL) or an active control 
condition. The active control condition was defined as either treatment as usual (TAU) or 
any other treatment strategies that provided a contact frequency comparable to the ones 
in the CBT, the pharmacotherapy or placebo condition. 
To obtain a single, jointly approved coding per article, between-rater differences in 
the separate coding forms were discussed and resolved by consensus or by referring to 
the data in the original article. 
Both authors also independently assessed the methodological quality of the included 
studies using the Amsterdam-Maastricht consensus list, ranging from 0 [poor quality] 
to 19 [excellent quality] (Van Tulder, Assendelft, Koes & Bouter, 1997). The Amsterdam-
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Maastricht consensus list has previously been used in meta-analytic reviews of RCTs of 
psychiatric disorders (Van Boeijen, Van Balkom, Van Oppen, Blankenstein, Cherpanath 
& Van Dyck, 2005; Oude Voshaar, Couvee, Van Balkom, Mulder 61 Zitman, 2006) and 
covers the Chalmers criteria usually applied in the assessment of study quality (Chalmers, 
Smith, Blackburn, Silverman, Schroeder, Reitman et al., 1981). 
Outcome analysis 
In our evaluation severity of anxiety represented the primary outcome measure and 
depressive symptoms a secondary outcome measure. The most frequently used outcome 
assessment methods in the effect studies of psychological interventions were the 
Beck Anxiety Inventory (Beck, Epstein, Brown & Steer, 1988), the Penn State Worry 
Questionnaire (Meyer, Miller, Metzger & Borkovec, 1990), the State-Trait Anxiety 
Inventory (Spielberger, 1983), the Hamilton Anxiety Rating Scale (Hamilton, 1959) and 
the Beck Depression Inventory (Beck, 1988). In the pharmacological studies the outcome 
assessments comprised the Hamilton Anxiety Rating Scale (Hamilton, 1959) and the 
Hamilton Depression Rating Scale (Hamilton, 1960). We computed treatment effect 
sizes (ES) within and between groups using Cohen's d (Cohen, 1988) of all primary and 
secondary outcome measures for all reported post-treatment and, if available, follow-up 
measures separately. Effect sizes were calculated as the difference between means 
divided by the pooled standard deviations of the means (Cohen, 1988). A composite ES 
for anxiety was computed by calculating the mean effect size for the outcome measures 
on severity of anxiety. The same procedure was used for computing a composite ES for 
depression. 
2.3 Results 
Search strategy 
We identified 56 titles as potentially relevant to the treatment of late-life anxiety 
disorders. Based on systematic screening we excluded 46 papers because they did not 
use a randomized controlled design or did not meet the diagnostic criteria of a specific 
anxiety disorder. Ultimately, the following 10 papers describing 12 studies met the full 
inclusion criteria of the current study: Barrowclough et al., 2001; Gorenstein, Kleber, 
Mohlman, De Jesus, Gorman & Papp, 2005; Lenze et al., 2005b; Mohlman et al., 2003; 
Schuurmans et al., 2006; Sheikh & Swales, 1999; Stanley et al., 1996; Stanley et al., 
2003a; Stanley et al., 2003b; and Wetherell et al., 2003. Although our search was directed 
at all ICD- and DSM-specified anxiety disorders, our selection procedure only yielded 
references for RCTs on GAD, panic disorder, or mixed populations with predominantly 
GAD and panic disorder. 
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Study quality 
Table 2-1 lists the sum scores of the Amsterdam-Maastricht consensus list (range 0-19) 
for all 10 studies indicating their study quality. Since in psychotherapy studies blinding 
to the treatment condition for patients as well as for therapists is difficult and is rarely 
realized, the expected maximum score is 17. Scores ranged from 12 to 17 (M = 14.0; SD 
= 1.6), reflecting a moderate to good study quality with few between-study differences 
(Van Tulder et al., 1997). 
Study characteristics and effect sizes 
In Table 2-2 the study characteristics are summarized per study retrieved. The selected 
studies included a total of 470 patients with a range of 12 to 84 patients per study. Mean 
ages varied from 61.3 to 72.0 years and 72.7% were women Five studies (Mohlman et 
al., 2003; Stanley et al., 1996; Stanley et al., 2003a; Stanley et al., 2003b; Wetherell et 
al., 2003) exclusively included patients with a primary diagnosis of GAD. Four studies 
(Barrowclough et al., 2001; Gorenstein et al., 2005; Lenze et al., 2005; Schuurmans et al., 
2006) examined a mixed population or various anxiety disorders with panic disorder, 
with GAD being the most frequent (> 70%). Comorbidity with depression (major 
depression or dysthymia) or another anxiety disorder was common and varied per 
study from 9.5% to 68% (mean: 46%). The mean dropout percentage was 26.4% (range: 
0%-41.2%; see Table 2-2). The active treatment phases ranged from 8 to 15 weeks. In 
the pharmacotherapy conditions medication was not tapered off. Eight studies reported 
follow-up data with follow-up intervals varying from 3 to 12 months. CBT was compared 
with medical treatment and WL (Schuurmans et al., 2006), with TAU (Stanley et al., 
2003a; Stanley et al., 2003b), with a WL condition (Mohlman et al., 2003; Schuurmans 
et al. 2006; Wetherell et al., 2003), with supportive psychotherapy (SUP; Barrowclough 
et al., 2001; Stanley et al., 1996) or with a discussion group (DG; Wetherell et al., 2003). 
The pharmacological treatments (Lenze et al., 2005b; Schuurmans et al., 2006, Sheikh & 
Swales, 1999) were compared with a WL condition and CBT (Schuurmans et al., 2006) 
or placebo (Lenze et al., 2005b; Sheikh & Swales, 1999). 
For anxiety the post-treatment CBT ES ranged from 0.4 to 2.0 and at follow-up from 
0.4 to 1.8. Pharmacotherapy was also effective with post-treatment ES ranging from 0.8 
to 1.5, with the one study that also presented follow-up data reporting an effect size of 
1.1 after 12 months (Schuurmans et al., 2006). Three CBT studies (Stanley et al., 1996; 
Barrowclough et al., 2001; Wetherell et al., 2003) included SUP or DG as the active control 
treatment and the post-treatment ES on anxiety for the two conditions ranged from 0.5 to 
0.9 and at follow-up from 0.5 to 1.0. With a range of -0.3 to 0.4 the ES for the WL control 
condition and TAU were small or even negative. For depression the post-treatment and 
follow-up ES for CBT and pharmacotherapy were equally large (Table 2-2). 
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Table 2-1. Validity scores for all included studies as based on the Amsterdam-Maastricht consensus list 
Study Stanley 
et al. 
(1996) 
Barrow-
dough et al. 
(2001) 
Mohlman 
étal . 
(2003) 
Stanley 
étal. 
(2003a) 
Stanley 
et al. 
(2003b) 
Wetherell 
et al. 
(2003) 
Gorenstein Schuurmans 
et al. et al. 
(2005) (2006) 
Sheikh fit 
Swales 
(1999) 
Lenze 
étal . 
(2005b) 
Validity criteria 
Adequate randomization procedure 
Concealed random allocation of 
treatments 
Baseline similarity tested 
Control for co-interventions in design 
Check for adherence to interventions 
Valid outcome measures 
Relevant outcome measures 
Outcome assessor blinded 
Therapist blinded 
Patient blinded 
Withdrawals and dropouts (proportion; 
inequality between groups; reasons for 
withdrawal/dropout reported) 
Identical timing of outcome assessment 
for all intervention groups 
Intent-to-treat analyses 
Descriptive criteria 
Specification of eligibility criteria 
Description of interventions 
Follow-up 
Adverse event 
Statistical criteria 
Sample size: to be presented at 
randomization and outcome 
Presentations of point estimates and 
distribution measures 
+ 
+ 
+ 
+ 
+ 
+ 
0 
0 
+ 
+ 
+ 
-
+ 
+ 
-
-
-
+ 
+ 
+ 
+ 
+ 
+ 
+ 
0 
0 
+ 
-t-
+ 
+ 
+ 
+ 
+ 
0 
0 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
0 
0 
+ 
+ 
+ 
-
+ 
+ 
0 
0 
+ 
Total score (range 0-19) 12 14 14 12 15 15 15 14 12 17 ζ 
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Table 2-2. Overview of all randomized controlled trials on late-life anxiety disorders (Cohen's d for pre-post 
Age (SD) Anxiety disorder Co- Comparison Treatment 
morbidity 
Stanley et al. 46 
(1996) 
Barrowclough 46 
et al. (2001) 
Mohlman et 42 
al (2003) 
Stanley et al. 12 
(2O03b) 
Stanley et al 80 
(2003a) 
Wetherell et 75 
al. (2003) 
Corenstem et 42 
al. (2005) 
Schuurmans 84 
et al. (2006) 
Sheikh & 25 
Swales (1999) 
Lenze et al. 34 
(2005b) 
68.3 (6.6) CAD 48% 
72 (6.2) Panic disorder with/without 23% 
agoraphobia, social phobia, 
CAD, anxiety disorder n.o.s. 
67 1 (5.3) GAD 58% 
65.7(4.7) 
68.5(11.4) 
66.9 (9.8) 
70.6 (5.6) GAD 
80 (5.0) GAD 
67.1 (8.2) CAD 
48% 
65% 
52% 
67.8(7.1) GAD, panic disorder with/ 9.5% 
without agoraphobia, anxiety 
68.7(6.6) disorder n.o.s. 
70.7 (6.6) GAD, panic disorder with/ 
69.8 (5.5) without agoraphobia, social 
66.9 (6.0) phobia 
61.3 (5.4) Panic disorder with/without 
62.8 (5.6) agoraphobia 
59.3(5.1) 
70.7 (6.8) GAD, panic disorder wi th/ 
68.1 (3.9) without agoraphobia, PTSD 
CBT 
SUP 
CBT 
SUP 
CBT 
WL 
CBT+ 
WL 
CBT + 
TAU 
CBT 
MCC 
CBT 
DG 
WL 
CBT+MM 
MM 
20% 
depression; 
43% 
anxiety 
disorder 
68% 
62% 
CBT 
SER 
WL 
IMI 
ALP 
PLAC 
CIT 
PLAC 
14 weekly group sessions 
8-12 weekly individual 
1 3 weekly individual 
sessions and 6 monthly 
FU-sessions 
Idem, but modified 
8 weekly individual 
sessions 
15 group sessions 
12 group sessions 
12 group sessions 
1 3 weekly individual 
sessions and medical 
consultation 
Medical consultation 
15 weekly individual 
sessions 
8 medical consultations 
(15 weeks) 
8 weeks 
8 weeks 
8 weeks 
8 weeks 
ALP = alprazolam, CIT = Citalopram, DG = discussion group; FU = follow-up, GAD = generalized 
anxiety disorder, IMI = Imipramine, MCC = mimmal contact control; MM = medical management, 
n.o.s = not otherwise specified, PLAC = placebo, PT = post-treatment; PTSD = posttraumatic stress 
disorder; SER = sertraline, SUP = supportive psychotherapy, TAU = treatment as usual; WL = waiting 
list. 
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Cohen's d for anxiety Cohen's d for depression 
PT FU3/6 FU 12 PT FU 3/6 FU 12 
Drop-out Antidepressants/ 
benzodiazepines 
0.9 
0.9 
1.4 
0.7 
0.7 
0.4 
1 2 
-0.1 
2.0 
-0.3 
0 9 
0.1 
0.9 
0.5 
0.1 
1.0 
1.2 
1 0 
1.6/1.7 
0.5/0.9 
0.6 
1.7 
1.1/1.1 
1.1 
0.6 
1.8 
0.8 
1.3 
1.1 
1.1 
1.3 
0.6 
0.6 
0.9 
1.4 
0.6 
1.0 
-0.5 
1 2 
0.2 
0.5 
0.4 
0.1 
1 1 
1.2 
1.0 
1.2/1.6 
0.4/0.6 
1.6 
1.7 
1.1/0.9 
0.8 
0.7 
1.5 
0.6 
1.4 
30.8% 
35.0% 
29.6% 
14.3% 
23.1% 
21.4% 
0% 
0% 
16.6% 
8.4% 
25 6% 
9.8% 
30.8% 
30.8% 
8.7% 
39.1% 
Wash-out 
100% 
Wash-out 
50% 
Wash-out 
29% daily 
100% (be cause of study-design) 
0.2 0.1 26.3% 
0.5 
1.0 
0.0 
0.4 
1.1 
0.4 
1.1 
0.3 
0.9 
0.0 
0.3 
0.9 
0.2 
0.8 
28.6% 
37.9% 
30.8% 
Fixed dosage for benzodiazepines 
1 5 
1.4 
1.8 
1.0 
1 4 
1.6 
0% 
10.0% 
85.7% 
17.6% 
11,7% 
Wash-out 
Fixed dosage for benzodiaz. (47% 
in CIT and 24% in PLAC) 
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The between-group post-treatment (and follow-up ES) for the anxiety measures revealed 
an advantage of CBT over SUP, DG, TAU and Minimal Contact Control (MCC; range 0.3 
- 0.8), but not for CBT versus sertraline (ES = -0.06 - -0.12; Schuurmans et al., 2006) 
and for CBT versus SUP at follow-up in one comparison (ES = 0.1; Stanley et al. 1996). 
In most CBT versus active control comparisons the between-group ES for depression 
varied between 0.2 and 0.9, except in the Gorenstein et al. (2005) and Schuurmans et al. 
(2006) studies whose ES varied between -0 11 and 0.21. An ES difference of 0.2 or more 
in between-group comparisons for active controls is considered as clinically significant 
(Yon & Scogin, 2007). 
2.4 Discussion 
Main findings 
With large effect sizes (> 0 8) in 9 of the 10 studies testing CBT and pharmacotherapy of 
late-life anxiety disorders relative to a waiting list or treatment as usual (TAU), our review 
found convincing evidence of superior treatment effects for CBT and medical interventions. 
The effect sizes for CBT were generally also larger than those for supportive psychotherapy 
or discussion groups, especially at follow-up. Interestingly, for anxiety CBT efficacy at 
follow-up had even improved in 7 of the 8 CBT studies. Moreover, CBT showed a superior 
effect on accompanying depressive symptoms. It is important to keep in mind that whereas 
pharmacotherapy was continued during follow-up in all studies, CBT was not 
Of the three studies that had tailored their CBT programme to their elderly target 
group (Mohlman et al., 2003; Stanley et al., 2003a; Stanley et al., 2003b), two showed that 
the adaptations had improved the efficacy of the treatment compared with non-tailored 
CBT. However, the comprehensive and methodologically more sophisticated study by 
Stanley et al. (2003a) failed to find similar positive results. 
Remarkably, one trial, i.e. the Schuurmans et al. study (2006), reported small CBT 
effect sizes that contrasted with all other studies we reviewed. Although Schuurmans 
and colleagues studied a mixed population, and thus had adopted less specific outcome 
measures, this was also the case in the Barrowclough et al. study (2001), which did show 
large effect sizes We discerned two differences in the two studies that might contribute 
to the lack of efficacy in the Schuurmans study Firstly, in the Barrowclough study the 
therapy sessions were audiotaped, which may have contributed to a strong protocol 
adherence, whereas in the Schuurmans study treatment adherence was monitored by 
means of the less accurate method of supervision meetings. Secondly, the therapists in the 
Schuurmans study reported problems with motivating their patients for the homework 
assignments, an essential element of CBT. No motivation problems were mentioned in 
the Barrowclough study. 
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Methodological considerations 
The main limitations of the current review are inherent to the limited number of relevant 
studies, their relatively small sample sizes and high attrition rates, all preventing a 
thorough quantitative analysis. Moreover, as most studies exclusively examined patients 
with generalized anxiety disorders (GAD), the reported results can be generalized to this 
population only. 
Given the average age of the elderly in Western-Europe and the USA, which is about 
78 years, another critical point is the relatively low average age range of the participants 
in the reviewed studies, i.e. 61 to 72 years. Treatment outcome data for the oldest old are 
simply not available. In fact, we do not know if the efficacy rates we found in this review 
would be maintained in the very old with the same approaches, especially in view of any 
increased somatic comorbidity. 
A recently published review on evidence-based psychological treatments of late-life 
anxiety analyzed 17 studies (Ayers, Sorrell, Thorp & Wetherell, 2007) and concluded, as 
we did in the present review, that the support for efficacy was strongest for CBT, and, to a 
lesser extent, for SUP and cognitive therapy. However, Ayers and team used less stringent 
inclusion criteria for diagnostic procedures, also included studies on subclinical anxiety 
symptoms in later life and failed to report dropout rates and within- and between-group 
effect sizes. 
Although more thorough, with our review we failed to find conclusive proof for the 
efficacy of psychological and pharmacological interventions in anxiety disorders in later 
life. We nevertheless feel that the conclusions we have drawn bear sufficient relevance to 
both future research and the clinical practice considering that GAD is the most prevalent 
anxiety disorder in later life. 
Clinical implications 
Late-life anxiety disorders are common and impose a substantial burden on the patients 
and society at large (De Beurs et al., 1999; Van Hout et al , 2004; Wetherell et al., 2004a), 
which contrasts sharply with the low proportion of patients (possibly less than 10%) 
receiving appropriate treatment. Evidence-based guidelines for the treatment of anxiety 
disorders in middle-aged adults mention CBT and pharmacotherapy as the treatments of 
choice. On the strength of the present review we underscore the importance of adhering 
to these guidelines. Although these guidelines underline that CBT and pharmacotherapy 
with selective serotonin reuptake inhibitors (SSRIs) are preferable to benzodiazepine-
based treatments since the latter may result in cognitive impairment, slip-trip-and-fall 
accidents, fractures and dependence or abuse (Hartikainen et al., 2007; Wang et al., 
2001a; Wang et al., 2001b), one has to take into account that both the preferred SSRIs and 
the TCAs are associated with an increased risk of falls and hip fractures (Ensrud et al., 
2002a; Ensrud et al., 2002b; French, Campbell, Spehar, Cunningham, Bulat & Luther, 
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2006, Hartikainen et al., 2007; Liu et al, 1998). More specifically, in view of the high 
prevalence of somatic symptoms like cardiovascular diseases or arthrosis in older adults 
and the subsequent use of other medications that could increase the risk of interaction 
with SSRls (e.g. the elevated risk of gastrointestinal bleeding due to the concurrent 
use of aspirin or NSAIDs (Weinneb et al., 2005; Yuan et al., 2006), we would like to 
advocate CBT as the optimal treatment in this population. Although proven effective 
in treating late-life anxiety disorders, many older patients have been found reluctant in 
accepting antidepressants (Givens et al., 2005). For CBT more post-treatment data are 
available, reflecting convincing effects, and our review revealed some promising long-
term follow-up outcomes. Although the available follow-up data suggest that the effect 
of SSRls is sustained when the drugs are continued (Blank, Lenze, Mulsant, Dew, Karp, 
Shear et al., 2006), the risk of relapse will probably be raised as a result of tapering off the 
drugs, which is typically not done before follow-up measurements. The follow-up data 
for CBT interventions, on the other hand, suggest that when CBT has been concluded, 
the favourable effects are sustained or may even increase, reducing the risk of relapse 
(Furukawa, Watanabe «Sr Churchill, 2006; Marks, 1997; Mitte, 2006; Nadiga, Hensley 
& Uhlenhuth, 2003). Finally, it needs to be noted that our review uncovered high CBT 
dropout rates, of which therapists working in the clinical practice need to be made aware 
Clearly, specific attention and measures directed at preventing premature discontinuation 
of CBT treatment are warranted. 
2.5 Final conclusion 
The empirical data reported thus far show CBT and antidepressants to be most effective 
in the treatment of anxiety disorders in older adults. The treatments hence merit more 
attention and should become an integral part of the routine clinical care provided by 
professionals in both primary and secondary (mental) health care Based on the larger 
volume of data on the efficacy of CBT in late-life anxiety disorders and because of the 
relative risk of interaction between the dedicated drug treatment with other, concurrently 
used medication, the increased risks of falls and relapse risks after drug withdrawal, 
CBT is to be preferred over pharmacological interventions 
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Cognitive-behavioural therapy 
for late-life anxiety disorders: 
A systematic review and 
meta-analysis 
Chapter 3 
This chapter has been published as: 
Hendriks, G J , Oude Voshaar, R C , Keijsers, G Ρ, Hoogduin, C A L & Balkom, A J van 
(2008) Cognitive-behavioural therapy for late-life anxiety disorders a systematic review 
and meta-analysis Acia Psychtatnca Scantimavica, 117,403-411 
A syslematic rewcw and meta analysis 
3.1 Introduction 
Anxiety disorders are highly prevalent in later life affecting up to 10-15% of the 
independently living elderly (Beekman et al , 1998) with generalized anxiety disorder 
(GAD) and phobias being the most common (6-month prevalence rates 7 3% and 
3 1%, respectively) However, the interpretation of these figures is hindered by the fact 
that pure anxiety disorders are rare as most patients have a comorbid second anxiety 
disorder or depressive disorder (Beekman et al, 2000, Flint, 2005a, Kessler, Chiù, 
Demier, Merikangas & Wolters et al , 2005b, Lenze et al , 2005a) Most older adults 
with anxiety disorders do not receive appropriate treatment with only 5 1% receiving 
psychological treatment and 3 8% being prescribed an antidepressant In contrast, the 
use of benzodiazepines, which are not without risk at old age, is as high as 25 8% (De 
Beurs et al , 1999) The negative impact of late-life anxiety on functioning, well-being 
and medical consumption calls for better treatment strategies (De Beurs et al , 1999, 
Schuurmans et al , 2005, Wetherell et al , 2005a) 
Cognitive-behavioural therapy (CBT) is recommended in guidelines (ΑΡΑ, 2002) 
as an evidence-based psychological treatment for anxiety disorders in the general 
population (Mitte, 2005a, Mute, 2005b, Furukawa et al, 2006, Norton &r Price, 2007) 
Previous systematic reviews and meta-analyses of psychological treatments of anxiety 
in older adults, however, are methodologically flawed (Ayers et al, 2007, Nordhus &r 
Pallesen, 2003, Pmquart & Duberstein, 2007) First, one systematic review did not 
include meta-analytic statistics (Ayers et al, 2007) Second, all studies also included 
uncontrolled trials that probably result in higher, but biased effect sizes (Nordhus 
& Pallesen, 2003, Pinquart & Duberstein, 2007) Third, all reviews included studies 
that failed to apply adequate psychiatric diagnoses by including patients with (only) 
subjective anxiety complaints (Ayers et al, 2007, Nordhus δι Pallesen, 2003, Pinquart & 
Duberstein, 2007) Fourth, two meta-analytic studies did not differentiate by the content 
of psychological strategies by lumping all psychological treatment strategies together 
(Nordhus & Pallesen, 2003, Pinquart & Duberstein, 2007) Finally, none of the previous 
studies did differentiate studies with respect to the type of control group, while it is 
known that non-specific therapy factors do have significant effects and clearly differ 
between waiting-list control condition and any other type of control condition in which 
some attention is paid to patients The positive results of CBT, specifically for anxiety 
disorders in general, and the preferences of older adults for psychological treatment 
(Wetherell, Kaplan, Kallenberg, Dresselhaus, Sieber & Lang, 2004b) prompted the need 
for a rigorous meta-analysis of the effect of CBT for anxiety disorders in later life To 
overcome the limitations of previous systematic reviews and meta-analyses, we used 
stringent criteria for study design, patient sample and definition of CBT in this study 
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Aims of the study 
The main objectives of this paper are 1) to provide a quantitative overview of the efficacy 
of cognitive-behavioural therapy (CBT) compared with a waiting-list control condition 
and an active control condition and 2) to provide efficacy data for the specific content of 
the CBT interventions 
3.2 Methods 
Identification of studies 
To identify relevant studies we conducted a search of the Cochrane Central Register 
of Controlled Trials and the databases MEDLINE and PsycINFO for the period 1977 
through November 2006 We used the text keywords late-life, elderly, aged or old age 
combined with the keywords anxiety, anxiety disorder, panic disorder, generaliz(s)ed 
anxiety disorder, social anxiety disorder, and social phobia, and the keywords therapy, 
psychotherapy, treatment, psychological treatment, cognitive treatment, or behavio(u)r(al) 
treatment This search strategy was repeated using the MESH-terms aged, aged, 80 and 
over, anxiety disorder (exploded) and psychotherapy (exploded) and subsequently extended 
by a manual search of the reference lists of all resultant randomized controlled trials 
evaluating psychological treatment(s) for late-life anxiety disorders 
Inclusion criteria 
Reports meeting the following criteria were included in the meta-analysis 
a Use of a randomized controlled research design, 
b Inclusion of patients with a mean or median age of at least 60 years, 
c Patients diagnosed with generalized anxiety disorder, panic disorder, social phobia, 
or agoraphobia according to the ICD-9,1CD-10, DSM-III, DSM-IIIR or DSM-IV and 
verified by a (semi-)structured clinical interview as these are the most prevalent 
anxiety disorders in later life, with high mutual comorbidity rates (Kessler et al, 
2005a, Kessler et al, 2005b), 
d Inclusion of a treatment arm with cognitive-behavioural therapy, defined as a 
protocol-based psychological treatment including at least psycho-education, 
relaxation training, cognitive restructuring of irrational and maladaptive anxiety 
beliefs and exposure to anxiety provoking situations, 
e Results for anxiety, worry and/or depression presented separately for each treatment 
arm, and 
f Use of valid outcome measures (self-report questionnaire or clinical interview) 
The first two authors (GJ Η and RCOV) independently checked the inclusion and 
exclusion criteria of the identified studies Excluded were outcome studies without a 
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randomized controlled design (e.g. open trials, case-series and case reports), review 
papers, and studies including mixed adult and elderly people. Publication in languages 
other than English was no exclusion criterion. 
Selection procedure, data extraction and quality assessment 
The first two authors subsequently coded the selected studies separately. Discrepancies 
in the two coding forms were resolved by consensus after discussion or by referring 
to the data in the original article, yielding one coding form per article consisting of 
the following items: year of publication, total number of patients included, number of 
completers and dropouts, diagnosis, diagnostic criteria, duration of the disorder, age, 
sex, type of treatment, duration of the treatment, presence and duration of follow-up, 
outcome measures and the results on post-treatment outcome measures of interest 
(see analyses) and finally type of control condition. Control conditions were classified 
as either a waiting-list or an active control condition during which patients received 
(specific) attention. The active control condition was defined as comprising either 
treatment as usual or any other strategies that provided a contact frequency comparable 
to the CBT condition. 
The methodological quality of the included studies was also independently assessed 
using the Amsterdam-Maastricht consensus list ranging from 0 [poor quality] to 19 
[excellent quality] and covers the Chalmers criteria usually applied in the assessment of 
study quality (Chalmers et al., 1981, Van Tulder et al., 1997). The Amsterdam-Maastricht 
consensus list is accepted by the Cochrane Review Group (Van Tulder et al., 1997) 
and has been used previously in systematic reviews of randomized controlled trials in 
psychiatric disorders (Oude Voshaar et al., 2006; Van Boeijen et al., 2005). 
Statistical analysis 
The primary outcome measure was the severity of anxiety. Secondary outcome measures 
were the severity of worrying, which is a common feature of anxiety disorders not specific 
for generalized anxiety disorder, and depressive symptoms, which often occur in patients 
with anxiety disorders (Starcevic, Berle, Milicevic, Hannan, Lamplugh & Eslick, 2007). 
To control for non-specific effects of attention paid to the patients and their symptoms, 
analyses were conducted separately for studies with a waiting-list control condition and 
those with an active control condition. We a priori decided to use the Beck Anxiety 
Inventory (Beck et al., 1988a) and, if not available, the Hamilton Anxiety Rating Scale 
(Hamilton, 1959) for anxiety; the Penn State Worrying Questionnaire (PSWQ) (Meyer et 
al., 1990) and, if unavailable, the Worry Domain Questionnaire (WDQ) (Van Rijsoort, 
1999) for worrying; and finally, the Beck Depression Inventory (Beck, 1988b) and, if 
unavailable, the Center for Epidemiological Studies rating scale for Depression (CES-D) 
(Radloff, 1977) for depressive symptoms. 
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In contrast to the previous systematic reviews and meta-analyses (Ayers et al., 2007; 
Nordhus & Pallesen, 2003; Pinquart & Duberstein, 2007) data were analyzed with 
RevMan 4.2 (Cochrane statistical software). At the moment Cochrane methodology is 
widely advised and accepted as the preferred method in meta-analytic studies. We used 
the standardized mean difference (SMD) as the summary statistic in our meta-analysis, 
which expresses the size of the treatment effect in each trial relative to the variability 
observed in that trial, enabling us to pool different scales assessing one outcome 
measure. The SMD thus reflects the difference in the mean outcome between groups 
divided by the standard deviation of outcomes among participants. We applied the chi-
square test for heterogeneity, and because the number of included studies was small a 
p-value < 0.10 was considered significant (Cochrane handbook for systematic reviews of 
interventions 4.2.5. The Cochrane Collaboration, 2005, pp. 135). We used a fixed effect 
model if homogeneity was found and a random effect model if not (although the latter 
model slightly compromised the statistical power of our analysis). As most studies only 
presented data of those participants who had completed the trial (Figs 3-1 and 3-2), 
summary statistics are based on available case analyses. For an adequate interpretation, 
dropout numbers per study and treatment condition are reported separately Publication 
bias was explored by preparing funnel plots for all outcome measures. 
3.3 Results 
Search strategy 
The initial search yielded 959 reference titles in a combined search in MEDLINE and 
PsycINFO and 111 in the Cochrane Library of which 56 titles were identified as having 
possible relevance to the treatment of late-life anxiety disorders by G.J.H or R.C.O.V. 
After screening of the abstracts and the full text, we excluded 49 papers. The reasons for 
exclusion were No RCT (n = 38); no proper diagnostic procedures (n = 7); evaluation 
of pharmacotherapy only (n = 3); inadequate study design (n = 1). The following seven 
papers met the inclusion criteria: Barrowclough et al. (2001), Mohlman et al. (2003), 
Schuurmans et al. (2006), Stanley et al. (1996), Stanley et al. (2003a), Stanley et al. 
(2003b), Wetherell et al. (2003) As Mohlman et al. (2003) described two different pilot 
trials, we considered these as two separate studies designated as a and b. Furthermore, as 
Wetherell et al. (2003) randomized patients over three conditions, viz. CBT, a discussion 
group and a waiting list, we used their CBT outcomes both vis-à-vis the results of the 
waiting-list and the active control condition. The study by Schuurmans el al. (2006) 
did only report change-scores, but this study could be included as the authors kindly 
provided their end-of-treatment scores on request of the researchers. 
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Study quality 
Appendix 3-A lists the scores for methodological quality of the studies as assessed with 
the Amsterdam-Maastricht consensus list. The sum score (range 0-19) is taken to reflect 
study quality but since neither patients nor therapists can be blinded to a psychological 
treatment condition, the maximum score in psychotherapy studies is 17. The narrow 
range from 12 to 15 indicates a moderate to good study quality without major differences 
between studies. Inter-rater discrepancies were limited to a one point difference in three 
of seven studies. 
Study characteristics 
The study characteristics are summarized in Table 3-1 by type of control condition. The 
four trials that compared CBT with a waiting-list condition comprised a total of 146 
patients with a mean age of 68 years of whom 73% were women Thirty-two patients 
(22%) dropped out prematurely; 23 (26%) patients in the CBT condition and 9 (16%) in 
the waiting-list condition (χ2 = 1.81; df = 1, ρ = 0.18). The five trials comparing CBT and 
an active control condition included 243 patients with a mean age of 69 years of whom 
77% were women. Sixty patients (25%) dropped out before the outcome assessment; 35 
(28%) patients in the CBT condition and 25 (21%) in the active control condition (χ2 = 
1.70; df= 1, ρ = 0.19). 
Table 3-1. Study characteristics of all studies reviewed 
Study 
Mohlmanetal (2003) 
Mohlman et al. (2003) 
Wetherell et al. (2003) * 
Schuurmans et al. (2006) 
Total CBT vs. waiting list 
Stanley et al. (1996) 
Barrowclough et al (2001] 
Stanley et al. (2003b) 
Stanley et al. (2003a) 
Wetherell et al. (2003) * 
Number of patients 
Included 
η 
27 
15 
49 
55 
146 
48 
I 55 
12 
85 
52 
Total CBT vs. active control 250 
Dropouts Completers 
η 
6 
-
10 
16 
32 
17 
12 
3 
21 
16 
67 
η 
21 
15 
39 
39 
114 
31 
43 
9 
64 
36 
183 
Sex 
female 
% 
70% 
60% 
80% 
73% 
73% 
7 1 % 
77% 
83% 
75% 
80% 
77% 
Mean 
age 
(years) 
66 
68 
67 
70 
68 
68 
72 
71 
66 
67 
69 
Primary No. of 
diagnosis sessions 
GAD 13 
GAD 13 
GAD 12 
GAD, PD, AG, 15 
SP" 
GAD 14 
GAD, PD, SP, 8 - 1 2 
AD-NOS*** 
GAD 8 
GAD 15 
GAD 12 
Group 
therapy 
No 
No 
Yes 
No 
Yes 
No 
No 
Yes 
Yes 
* This study had a three-condition design evaluating CBT with active control and waiting list and was therefore 
included in both meta-analyses. 
** GAD: 35%; PD: 40%; AG without history of PD: 13%; SP: 1 3%. 
*"GAD: 19%; PD: 5 1 % ; SP: 2%; AD-NOS: 28%. 
Abbreviations: GAD = generalized anxiety disorder; PD = panic disorder with and without agoraphobia; SP = social 
phobia; AD-NOS = anxiety disorder not otherwise specified; AG = agoraphobia 
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Most studies included patients with a primary diagnosis of GAD only. However, two 
studies also included patients suffering from panic disorder, social phobia or anxiety 
disorder not otherwise specified (Barrowclough et al. 2001; Schuurmans et al., 2006). All 
studies allowed a comorbid diagnosis of anxiety and affective disorder (limited to major 
depression and dysthymia) provided that the anxiety disorder was the primary diagnosis. 
The active treatment phase ranged from 8 to 15 weekly sessions, delivered either in a group 
format (4 comparisons) or individually (5 comparisons). The active control condition 
involved minimal contact including weekly telephone calls and consultation on demand 
(Stanley et al., 2003a), usual care (Stanley et al., 2003b), supportive psychotherapy 
(Barrowclough et al., 2001; Stanley et al., 1996), and a discussion group (Wetherell et 
al., 2003). 
Meta-analyses 
The results for the primary outcome variable, level of anxiety, of the two analyses are 
presented in Figures 3-1 and 3-2. 
Figure 3-1. The effects of cbt versus waiting-list control conditions on the level of anxiety in 
patients over 60 years 
Review: Cognitive-behavioural therapy for anxiety disorders in later life 
Comparison: 01 CBT versus waiting list 
Outcome 01 Effect on anxiety level 
Study Treatment Control SMD (fixed) Weight SMD (fixed) 
or sub-category Ν Mean (5D) Ν Mean (SD) 95% CI % 95% CI 
Mohlman el al. (2003a) 
Mohlman et al (2003b) 
Wetherell et al (2003a) 
Schuurmans et al (2006) 
Total (95% CI) 
Test for heterogeneity χ1 
Test for overall effect Ζ = 
11 10.25(7 03) 
8 -1 35(1 00) 
18 12 90(9.60) 
30 14 34(12 85) 
67 
10 
7 
21 
9 
47 
= 2 88, df = 3 ( p = 0.41), l 2 = 
2 17 (p = 0 03) 
11 45(4.87) 
1 65(3 41) 
19 10(10 90) 
15 67(8 72) 
0% 
_ 
_ _ 
-
• 
21 34 
12 45 
37 89 
28 32 
100 00 
-0 19[-1 0 5 , 0 67] 
-1.16[-2 29,-0 04] 
-0.59 [-1.23, 0.06] 
-0.11 [-0 85,0.64] 
-0 44 [-0 84, -0 04] 
- 4 - 2 0 2 4 
The four studies comparing CBT with a waiting-list condition and the five comparing 
CBT with an active control condition were all homogeneous with respect to the primary 
outcome parameter (p = .41 and ρ = 0.12, respectively) and yielded a pooled standardized 
mean difference of-0.44 [95% CI: -0.84, -0.04] and -0.51 [95% CI: -0.81, -0.21] in favour 
of the CBT condition (Z = 2.17; ρ < .05 and Ζ = 3.32; ρ <.001, respectively). 
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Figure 3-2 The effects of CBT versus active control conditions on the level of anxiety in patients 
over 60 years 
Review: Cognitive-behavourial therapy for anxiety disorders in later life 
Comparison: 02 CBT versus waiting list 
Outcome 01 Effect on anxiety level 
Study 
or sub-category 
Treatment 
Ν Mean (SD) 
Control 
Mean (SO) 
SMD (fixed) 
95% CI 
Weight SMD (fixed) 
% 95% CI 
Stanley et al (1996) 18 
Barrowclough et al (2001) 19 
Stanley et al (2003a) 
Stanley et al (2003b) 
Wetherell et al (2003a) 
Total (95% CI) 
Total (95% CI) 
Test for heterogeneity χ2 
Test for overall effect Ζ = 
5 
29 
18 
89 
= 7 32, 
3 32 (ρ 
12 00(5 75) 
11 58(9 1 7) 
9 20(4 92) 
1 3 50(5.20) 
12 90(9 60) 
13 
24 
4 
35 
18 
94 
df = 4 (β = 0 12), I2 = 
= 0 0009) 
11 67(4 94) 
1746(12 17) 
19 80(14 00) 
19 70(6 93) 
14 20(10 40) 
45 3% 
I 
J_ 
- -
·• 
1 
-
1 
17.69 
23 96 
4 34 
32.95 
21.05 
100.00 
1 
0 0 6 [ - 0 65,0.77] 
-0 5 3 [ - l 14,0.09] 
-0 95 [-2 39, 0.49] 
-0 99[-1 51,-0 46] 
-0 1 3 [-0 78, 0 53] 
-0 51 [-0 81,-0 21] 
- 4 - 2 0 2 4 
Favours Favours control 
treatment 
Table 3-2 presents the summary statistics of the meta-analyses for the two secondary 
outcome measures. The CBT versus waiting-list comparisons were also homogeneous 
both with respect to their effect on worrying (p = 0.58) and on depression (p = 0.35). For 
both outcome measures, the pooled effect of CBT was superior to that of the waiting-list 
condition (see Table 3-2). The analyses of the CBT versus active control studies generated 
homogeneous results for depression, again demonstrating a significant superior effect 
for CBT after pooling. The results relating to worrying were, however, heterogeneous (p 
Table 3-2. The effect of CBT on worrying and depressive symptoms associated with late-life anxiety 
disorders 
No. of patients 
CBT Control 
CBT versus waiting-list control condition 
Worrying 54 47 
Depression 54 47 
CBT versus active control condition 
Worrying 70 70 
Depression 89 94 
Test for 
heterogeneity 
X 2 =1.97;df = 3;p = 0.58 
X i 2 = 3 . 3 2 ; d f = 3 ; p = 0.35 
X i 2 = 7 . 3 4 ; d f = 3 ; p = 0.06 
X 2 =7.62;df = 4 ; p = 0.11 
Pooled standardized 
mean difference [95% CI] 
-0.57 [-0.97,-0.17] 
-0.54 [-0 94,-0.14] 
-0.54 [-1.1 3, 0.04]* 
-0.35 [-0.64, -0.05] 
p-
value 
.005 
.008 
.07 
.02 
A random effect model was applied to correct for the heterogeneity as indicated by a significant (p < .10) 
test for heterogeneity 
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= 0.06). Subsequent application of a random effect model did not yield any significant 
effects, although it did reveal a trend in favour of CBT (p = 0 07). 
Due to the limited number of studies included and comparable effect sizes in both 
comparison groups (i.e. comparison with a waiting-list control condition or an active 
control condition), we prepared funnel plots for all studies together. The funnel plots 
were asymmetrical for all outcome measures (anxiety, worrying and depression) due 
to one small study by Stanley et al. (2003b). Excluding this study did not affect the 
outcome. 
3.4 Discussion 
Main findings 
The present meta-analysis shows the efficacy of CBT in the treatment of anxiety 
disorders (as based on DSM-IV criteria) occurring later in life. Not only was its efficacy 
demonstrated in various samples of over-60s when compared to a waiting-list condition, 
it was also shown relative to an active control condition. The same magnitude of the 
effect size in both comparisons contrasts with our expectation that the effect of CBT 
would be greatest with respect to the waiting-list control condition. These differences 
are caused by the high effect sizes of both studies by Stanley et al. (2003a, 2003b), which 
might be explained by a lower impact of non-specific therapy factors due to the relative 
short duration of therapist-patient contact in both control conditions of these studies 
This explanation, however, is not consistent with the fact that the effect sizes of these 
studies are also much higher compared to three of the four trials that included a waiting-
list control condition. Therefore, in our opinion the same magnitude of the effect size 
in both comparisons is most likely explained by the low number of studies in both 
analyses, which may lead to a high impact of individual studies. 
Interestingly, CBT also proved significantly superior in its effect on the concurrent 
symptoms of worrying and depression, although, relative to the active control conditions 
its outcome on worrying did not reach significance (p = .07). This latter lack of effect 
may be attributable to the fact that power was reduced due to exclusion of the study 
by Barrowclough et al. (2001), which did not provide outcome data for worrying. This 
explanation seems plausible, because the effect size they report for anxiety was similar 
to the size we generally found for worrying. 
Methodological considerations 
The main limitation of the current meta-analysis is the limned number of eligible studies 
and the relatively small sample sizes that were used, which makes the results prone to 
publication bias. Although the funnel plot is not conclusive, it is also not suggestive for 
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publication bias. Interestingly, all individual authors of the included studies argued in 
favour of the efficacy of CBT, while our analyses yielded only significant results in 2 out 
of 9 trials by analysing them on outcome measures only (as proposed by the Cochrane 
Collaboration, see Figs 3-1 and 3-2). This can be explained by baseline differences 
between the CBT and control groups with more severely affected patients in the CBT 
conditions. As the analyses were completer-based, this might suggest both, biased 
randomization procedures or selective dropout (although the actual number of dropouts 
did not differ significantly between the CBT and control conditions). Nevertheless, their 
assertions are corroborated by significant results obtained by pooling the individual 
trial outcomes, which indicates the importance of meta-analysis in this field of research. 
However, the small number of studies, the lack of data for different diagnostic groups, 
and most importantly, high comorbidity rates precluded subgroup analyses for the 
separate anxiety disorders Two studies included a population suffering from mixed 
anxiety disorders, while the other studies included patients with GAD. Because all 
studies had high comorbidity rates with other anxiety disorders and depression and 
outcome measures were not specific for diagnostic categories, as presented in Table 3-1, 
we considered these differences as minimal. However, since the majority of the studies 
were limited to older patients suffering from at least GAD, the present findings may be 
most generalizable to older GAD patients. Considering that GAD is the most prevalent 
anxiety disorder in later life, our meta-analysis nevertheless underscores the importance 
of CBT in this growing part of the general population. 
Finally, with our a priori exclusion criteria we eliminated reports that had not 
adhered to valid diagnostic procedures at baseline, thus having ensured that the patients 
assessed were in actual fact suffering from a psychiatric disorder and not from non-
specific anxiety complaints due to a variety of temporary stressors and that the anxiety 
disorder indeed was the primary diagnosis. 
Clinical implications 
Since late-life anxiety disorders are common and significantly reduce quality of life, 
adequate treatment strategies are urgently needed. Yet, the prevalence rates of adequate 
treatment contrast sharply with the estimates of less than 10% of the over 60s receiving 
appropriate treatment for their complaints. Our results confirm that CBT may be an 
adequate treatment strategy for this elderly patient group. Many elderly people resist the 
use of antidepressants based on fear of dependence, prior negative experiences, resistance 
to viewing their symptoms as a medical illness, and concern that antidepressants 
will prevent natural feelings (Givens et al., 2006). From a clinical point of view, the 
high prevalence of somatic syndromes such as cardiovascular diseases and arthrosis 
in the elderly and the subsequent use of medications increase the risk of interaction 
with selective serotonin reuptake inhibitors (SSRIs) The concurrent use of SSRIs and 
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aspirin or NSAIDs (Weinrieb et al., 2005; Yuan et al., 2006), for example, raises the 
risk of gastrointestinal bleeding. Finally, the evidence for the efficacy of antidepressants 
for late-life anxiety disorders is limited with only three valid randomized controlled 
trials published thus far (Katz et al., 2002; Lenze et al., 2005; Schuurmans et al., 2006). 
CBT may also be a viable, more constructive alternative for those elderly patients that 
are currently being prescribed benzodiazepines or antidepressants for their anxiety, 
as longer-term use of benzodiazepines and antidepressants can result in a 1.4 to 2.4 
fold increased risk for cognitive impairment, shp-and-fall accidents, fractures and 
dependence or abuse (Ensrud et al., 2003; French et al, 2006, Kurzthaler, Warnbacher, 
Golser, Sperner, Sperner-Unterweger & Haidekker et al., 2005; Liu et al., 1998; Paterniti 
et al., 2002; Wang et al., 2001a). However, some difficulties can occur in conducting CBT 
to older people. The elderly tend to discuss their problems more in terms of physical 
symptoms, seem to have difficulties in applying cognitive techniques and in adhering 
strictly to the CBT protocol (Hyer, Kramer & Sohnle, 2004; Rainsford, 2002; Schuurmans 
et al., 2006). To enhance outcome it is advised to give special attention in establishing a 
strong therapeutic alliance, pay particular attention to motivating strategies to empower 
patients to overcome their, most often, longstanding complaints, include extra sessions 
for psycho-education, give special attention to doing homework, contacting family, and 
visiting patients at home (Barrowclough el al., 2001; Mohlman et al., 2003, Stanley et al., 
2003a; Wetherell et al., 2003; Hyer et al., 2004) 
Because of the lack of follow-up data for the control conditions, we could not include 
CBT follow-up data in our formal meta-analysis. Nonetheless, 5 of the 7 studies reporting 
follow-up data showed a further decline of anxiety levels (Barrowclough et al., 2001; 
Mohlman et al , 2003; Stanley et al., 1996; Stanley et al., 2003a; Wetherell et al., 2003), 
whereas 2 trials reported a minimal increase (Barrowclough et al., 2001; Mohlman et 
al., 2003), which is similar to longer-term CBT-efficacy studies in adult patients (Barlow, 
Gorman, Shear & Woods, 2000; Bockting, Spinhoven, Koeter, Wouters, Visser & Schene, 
2006; Furukawa et al, 2006; Marks, 1997; Mitte, 2005b; Mute, 2006; Nadiga et al, 2003; 
Norton & Price, 2007). 
Final conclusion 
Cognitive-behavioural therapy is an effective, evidence-based therapy for adults over 
60 suffering from anxiety disorders, which therefore deserves more research and more 
attention in the routine clinical care of both primary health-care workers (general 
practitioners, social workers) and secondary mental health-care professionals. 
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Appendix 3-A. Validity scores of the studies evaluated according to the Amsterdam-Maastricht consensus list 
Study Stanley et Barrowclough et Mohlman et Stanley et Stanley et Wetherell et Schuurmans et 
al. (1996) al. (2001) al. (2003) al. (2003b) al. (2003a) al. (2003) al. (2006) 
Validity criteria 
Adequate randomization procedure 
Concealed random allocation of treatments 
Baseline similarity tested 
Control for co-interventions in design 
Check for adherence to interventions 
Valid outcome measures 
Relevant outcome measures 
Outcome assessor blinded 
Therapist blinded 
Patient blinded 
Withdrawals and dropouts (proportion; inequality 
between groups; reasons for withdrawal/dropout 
reported) 
Identical timing of outcome assessment for all 
intervention groups 
Intent-to-treat analyses 
Descriptive criteria 
Specification of eligibility criteria 
Description of interventions 
Follow-up 
Adverse events 
Statistical criteria 
Sample size: to be presented at randomization 
and outcome 
Presentations of point estimates and distribution 
measures 
+ 
-
+ 
+ 
+ 
+ 
0 
0 
0 
+ 
+ 
+ 
-
+ 
+ 
+ 
+ 
-
, 
+ 
-
+ 
+ 
+ 
+ 
+ 
+ 
0 
0 
+ 
-
+ 
+ 
-
+ 
+ 
-
-
-
+ 
-
+ 
+ 
+ 
+ 
+ 
+ 
0 
0 
+ 
-
+ 
+ 
+ 
+ 
+ 
+ 
0 
0 
-
+ 
+ 
+ 
-
+ 
+ 
-
0 
0 
Total score (range 0-19) 12 14 14 12 15 15 14 
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Cognitive-behavioural therapy 
4.Ί Introduction 
Even though the estimated life-time prevalence of panic disorder with or without 
agoraphobia (PD(A)) seems lower in elderly people compared to younger and middle-
aged adults, it is still as high as 2% (Kessler et al., 2005a). In later life the effects of 
ageing become increasingly more pronounced and heterogeneous, not only deepening 
the differences between younger and older adults, but also those between the elderly 
themselves. Yet, possibly due to ageism, relatives often interpret anxiety symptoms and 
avoidance behaviour in an elderly person as normal and more or less acceptable while he 
or she may be suffering from a phobic disorder (Lindesay, 1991). As a result of the ageing 
process itself somatic morbidity increases and may partially overlap certain panic and 
anxiety symptoms (Hocking & Koenig, 1995). In addition, panic physiology and anxiety 
cognitions tend to decline with increasing age and in the elderly in whom the onset of 
PD(A) occurs beyond the age of 60 years specific symptoms usually are less severe than 
they are in younger patients (Flint, Koszycki, Vaccarino, Cadieux, Boulenger &r Bradwejn, 
1998, Segui et al., 2000; Sheikh et al., 2004a). Based on these findings, some authors 
characterized PD(A) in later life as a less severe disorder (Segui et al., 2000; Sheikh et al, 
2004a). 
By contrast, agoraphobic symptoms do not seem to decline with age (Segui el al., 
2000). Compared to panic attacks and anxiety cognitions, agoraphobia, moreover, is 
more susceptible to improvement following treatment in younger PDA adults and may be 
more reliable and valid in reflecting symptom severity (Basoglu, Marks, Kihc, Swinson, 
Noshirvani, Kuch et al., 1994; De Beurs, Lange, Van Dyck & Koele, 1995). For a subgroup 
of elderly patients with an onset at an older age, the agoraphobic symptoms may, however, 
be less severe than in younger adults suffering from the disorder, while in elderly patients 
with disease onset at a younger age the phenomenology may initially have been more 
disguised due to overlapping, comorbid somatic disorders dampening panic physiology 
and an environment that is more tolerant towards agoraphobic behaviour. These changes 
may hinder appropriate diagnosing of PD(A), leaving older patients undiagnosed and 
untreated. In fact, in clinical practice less than 10% of the elderly suffering from anxiety 
disorders is offered psychological treatment or antidepressant therapy while more than 
25% is prescribed benzodiazepines, which is clearly not the treatment of choice (De 
Beurs et al., 1999) The consequences of late-life anxiety disorders going undiagnosed 
and untreated are large. Recent findings showed that late-life anxiety has a tendency to 
become chronic and is associated with a substantial risk of major depression, increases 
in health-care consumption, reduced quality of life and more disability (Beekman et al., 
2000; Brenes et al., 2007; De Beurs et al., 1999; Schuurmans et al., 2005; Wetherell et al, 
2004a; Wetherell et al., 2005). 
Well-developed and evidence-based treatment algorithms for PD(A) are available 
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in guidelines (e g NICE') but research findings are limited to adult populations aged 
between 18 and 65 years and the number of randomized controlled trials (RCTs) 
investigating late-life anxiety disorders is modest Although restricted to studies on 
generalized or mixed anxiety disorders, recently published meta-analytic reviews of 
the use of cognitive-behavioural therapy (CBT) and antidepressants in the treatment 
of elderly patients showed both approaches to be effective, with a suggested advantage 
of antidepressants over CBT (Hendriks et al , 2008a, Pinquart &r Duberstein, 2007) 
However, with 9-18% in the younger aged patients and 27% in the older patients dropout 
rates were relatively higher for CBT in the elderly patients, which suggests a relative 
and age-related intolerance of CBT in elderly patients suffering from anxiety disorders 
(Hendriks et al , 2008a, Pinquart & Duberstein, 2007, Mute, 2005a, Mitte 2005b) In 
contrast, with 23-25% in the younger aged patients and 22% in the elderly patients, 
the overall dropout rates for pharmacotherapy were comparable in both age groups 
(Hendriks et al, 2008a, Pinquart & Duberstein, 2007, Mitte, 2005a, Mitte 2005b) In 
short, it remains unclear from mentioned reviews whether the recommendations in the 
guidelines for the treatment of PD(A) can be extrapolated to older PD(A) patients 
To date, only three studies, viz a randomized, placebo-controlled pilot study of 
Imipramine and alprazolam (Sheikh & Swales, 1999), an open CBT study (Swales et al, 
1996), and one open study of sertraline (Sheikh, Lauderdale & Cassidy, 2004b), have 
specifically tested treatment outcomes for late-life PD(A) Two trials reported dropout 
rates, 28% (n = 7) prematurely left the study in the pharmacotherapy trial (Sheikh & 
Swales, 1999) and in the CBT study 25% (n = 5) dropped out (Swales et al, 1996) The third 
study with 10 participants (Sheikh et al, 2004b) reported no dropout rates None of the 
studies mentioned specific age-related factors to explain dropout In the completers both 
pharmacotherapy and CBT were well tolerated and effective Investigating mixed anxiety-
disorder populations (Barrowclough et al, 2001, Schuurmans el al, 2006), two studies also 
reported on substantial proportions of patients with late-life PD (51% and 45%, respectively) 
Although again CBT and pharmacotherapy were both found to be effective, these studies 
were also hampered by dropout rates (22% (n = 12) and 32% (n = 27), respectively) as well 
as a lack of specified outcome measures for PD Thus, because of the relatively large dropout 
rates, the limited sample sizes, and the absence of well-delineated PD outcome measures 
the conclusions of these studies also failed to provide definitive answers 
To help resolve these inconclusive findings, we conducted an RCT in patients aged 
over 60 years that were all diagnosed with PD(A) in accordance with the well-established 
guidelines for younger adults More specifically, we examined the effects of individual 
CBT and an SSRI (paroxetine) relative to a waiting-list control group To our knowledge, 
ours is the first trial to do so exclusively in this age group 
1 hup //www nice org uk/guidance/index jsp 
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Aims of the study 
The main objectives of our RCT were: i) to examine the effectiveness of paroxetine and a 
protocolized, individual CBT originally developed for younger adults in elderly patients 
suffering from panic disorder and to compare the outcomes to those obtained in patients 
on a waiting list, n) to compare the effectiveness of paroxetine with protocolized, 
individual CBT, and iii) to examine the feasibility of both treatment arms 
4.2 Material and methods 
Patient selection 
Eligible were all adults aged over 60 years with a principal diagnosis of panic disorder 
(PD) or PD with agoraphobia (PDA) (APA, 1994) undergoing treatment in our outpatient 
clinic specialized in the treatment of anxiety disorders. All patients were referred by 
their primary care physician. Exclusion criteria were the presence of severe psychiatric 
disorders (e.g. psychotic disorder, bipolar disorder), a severe somatic condition that 
would hinder appropriate application of CBT (e.g. severe cardiovascular disease), a 
contraindication for paroxetine, current use of an antidepressant in an adequate dose, 
current and adequate psychological treatment, failure of paroxetine or CBT in the past, 
abuse of or dependency on alcohol or psychoactive substances, dementia, and a score of 
23 or less on the Mini-Mental State Examination (Folstein, Folstein & McHugh, 1975). 
Comorbidity with other anxiety disorders, depression or dysthymia was allowed as long 
as PD(A) was the principal diagnosis. Participants using benzodiazepines were asked 
to adhere to a fixed daily dose for the duration of the study (also see the Procedure and 
Treatment sections). 
Procedure 
After referral to our outpatient clinic all patients took part in two intake sessions at 
week -2 and week 0 during which the PD(A) diagnoses were verified using the Dutch 
version of the Anxiety Disorders Interview Schedule-Revised (ADIS-1V), which was 
administered by independent and trained assessors (DiNardo et al., 1994; Bouman et 
al., 1997). Following confirmation of the diagnoses and an oral description of the study, 
written informed consent of the patients was obtained after which they were randomly 
assigned to one of the three study conditions according to a 2:2:1 schedule To this 
end, a sealed envelop was selected from an initial total of 75 envelopes containing the 
treatment assignments, with 30 being labelled as 'CBT', 30 as 'paroxetine' and 15 as 
'waiting list'. The randomization schedule was based on the assumption that the waiting-
list condition would show no effects (Wetherell et al., 2003). The patients allocated for 
treatment subsequently took the first baseline assessment by completing several self-
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report questionnaires (see below). They completed the same instruments again at 
week 8, week 14 (coinciding with CBT completion), and week 26 (the 3-month post-
treatment follow-up). Patients assigned to the waiting-list condition were also first 
assessed immediately following randomization, and subsequently at weeks 8 and 14, 
after which they were offered their preferred treatment (CBT or antidepressant). They 
were not further tested for the present study. As these patients were in need for treatment 
a waiting-list condition up to week 26 was not allowed by the Medical Ethical Review 
Board of the University Medical Centre of Nijmegen. 
Instruments 
Anxiety cognitions and phobic avoidance were the primary outcome measures and were 
evaluated using the Dutch adaptations (De Beurs, 1993) of the Agoraphobic Cognitions 
Questionnaire (ACQ) (Chambless, Caputo, Bright, & Gallagher, 1984) and the Mobility 
Inventory Avoidance scale (Ml-A) (Chambless, Caputo, Jasin, Gracely <Sr Williams, 1985). 
The original instruments have frequently been used in PD treatment outcome studies. 
The ACQ consists of 14 items that have to be rated on a 5-point rating scale and aims 
to assess the severity of catastrophic agoraphobic cognitions. Good reliability estimates 
have been reported, with test-retest correlations varying between 0.71-0 86 and a 
Cronbach's alpha varying between 0.72-0.84 (29, 30). In our sample with elderly people, 
the Cronbach's alpha was 0.63, which is lower than reported for younger age samples. 
The MI gauges the severity of phobic avoidance of 27 situations using two subscales: 
avoidance when alone (MI-AAL) and avoidance when accompanied (MI-AAC), and one 
subscale consisting of 1 item to assess the frequency of panic attacks (MI-PF). Good 
test-retest reliability (r vanes between 0.76-0.90) and Cronbach's alpha (range 0.91-0.97) 
have been reported (29, 31). In our population, the Cronbach's alpha was 0.93 for the 
MI-AAL and 0.94 for the Ml-AAC, similar to those reported in younger age samples. The 
MI-PF gives a definition of panic attacks according to the DSM-IV followed by a question 
inquiring about the number of panic attacks that occurred during the past seven days. As 
the frequency of panic attacks is largely dependent on the level of avoidance behaviour 
and given that avoidance behaviour is associated with the severity of PDA (Basoglu et 
al., 1994a; De Beurs et al., 1993), we opted to use the total MI-Α mean scores for our 
analyses (Kampman, Keijsers, Hoogduin & Hendriks, 2002). A patient was classified as 
being panic-free when he/she reported zero panic attacks during the preceding week. As 
a panic-free status does not correspond with improvement on the ACQ or the MI-Α, we 
used this dimension as a secondary outcome measure (Van Balkom, Spinhoven, Bakker, 
Rammeloo, Graatsma, Adnaanse et al., 2000). 
General psychopathology was assessed as the additional secondary outcome measures 
using the Dutch version of the Symptom Checklist (SCL-90) (Arrindell & Ettema, 1986; 
Derogatis, Rickels & Rock, 1976). The SCL-90 is a frequently used outcome measure 
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with good psychometric properties (Arrindell 61 Ettema, 1986; Derogatis et al., 1976). 
Treatment feasibility was determined using a proxy variable, i.e., the proportion 
of patients that withdrew prematurely from either CBT or paroxetine treatment. All 
assessments were administered by trained, independent psychologists who were blind 
to the study and treatments delivered. 
Treatment 
During the 26-week study period concomitant treatment was not allowed, while patients 
taking benzodiazepines (oxazepam or equivalent agents) were kept at a fixed dose of 10 
mg/d. 
Individual CBT consisted of 14 weekly sessions of fifty minutes each consistent with 
Craske and Barlow (Craske, Meadows & Barlow, 1994). The standardized programme 
comprised the following five components: (1) education about panic and anxiety, (2) 
relaxation techniques, (3) interoceptive exposure, (4) cognitive therapy, and (5) exposure 
in vivo. After the 14'h session CBT was tapered off within a maximum of 6 sessions 
during the 12-week follow-up period. 
Patients in the paroxetine condition were treated according to a fixed-dose schedule. 
The daily 10 mg starting dose in week 1 was increased with 10 mg a week to 40 mg/d in 
week 4, during which period patients were seen during 30-minute weekly consultations. 
To control for any adverse events and to encourage patients to adhere to the treatment 
protocol, from week 5 to week 14 all patients attended five 30-minute medical consultations 
once every two weeks during which their queries were addressed and information about 
the expected (side) effects of the treatment was provided. Paroxetine was maintained in 
a 40 mg/d dosage during weeks 14 to 26. 
Therapists 
The therapists were all psychologists trained at the master of science level with extensive 
experience in cognitive-behavioural techniques for adults with PD(A) Throughout the 
study they were weekly supervised by a registered supervisor (a member of the Dutch 
Association of Behavioural and Cognitive Therapy). Per session the therapists recorded 
which specific CBT component they had applied and any deviations from the treatment 
manual were discussed. Adaptations to the specific circumstances of the patients were 
allowed (e.g. adapting interoceptive exposure exercises to the physical condition of 
the patient in case of COPD), provided they did not conflict with the manual. In the 
paroxetine condition patients were seen by a (resident) psychiatrist. 
Statistical analysis 
Outcome scores were analyzed using a mixed-model procedure, which allows all available 
data for all subjects to be entered into the analyses, preventing the loss of subjects for whom 
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data were incomplete and thus precluding ad-hoc (e.g. 'last observation carried forward') 
solutions. We analyzed our outcome variables using the MIXED procedure in SPSS with 
the Conditions (paroxetine, CBT, and WL) and Time (week 0, week 8, week 14, week 26) 
as the main fixed effects, Condition by Time as the interaction factor, and the Patients 
as the random effects within Time. The random effect covanance matrix was specified 
as unstructured, implying it had no restrictions imposed on it. The SPSS mixed-model 
procedure provides Estimated Marginal Means (EMM), which are model-predicted means 
that allow easy testing of custom hypotheses contrasts. Instead of testing the main effect of 
the Condition factor, we were a priori interested in two custom contrasts: the Paroxetine-WL 
and the CBT-WL contrasts both at week 14. Further, and by post hoc analyses, we 
investigated Paroxetme-CBT contrasts at weeks 8,14, and 26. Paroxetine-WL and CBT-WL 
contrasts were investigated by computing t-values for the differences in the EMMs. For the 
post-hoc Paroxetine-CBT contrasts Sidak's adjustment for multiple comparisons was used. 
For clinical interpretation we calculated the pre-post Cohen's d effect size per treatment 
condition, as well as the baseline corrected between-group Cohen's d. Furthermore, we 
analyzed the proportion of patients that improved more than 30% on one of the primary 
outcome scales, as an improvement of 30% on disorder specific anxiety scales indicates a 
clinically relevant improvement (Bandelow, 2004; Bandelow et al., 2006). 
Changes in panic-free ratios were analyzed using the Wilcoxon Signed Rank Test for 
Paired Comparisons. Effects were considered statistically significant at ρ < .05. The 
Statistical Package for the Social Sciences (SPSS) 15.0 was used for all analyses (SPSS 
inc., 2006). 
4.3 Results 
A total of 153 older adults reporting anxiety symptoms that had been referred to our 
outpatient clinic were screened. Ninety-four patients were excluded as they did not meet 
the inclusion criteria (no principal diagnosis of panic disorder according to DSM-IV 
criteria, η = 85; interfering medications, η = 9; history of treatment with CBT, η = 0, 
previous treatment with paroxetine, η = 0) and another 10 patients refused randomization. 
The remaining 49 patients fulfilled all criteria and were randomly assigned to one 
of the three study conditions (see Table 4-1). Comorbidity was common: 33 (67 3%) 
patients suffered from a chronic somatic disorder, with 23 (46.9%) patients having a 
cardiovascular disease and 5 (10 2%) a chronic obstructive pulmonary disease, while 14 
(28.6%) patients had a comorbid psychiatric diagnosis: 7 (14.3%) patients were diagnosed 
with another anxiety disorder, 6 (12.2%) with a mood disorder, and 3 (6.1%) with a 
somatoform disorder. Although there was a significant group difference for psychiatric 
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Table 4-1. Baseline patient characteristics for the three conditions (individual CBT, 40 mg/d par­
oxet ine, and 14-week w a i t i n g l ist) 
Variable CBT Paroxetine Waiting list Total Test statistic ρ 
(π = 20) (π=17) ( n = 1 2 ) (η = 49) 
Age M (SD) 
Duration of anxiety (yrs) M (5D) 
Female η (%) 
Living alone* η (%) 
Education η (%) 
Low η (%) 
Medium η (%) 
High η (%) 
PD with agoraphobia η (%) 
Comorbid psychiatric diagnosis** 
π (%) 
Comorbid somatic disorder*** 
n(%) 
Oxazepam 10 mg (or equivalent) 
«(%) 
ACQ (5D) 
MI-Α (SD) 
SCL-90 (SD) 
69.6 (5.0) 
12.3(14.2) 
11 (55.0) 
10(50 0) 
6 (30.0) 
9 (45 0) 
5 (25 0) 
20(100) 
2(10.0) 
12(60.0) 
6 (30.0) 
1.6(0.5) 
2.4(1.0) 
168.4(48.6) 
68.8 (4.3) 
12.3(17.5) 
10(58.8) 
6(35.3) 
6(35.3) 
6(35.3) 
5 (29.4) 
16(94.1) 
8(47.1) 
13(76.5) 
7(41 2) 
1.8 (0.4) 
2.3 (0.8) 
166.8(27.4) 
66.8 (4 2) 
18.4(16 5) 
9(75.0) 
3(25.0) 
5(41.7) 
4(33.3) 
3(25.0) 
12(100) 
4(33.3) 
8(66.7) 
9(75.0) 
1.7(0.4) 
2.72(1.2) 
68.6 (4.6) F(2,46) = 1.38 
13.8(15.8) F(2/46) = .662 
30(61.2) 
19(38.8) 
17(34.7) 
19(38.8) 
13(26.5) 
48 (97.9) 
14(28.6) 
33 (67.3) 
22 (44.9) 
1.7(0.5) 
2.4(1.0. 
X 2 (2)=1.33 
X2(2) = 2.11 
X2(8) = 4.54 
X 2 (2)=1.92 
X2(2) = 6.36 
χ
ι(2) = 1.14 
X2(2) = 6.28 
F(2,46) = .34 
F(2,44) = .71 
1 71.10 (43 2) 168.4 (39 8) F(2,43) = .04 
26 
.52 
.51: 
.34' 
.81 
.38 
.04 
.57 
.04 
.68 
.50 
.97 
* widow/widower, divorced, never married 
** anxiety disorder, depression and/or somatoform disorder 
*** mostly cardiovascular diseases (n = 23) or chronic obstructive pulmonary diseases (n = 5) 
PD = Panic Disorder; ACQ = Agoraphobic Cognitions Questionnaire; BDI = Beck Depression Inventory; Ml-A 
= Mobility Inventory Avoidance scale; SCL-90 = Symptom Checklist 
comorbidity (in favour of the paroxetine condition), there were no significant between-
group differences on the SCL-90 sum scores or any of the outcome measures reflecting 
the severity of the underlying psychiatric diagnoses. No between-group differences were 
found for patient demographics. 
Five patients (10.2%) failed to complete the 14-week treatment protocol: three dropped 
out in the paroxetine condition (side effects, η = 1; protocol violation, η = 1; broken hip, 
η = 1), one in the CBT condition (protocol violation), and one in the WL condition 
(severe somatic illness). Another three patients (6.1%), two treated with paroxetine and 
one with CBT, refused further participation in the follow-up assessment at week 26 
(see Figure 4-1). In the CBT condition eight patients terminated treatment immediately 
after succesfully completing the protocolized 14 weekly sessions and consulting their 
therapist. In 12 patients CBT was tapered off in 4.2 (SD = 1.8) sessions on average. All 11 
patients assigned to the waiting-list control condition chose CBT as their treatment of 
choice after their waiting-list period was concluded. 
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Figure 4-1. Changes in the Mobility Inventory (Ml-A) total score & Agoraphobic Cognitions Ques­
tionnaire (ACQ) total score 
3,5 
2,5· 
2 
1,5 
σ 
υ < 
2,4 
2,2 
1,4 
1,4 
1,4 
1,4 
1,2 
8 14 
Time (Weeks) 
• Par • CBT -*- WL 
26 8 14 
Time (Weeks) 
Par • CBT -*- WL 
26 
Abbreviations PAR = paroxetine, CBT = cognitive-behavioural therapy, WL = waiting list 
Compared to the ACQ scores obtained in the WL condition, the 8- and 14-week scores 
were significantly improved both for the paroxetine (t (44) = -2 32, ρ < 05 and t (44) 
= -2 43, ρ < 05, respectively) and the CBT condition (t (42) = -2 14, ρ < 05 and t (43) = 
-2 02, ρ = 05 respectively), which also held for the MI-Α scores with t (48) = -2 50, ρ < 
05 and ί (46) = -2 56, ρ < 05 for the paroxetine and ί (47) = -2 23, ρ < 05 and £ (45) = 
-3 36, ρ < 01 for the CBT group Furthermore, Table 4-2 and Figure 4-1 show that the 
improvements achieved with CBT and paroxetine were sustained (and actually further 
slightly improved) at the 26-week follow-up Both the baseline corrected Cohen's ds for 
between-group effects (compared to the WL condition) as the Cohen's ds for within-
group effects for the primary outcomes (ACQ, MI-Α) were moderate-to-large for both 
treatment arms compared to the WL condition Furthermore, a clinically relevant 
improvement was found for 7/14 (50%) paroxetine treated patients, for 9/18 (50%) CBT 
treated patients and for 1/10 (9%) patients assigned to the waiting-list control condition 
(χ2 (2) = 5 7, ρ = 057) (Table 4-2) 
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Table 4-2. Mean scores and standard deviations for all outcome measures at weeks 0 to 26 and treat­
ment versus waiting-list effect sizes at week 14 per condition 
Baseline End of 
treatment 
Follow-up 
Within-group Between-
Cohen's d group 
Cohen's d 
Condition WeekO WeekB Week 14 Week 26 Week 14 Week 26 Week 14 
Paroxetine 
ACQ, mean (sd) 1.8 (0 4) 1.5 (0.4) 1.4 (0.4) 
MI-Α, mean (sd) 2.3(0.8) 1.9(0.8) 1.9 (0.7) 
SCL-90, mean (sd) 166.8(27.4) 145.7(28.6) 135.9(24.8) 
CBT 
ACQ, mean (sd) 1.6 (0.5) 1.6 (0.4) 1.4 (0.4) 
MI-Α, mean (sd) 2.4 (1.0) 2.0 (0.9) 1.7 (0.9) 
SCL-90, mean (sd) 168.4(48.6) 159.6(42.6) 145.4 (32.8) 143.4(32.7) 
Waiting list 
ACQ, mean (sd) 1.7(0 4) 1.9(0.6) 1.7(0.6) 
Ml,mean(sd) 2.7(1.2) 2.8(1.1) 2 7(1.2) 
SCL-90, mean (sd) 171.1(43.2) 176.6(49.3) 169.7(52.0) 
1.3(0.3) 
1.8(1.0) 
133.1 (29.0) 
1.3(0.4) 
1.7(0.8) 
1.0 
0.5 
1.2 
0.4 
0.7 
0.6 
0 
0 
0 
1.4 
0.6 
1.2 
0.7 
0.8 
0.6 
0.9 
0.4 
0.8 
0.4 
0.7 
0 5 
Abbreviations: ACQ = Agoraphobic Cognitions Questionnaire, Ml-A = Mobility Inventory Avoidance scale, 
SCL-90 = Symptom Checklist. 
The two treatments also showed better results on the secondary outcome measures 
relative to the WL scores: a significant change was found for the SCL-90 in the paroxetine 
condition at week 14 (£ (45) = -2.18, ρ < .05) but the change in the CBT condition did not 
reach significance (t (44) = -2.00, ρ = .052) 
With the mixed-model procedure yielding p-values ranging between .54 and .97, the 
post-hoc comparisons of the 14- and 26-week outcome effects of both active treatments 
did not reveal any statistically significant differences for any of the measures 
Because fluctuations in the frequency of the self-reported panic attacks were large 
across all measurements - probably due to variations in avoidance behaviour or recall 
bias - we used, in line with previous research (Kampman, Keijsers, Hoogduin & 
Hendriks, 2002) the proportion of patients that had not experienced any panic attacks 
the week prior to the relevant assessment as a qualitative measure to evaluate treatment 
efficacy and defined it as the panic-free ratio (Figure 4-1). At week 14 the panic-free ratio 
in the paroxetine condition had increased significantly from 23.5% (n = 4) to 86% (n = 
12; £ = -2.83, ρ < .05), which improvement was sustained at week 26 (83%, π = 10 (t = 
-2 45, ρ < .05). Although not significantly, in the CBT condition the baseline-to-14-week 
ratio had risen from 55% (n = 11) to 72% (n = 13; Τ = -1.41, ρ = .16) and had improved 
further at follow-up (78%, η = 14; t = -1.89, ρ = .06). The panic-free ratio for the WL 
showed no change (baseline 42% (n = 5); 14 weeks: 46% (n = 5); t = 0, ρ = 1.0). Both 
paroxetine and CBT were well tolerated as only four patients withdrew from treatment 
due to intolerance. 
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Entering oxazepam or equivalent agent as a fixed factor in the mixed-model analyses did 
not show any significant effect of benzodiazepine use. Nor did the results change when 
correcting for the number of psychiatric comorbid conditions at baseline. 
4.4 Discussion 
Main findings 
The results of our study, the first RCT to test two treatment approaches for late-life 
panic disorders with or without agoraphobia, supported our hypotheses that both 
protocolized CBT and paroxetine are effective and well-tolerated treatments for 
elderly patients. Previous RCTs that primarily studied patients with generalized late-
life anxiety disorders reported attrition rates between 20% and 30% (Hendriks et al, 
2008a; Pinquart & Duberstein, 2007). With only three patients (17.6%) prematurely 
ending pharmacotherapy because of intolerance and one (5%) abandoning CBT because 
of significant stress caused by daily home work and exposure exercises within the first 
14 weeks of the trial, our study showed both treatments to be well tolerated. Scores 
for phobic avoidance (Ml) and catastrophic agoraphobic cognitions (ACQ), indicative 
of PD seventy, showed statistically significant reductions in both treatment conditions. 
As benzodiazepines were only allowed in one prescribed low fixed dose throughout the 
study, the observed reductions in symptoms cannot be attributed to these agents. Further, 
with respect to the WL condition, the between-group effect sizes were satisfactory for 
both paroxetine and CBT, ranging from 0.6 to 0.9. These results are consistent with those 
of previous studies examining the efficacy of SSRls or CBT for late-life anxiety disorders 
(Hendriks et al., 2008a; Pinquart & Duberstein, 2007) and are comparable to those 
found (i.e. 0.7) in a recent meta-analysis in younger PD(A) populations (Haby, Donnelly, 
Corry & Vos, 2006) 
The panic-free ratio improved significantly in the patients receiving paroxetine 
but not in the patients receiving CBT It is important, however, to emphasize that in 
both treatment conditions almost 80% of the patients were panic-free at the 26-week 
follow-up. Both treatments also revealed reduced general psychopalhological symptoms 
(SCL), with paroxetine showing a significant effect and CBT a trend (p = .052) towards 
significance. 
Strengths and limitations 
We used a protocol-based and guideline-recommended CBT in an individual format that 
was specifically targeted at PD(A) although not expressly adapted to elderly patients. 
There is abundant empirical evidence supporting PDA-specific, individual CBT (Mitte, 
2005a). 
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Although it is assumed that age-specific adaptations may help increase the efficacy of CBT 
for late-life anxiety (Stanley et al., 2003a) here, also, empirical evidence is scarce. Two, 
albeit small-scale trials testing dedicated CBTs for generalized anxiety disorders indeed 
showed superior outcomes. A pilot study found primary-care CBT that was specifically 
adapted to older patients to be more effective in improving worry and depression than 
treatment as usual (Stanley et al., 2003b) and another trial that directly compared a 
standard and an enhanced, age-adapted CBT also concluded that the latter approach 
seemed to increase treatment efficacy (Mohlman et al., 2003). 
Several critical remarks about our study are warranted. Firstly, small group sizes 
cannot prevent between-patient differences from being equally divided across the various 
groups. However, correcting for these differences did not change our results. 
Secondly, the self-report instruments we used to evaluate treatment effects in our 
PD(A) patients have been validated in younger populations (18-65 yrs) only, which 
may imply that the scales are less valid for older patients, such as our 60-plus cohort. 
Validation studies in 60-plus samples are scarce, but the available results showed few 
objections for their use in this age range (Fuentes & Cox, 2000; Crittendon & Hopko, 
2006) Nevertheless, the findings for anxiety cognitions in our elderly PD(A) patients 
are modest. The only study comparing the ACQ in older and younger patients found 
lower baseline scores for the older patients (Sheikh et al., 2004a). In fact, the scale may 
be less suitable for assessing anxiety cognitions in elderly PD(A) patients. However, 
validated instruments for assessing agoraphobic cognitions in elderly PD(A) patients 
are not available yel. Observer-rated instruments like the Panic Disorder Severity Scale 
(PDSS; Shear, Rucci, Williams, Frank, Grochocinski, Vander et al., 2001) or the Panic 
Agoraphobia Scale (PAS; Bandelow, Broocks, Pekrun, George, Meyer, Pralle el al., 2000) 
may be more appropriate but, until now, neither were examined in elderly PD(A) patients. 
Thirdly, we did not repeat formal diagnostic procedures post-treatment. Therefore, we 
are not able to report how many patients still met DSM-1V criteria of panic disorder 
post-treatment. However, in both treatment conditions half of the patients achieved a 
clinically relevant improvement, against only 9% in the control condition. 
Based on our and earlier findings and connotations and given the need for additional 
research into late-life PD in larger cohorts, we wish to offer several recommendations 
for future research As observational instruments such as the Panic Disorder Severity 
Scale (Shear et al., 2001) and the Panic Agoraphobia Scale (Bandelow et al., 2000) are 
now available in various languages, we recommend them as the preferred tools or advise 
their use to complement other (self-report) scales to establish treatment efficacy in this 
population. Secondly, as elderly patients tend to be averse to the use of antidepressants 
(Givens et al., 2006) and prefer behavioural and cognitive therapies (Wetherell et al., 
2004b), research into how treatments can best be tailored to their needs and preferences 
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is indispensable. Finally, because we found no relevant differences in the effects of 
antidepressant treatment and CBT, further efficacy studies are required to establish 
which of the two treatment arms is most effective, especially when CBT is tailored to 
60-plus patients. 
In conclusion, despite its drawbacks and pending corroboration, but comparable to earlier 
reports on younger adults, the present study suggests that both the SSRI paroxetine and 
CBT are effective in the treatment of PD in elderly patients. 
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Agoraphobic cognitions in 
old and young patients with 
panic disorder 
A revision of this chapter has been resubmitted for publication to the American 
Journal of Geriatric Psychiatry: 
Hendriks, GJ., Keijsers, G.PJ., Kampman , M., Oude Voshaar, R.C. & Hoogduin, C.A.L 
Agoraphobic cognitions in old and young patients with panic disorder. 
Agoraphobic cognilions 
5.1 Introduction 
It has been suggested that elderly people tend to report less severe cognitive anxiety 
than younger individuals (Brenes, 2006; Crittendon & Hopko, 2006; Goldberg el 
al., 2003), which may be attributable to a natural, age-related decrease in emotional 
responsiveness, i.e., a dampening of affective reactivity (Gross et al., 1997; Lau et al., 
2001). If true, one would expect elderly respondents to have lower scores on self-report 
instruments measuring the severity of cognitions related to the disorder under study. 
To date, only one study directly compared the frequency or severity of agoraphobic 
cognitions of younger and older adults diagnosed with panic disorder (PD) and it indeed 
showed the older patients to have significantly fewer agoraphobic cognitions (Sheikh et 
al., 2004a). These findings have to be interpreted with caution, however, as most self-
report instruments were developed for younger patients and might thus be less applicable 
in later life as the content of agoraphobic cognitions may change with age (Griez et al., 
2007). To substantiate this assumption, in this study we analyse age-related effects at the 
item level using the scores of PD patients on the Agoraphobic Cognitions Questionnaire 
(ACQ). 
5.2 Method 
We ran a cross-sectional analysis of the data we obtained from patients suspected of 
panic disorder with agoraphobia (PDA) that were referred to our specialized outpatient 
anxiety clinic. Exclusion criteria were the current use of an antidepressant or a primary 
psychiatric diagnosis of a psychotic, bipolar or substance use disorder, or dementia. 
A comorbid diagnosis of another anxiety disorder, depression or dysthymia was 
allowed as long as PDA was the primary diagnosis. All patients who consented to the 
present study received a baseline assessment in which a primary diagnosis of PDA was 
confirmed using the Anxiety Disorders Interview Schedule-Revised (ADIS-IV; Bouman, 
et al, 1997; DiNardo et al., 1994). The ADIS-IV was administered by independent and 
trained assessors. Subsequently, the confirmed patients completed several self-report 
instruments among which the two we analyzed for this study. 
The severity of catastrophic cognitions was assessed using the 14-item Agoraphobic 
Cognitions Questionnaire (ACQ; Chambless et al , 1984; De Beurs, 1993), with each 
item to be rated on a 5-point scale. The inventory may be scored as a total scale, or 
according to its two subscales Loss of Control and Physical Concerns, each comprising 
7 items. The subscale scores or total score are calculated by averaging the responses on 
the individual items composing that score. The ACQ is well validated in both the English 
and the Dutch version, yielding good test-retest reliability, high internal consistencies, 
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and reasonable concurrent validity (De Beurs, 1993; Chambless et al., 1984). 
The Mobility Inventory Avoidance scale (Ml-A; Chambless et al., 1985) was used to 
assess agoraphobic avoidance as a proxy of PDA severity (Basoglu et al., 1994a; De Beurs 
et al., 1993). 
Statistical differences between the two age groups (see below) were analyzed using 
student t-tests (ACQ total and subscale scores) and the item comparisons were performed 
using a Mann-Whitney U-test. Effects were tested two-sided. In order to correct for 
multiple testing, a Bonferroni correction was applied. Results were considered significant 
at ρ < .004 ( 05 / 14 items), p-values between .05 and .004 are considered to reflect a 
potentially interesting trend. The SPSS 16.0 statistical analysis package was used (SPSS 
ine, 2008). 
5.3 Results 
A total of 205 confirmed PDA patients were included and evaluated in two age groups 
157 patients in the 18-to-60-year group (mean age: 35 years, SD:10) and 48 patients in 
the 60-plus group (mean age: 68 years; SD: 5). The groups did not differ with respect to 
sex (male: 36% vs. 35%; χ2 <. 01, df = 1, ρ = .98) or duration of illness (DOI: 12.1 (15.6) 
vs. 7.7 (9.3) years; ί = -.73, df = 202, ρ = .47). Please note that the i-test was performed 
after log transformation of the DOI in order to normalize the skewed distribution of this 
variable. PDA severity also did not differ between the age groups given that their levels 
of MI agoraphobic avoidance were similar (mean Ml score 2.4; SD 0.9) vs. 2.4 (0.8); ί = 
-.028, df= 202, ρ = .78). 
The mean (SD) ACQ total score was significantly lower in the older patients (1.6 (0.5) 
vs. 2.1 (0.6); t = 5 7, df = 203, ρ < .001). Similar results were found for the Loss of Control 
subscale (1.6 (0.6) vs. 2.2 (0.9); t = 4.3, df = 203, ρ < .001) and Physical Concerns subscale 
(1.6 (0.5) vs. 2.1 (0.6); ί = 4.5, df = 203, ρ < .001). 
Figure 5-1 presents the mean scores for the 14 ACQ items in order of increasing severity 
as observed in the younger age group. Apart from scoring numerically lower on the total 
scores, the item order for the 60-plus patients also differed from the order we found for the 
younger respondents, with the items fear of screaming, going crazy, and acting foolishly 
being less prevalent in the late-life PDA group. Five items (fear of going crazy, acting 
foolishly, passing out, losing control, and brain tumours) showed a clear, statistically 
significant age-related difference (p < .004), six items (fear of throwing up, choking, 
hurting someone, getting a stroke, screaming, babbling) a trend towards significance 
(.004 < ρ < .05), while three items (fear of a heart attack, going blind, and being paralyzed 
by fear) showed no statistical difference (p > .05). 
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Figure 5-1. ACQ-uem scores in order of increasing severity in elderly and younger patients 
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5.4 Discussion 
Comparing younger and older patients with agoraphobic panic disorder, we found that 
the seventy of agoraphobic cognitions in the 60-plus patients was significantly lower than 
the levels obtained in their younger counterparts, whereas MI agoraphobic avoidance, 
the major measure of PDA seventy, did not differ between the two age groups. The only 
study to also directly compare the ACQ in older and younger PDA patients had found 
similar, lower scores in the older patients (Sheikh et al., 2004a). 
Comparing the age groups at the ACQ item level, we found only three items that were 
scored comparably by the younger and older respondents, i.e., the classic anxiogemc 
cognition of getting a heart attack and the cognitions of fear of becoming blind (with 
low prevalence rates in both age groups, probably reflecting a floor effect) and becoming 
paralyzed. 
But what are the underlying mechanisms explaining these age-related differences? 
Firstly, the largest differences occurred in the fear of losing control, going crazy, and 
acting foolishly items, which may indicate an age-related decrease of the lesser 'loss of 
control' cognitions. In view of the outcomes of a carbon dioxide challenge test in healthy 
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controls, Griez et al. (2007) found it plausible that thoughts of losing control during 
panic attacks decline with age. Secondly, the fact that the catastrophic cognitions relating 
to physical concerns (which may become much more realistic in later life) were also less 
severe in the 60-plus group suggests that elderly patients are indeed less inclined to 
interpret physical symptoms as catastrophic. Both explanations hence seem to suggest 
that PDA in later life is less severe in its manifestations than it is in younger adults. 
Yet, agoraphobic avoidance, the most important indicator of PDA severity, did not 
differ between our two age groups, which would point to a third mechanism: as the 
agoraphobic avoidance had run a longer, chronic course in the 60-plus patients, an age-
related change in other agoraphobic cognitions seems more likely. However, we cannot 
substantiate this postulation as we did not perform a qualitative analysis of cognitions 
that are not incorporated in the ACQ and that might have been more prevalent in 
the older patients and thus significantly more related to their agoraphobic avoidance 
patterns Such an analysis would be especially relevant for the development of an age-
sensitive instrument gauging agoraphobic cognitions. Based on our current and earlier 
findings, and until new, age-sensitive tools are devised, we would recommend health 
professionals to rely on the severity of agoraphobic avoidance when assessing the extent 
of agoraphobic panic disorder in older adults. 
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A comparison with younger palienls 
6.1 Introduction 
Even though 2.8% of the elderly population suffer from panic disorder with or without 
agoraphobia (PD(A); Grant, Hasin, Stinson, Dwason, Goldstein, Smith et al., 2006), few 
treatment studies of PD(A) in later life are available. This is especially worrying as late-
hfe anxiety disorders are associated with elevated health-care consumption, lowered 
quality of life and more (severe) disability (Beekman et al., 2000; De Beurs et al., 1999; 
Schuurmans et al., 2005; Wetherell et al., 2004b). Cognitive-behavioural therapy (CBT) 
and antidepressants have empirically been well established and are commonly effective 
treatments for PD(A) (Furukawa et al., 2006; Mitte, 2005a), but belonging to an older 
age group seriously decreases the likelihood of actually receiving these recommended 
treatments (Wang et al., 2005a) In fact, less than 10% of the elderly suffering from an 
anxiety disorder is offered psychological treatment or is prescribed an antidepressant 
(De Beurs et al., 1999) 
The underireatment of late-hfe anxiety disorders may be explained by the low referral 
rate for targeted treatment, which is three times lower than the rate for late-life major 
depression (17% versus 55%; Ettner &r Hermann, 1997). Also the assumption that in the 
elderly anxiety disorders constitute only a minor health problem that does not require 
(explicit) treatment may hinder appropriate referral and treatment (Wetherell et al., 
2005a). More specifically, in clinical practice many therapists consider manualized CBT 
inappropriate, being convinced that patients need personalized treatment plans adapted 
to their individual needs, with which stance they undermine CBT in specific target groups 
like elderly PD patients. Empirical evidence for these assumptions, however, is hardly 
available (Wilson, 1996). As older patients generally prefer psychological treatment over 
drug therapy (Givens et al., 2006) and physicians generally fear adverse drug events in 
elderly people, further research into the effects of CBT in late-hfe anxiety disorders is 
needed. 
The only randomized controlled trial (RCT) conducted with 25 patients with later life 
PD(A) showed that both alprazolam and Imipramine were superior to a placebo (Sheikh <Sr 
Swales, 1999). Unfortunately, for CBT no controlled comparisons are available. Another 
small-scale but uncontrolled trial with 20 elderly PD(A) patients suggested that CBT was 
efficacious (Swales, Solfvin & Sheikh, 1996) but, besides the study's uncontrolled nature 
and small sample size, interpretation of the results is also hampered by the high dropout 
rate (25%) and the lack of control for concurrent psychotropic drug use. 
Despite the lack of evidence proving the efficacy of treatments of late-life PD(A), 
two recent meta-analyses of mixed patient groups suffering from later life anxiety 
disorders clearly showed both CBT and antidepressants to be effective (Hendriks et al., 
2008a; Pinquart & Duberstein, 2007), with the Pinquart and Duberstein study showing 
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antidepressants to be more effective than CBT In younger and middle-aged adults, 
however, CBT was found to be more effective than antidepressants in the acute phase of 
PD(A) (Furukawa et al, 2006) Together, the results to date suggest a lower treatment 
efficacy for CBT relative to antidepressants in later life PD(A) Again, it needs to be 
noted that the majority of the available empirical and controlled studies was limited to 
generalized or mixed anxiety disorders while the few trials into PD comprised small 
numbers of patients 
As far as we are aware, only one study directly compared CBT outcomes in younger 
and older patients with mixed anxiety disorders and depression (Walker and Clarke, 
2001) showing similar effects in both age groups This study was, however, also limited 
by its small sample size (n = 32) as well as the heterogeneity of the patient group 
Using a quasi-experimental design, in the current study we directly compare the 
effectiveness of CBT for PD(A) in younger and older patients The main objectives were 
1) to examine the differential effects of manualized CBT for PD(A) as developed by 
Craske and Barlow (Craske & Barlow, 1993, Craske et al, 1994) in patients under and 
over the age of 60 years and 2) to examine age-related differences in feasibility as defined 
by dropout rates 
6.2 Method 
Design and patients 
The present report describes an naturalistic, age-stratified treatment study of 172 patients 
diagnosed with PD(A) who were referred to our outpatient anxiety clinic (Forum GGz-
Nijmegen, the Netherlands) Participants in the 18-to-60-year age bracket were recruited 
between January 1997 and December 2001 as part of a stepwise PD treatment study 
in which all patients first received protocohzed CBT and, in case of non-response, 
subsequent random allocation to drug therapy (Kampman et al , 2002) AU 60-plus 
participants were recruited between January 1999 and December 2005 as part of an RCT 
comparing protocohzed CBT, paroxetine, and a waiting-list control condition (Hendriks, 
Keijsers, Kampman, Oude Voshaar, Verbraak, Broekman et al , submitted) Of this latter 
study, we included those clients that were directly randomly allocated to CBT and those 
that had been offered CBT because of an express preference The recruitment, assessment 
and treatment procedures were identical for both studies and performed by the same 
research group and psychotherapists (see below) 
We approached all the participants whose diagnosis of PD(A) had been confirmed 
upon intake and who did not meet any of the studies' exclusion criteria, which were 
1) severe somatic illnesses that could interfere with the CBT, 2) current use of an 
76 
A companson with younger palients 
antidepressant in an adequate dosage, 3) current and adequate psychological treatment, 
and 4) the presence of a primary psychiatric diagnosis of a psychotic, a bipolar, or a 
substance use disorder, and dementia. A comorbid diagnosis of other anxiety disorders, 
depression or dysthymia was allowed as long as PD(A) was the primary diagnosis. 
Those patients that consented to the present study received a baseline assessment in 
which the primary diagnosis of PD(A) was again confirmed using the Anxiety Disorders 
Interview Schedule-Revised (ADIS-1V; Bouman, et al., 1997; DiNardo et al., 1994), which 
was administered by independently trained assessors who were not involved in CBT 
delivery. Subsequently, the confirmed patients completed various questionnaires (see 
below), after which they started the 14-week treatment program. Following treatment 
completion they took an outcome assessment at week 15 using similar questionnaires. 
6.3 Treatment protocol 
Treatment was delivered individually and consisted of 14 weekly CBT sessions of 
fifty minutes each. Patients using benzodiazepines were tapered off before the start of 
the treatment under medical supervision or adhered to a fixed daily dose during the 
treatment. 
The CBT was protocol-based and followed the Dutch version (Kampman & Keijsers, 
1997) in accordance with the protocol of Craske and Barlow (1993) and compromised the 
following five components: 1) the provision of 'psycho-education' about panic, anxiety 
and avoidance behaviour, including the treatment rationale, 2) teaching relaxation 
techniques (applied relaxation), 3) interoceptive exposure, 4) cognitive therapy, and 5) 
exposure in vivo. 
Therapists were experienced psychologists (MSc level) who had been extensively 
trained in the program Throughout the study period they were weekly supervised 
by senior therapists certified as supervisors by the Dutch Association for Behavioural 
and Cognitive Therapy to safeguard adequate application of the CBT techniques and 
adherence to the manual. Per session the therapists recorded which CBT components 
had been addressed and discussed these and any deviations from the manual with their 
supervisor. Adaptations to the intervention to meet a patient's specific circumstances 
were allowed if they were not in conflict with the manual. 
6.4 Outcome measures 
The primary outcome measure was PD(A) seventy, defined as the extent of a patient's 
agoraphobic cognitions and agoraphobic avoidance. Agoraphobic avoidance was measured 
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with the Dutch version of the Mobility Inventory Avoidance scale (MI-Α, Chambless et 
al , 1985) The MI-A has three subscales avoidance when alone (MI-AAL), avoidance 
when accompanied (MI-AAC), and frequency of panic attacks (MI-PF) The latter 
subscale offers a definition of panic attacks as formulated in the DSM-IV, after which the 
respondent is asked to indicate the number of actual panic attacks during the past seven 
days As the frequency of panic attacks is largely dependent on the level of agoraphobic 
avoidance and agoraphobic avoidance is a better predictor of treatment effects than the 
frequencies of panic attacks (De Beurs é tal , 1995, Basoglu, Marks, Swinson, Noshirvani, 
O'Sulhvan & Kuch, 1994b), we opted to use the total mean scores on the Ml for our 
analyses (Kampman et al , 2002) The severity of agoraphobic cognitions was measured 
by the Dutch adaptation of the Agoraphobic Cognitions Questionnaire (ACQ, Chambless 
et al , 1984, De Beurs, 1993), a self-report questionnaire comprising 14 items to be rated 
on a 5-point scale The Ml-A, the ACQ, and their Dutch adaptations are frequently used 
instruments in PD treatment outcome studies and have good test-retest reliability, high 
internal consistencies and reasonable concurrent validity (De Beurs, 1993, Chambless et 
al , 1984, Chambless et al , 1985) 
Depressive symptoms and general psychopathology were evaluated as secondary 
outcome measures Depressive symptoms were assessed using the 20-item Beck 
Depression Inventory (BDI, Beck, 1988, Bouman, Luteijn & Albersnagel, 1985) The 
BDI has a sufficient and reasonable internal consistency and test-retest reliability and a 
good construct and discriminative validity General psychopathology was assessed with 
the 90-item Symptom Checklist (SCL-90), a self-report questionnaire divided into eight 
subscales (Derogatis et al , 1976, Arrindell & Ettema, 1986) The total sum score is a 
good reflection of the level of general psychopathological distress and as such included 
in our analyses The two scales and their Dutch adaptations are frequently used outcome 
measures and have good psychometric properties (Arrindell &r Ettema, 1986, Beck & 
Steer, 1984, Beck, 1988, Bouman et al , 1985, Derogatis et al 1976) 
The feasibility was evaluated by a proxy, namely the proportion of patients that 
withdrew during the 14-week treatment phase 
6.5 Statistical analysis 
Statistical differences between the two age groups at baseline were analyzed using chi-
square tests or student i-tests To analyze treatment effects and potential between-group 
differences an overall 2 x 2 (Group < 60 years, & 60 years χ Time pre-treatment, post-
treatment) MANOVA with repeated measures was performed for all outcome measures 
separately Dependent variables were agoraphobic avoidance (MI-Α), agoraphobic 
cognitions (ACQ), general psychopathology (SCL-90), and depressive symptoms (BDI) 
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All analyses were corrected for gender, duration of illness and use of benzodiazepines 
and conducted both on a completer basis and an intent-to-treat basis, with the last 
observation carried forward (LOCF) in case of missing values at outcome, which latter 
analysis was considered to be the main analysis. 
The SPSS 16.0 statistical analysis package was used (SPSS ine, 2008) Effects were 
tested two-sided and are reported as significant at a level of ρ < .05. 
6.6 Results 
Patient recruitment 
A total of 208 patients received a diagnosis of PD(A), of which 189 gave their informed 
consent for participation. More specifically, in the 18-to-60 year age bracket 19 patients 
refused to participate, while all patients over 60 years consented to take part in the study. 
Two patients were subsequently excluded as their PDA diagnoses were not confirmed by 
the AD1S-1V (social phobia, η = 1; specific phobia, η = 1). As the ADIS-1V confirmed the 
diagnoses of PDA of all 60-plus patients, we excluded 15 of the younger patients with 
a diagnosis of panic disorder without agoraphobia to increase the comparability of the 
two age groups. The final study sample accordingly comprised 172 patients of whom 141 
were under and 31 over 60 years of age. 
Baseline comparison 
Table 6-1 presents the demographic variables and diagnostic information for both age 
groups. The 60-plus patients were more frequently married or widowed (χ2 = 47.4, df = 3, 
ρ <.001) and had a lower prevalence of panic attacks in the week preceding the baseline 
test (χ2 = 5.07, df = 1, ρ = .024) compared to their younger counterparts. 
Psychiatric comorbidity was common in both groups. In the under-60s group 46/141 
(33%) patients were diagnosed with one (n = 39) or two (n = 7) comorbid disorders: 31 
(22%) with an anxiety disorder, 14 (10%) with major depression or dysthymia, and 8 (6%) 
with a somatoform disorder. In the 60-plus group 7/31 (23%) patients were diagnosed 
with one (n = 5) or two (n = 2) comorbid disorders: 3 (10%) with an anxiety disorder, 2 
(6%) with major depression or dysthymia, 2 (6%) patients with a somatoform disorder, 
and 2 (6%) other. The higher prevalence of comorbid anxiety disorders in the younger 
age group did not reach statistical significance (χ2 = 2.43, df = 1, ρ = 0.12) compared to 
the 60-plus patients and could be explained by the presence of 15 patients (11%) with a 
specific phobia, which phobias did not occur in the 60-plus group. 
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Table 6-1. Patient characteristics at baseline (n = 172) for the two age groups 
Variables 
Age (yrs) 
Duration of anxiety (yrs) 
Female 
Marital status: 
Married/living together 
Divorced 
Widow/widower 
Never married 
Living alone 
Education 
Low 
Medium 
High 
Panic attacks previous week 
Benzodiazepines 
M (SD) 
M (SD) 
n ( % ) 
η ( % ) 
π(%) 
n ( % ) 
n ( % ) 
n<%) 
n ( % ) 
n ( % ) 
n ( % ) 
n ( % ) 
/ 7 ( % ) 
Patients 
aged 18-60 years 
(π = 141) 
35 2(10.3) 
7.8 (9.4) 
93 (66) 
66 (47) 
6 ( 4 ) 
0 
69 (49) 
44(31) 
40 (28) 
53 (38) 
48 (34) 
102(72) 
43(31) 
Patients 
aged £60 years 
( 0 = 3 1 ) 
67.9 (5.0) 
12.0(14.7) 
21 (68) 
21 (68) 
2(7) 
7(23) 
1(3) 
11(36) 
14(45) 
10(32) 
7(23) 
16(52) 
8(26) 
Statistics 
t = -17.2, df = 26.1,p<.001 
f =-2.0, d f = 3 5 . 6 , p = .14 
χ
2
 = 0 85, df = 1, ρ = .84 
χ
2
 = 47.4, df = 3, ρ < 001 
X2 = 0 . 2 1 , d f = 1 , p = . 6 4 
χ
2
 = 3.52, df = 2, ρ = .1 7 
χ
2
 = 5.07, d f = 1 , p = .024 
χ
2
 = 0.27, d f = l , p = . 6 1 
Treatment feasibility 
The overall dropout rate was 18% (n = 31). Twenty-nine patients in the under-60s group 
(21%) did not complete the full treatment, while only two 60-plus patients (7%) dropped 
out. Although dropout was substantially lower in the 60-plus group, the difference was 
not statistically significant (χ2 = 3.43, df = 1, ρ = 0.06). Availability of post-treatment 
outcomes was related to dropout as all patients that withdrew from treatment (n = 31) 
also did not complete the post-treatment assessment, whereas in the completers (n = 141) 
only two patients did not take the final assessment (1%). 
Treatment effects 
Table 6-2 presents the means and standard deviations of all baseline and post-treatment 
outcome measures including the effect size expressed as Cohen's d values. The overall 
scores of the two groups differed both with respect to the ACQ (Completers: F = 19.5, df 
= 132,1, ρ < .001; LOCF: F = 24.2, df = 165,1, ρ < 001) and the BDI (Completers: F = 27.5, 
df = 133,1, ρ < .001; LOCF: F = 32.6, df = 166,1, ρ < .001), with significantly lower pre- and 
post-treatment scores on the ACQ and higher scores on the BDI for the older patients. 
The MI-Α agoraphobic avoidance scores yielded a significant main effect of Time 
(Completers: F = 8.80, df = 133,1, ρ = .004; LOCF: F = 6.27, df = 166,1, ρ = .013) indicating 
improvement at follow-up in both age groups. This effect was significantly larger for the 
60-plus group as is reflected in the significant Time by Age interaction (Completers: 
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Table 6-2. Pre- and post-treatment outcomes and effect sizes for the two age groups 
Condition 
Patients aged • 
ACQ 
Ml-A 
SCL-90 
BDI 
Patients aged : 
ACQ 
Ml-A 
SCL-90 
BDI 
Abbreviations: 
Pre-treatment 
Mean (SD) 
<60 years (n = 141) 
2.2 (0 6) 
2.5 (0.8) 
184.6(49.3) 
13.5(7.6) 
£60 years (n = 31) 
1.6(0.5) 
2.5(1.0) 
167.4(48.0) 
13.1 (8.9) 
Post-treatment 
Mean (SD) 
Completers 
1.9 (0 6) 
2.0 (0.8) 
147.7(40.4) 
8.7 (6.2) 
1.4 (0.4) 
1.8 (0.9) 
142.0(33.0) 
10.2(7 1) 
LOCF 
1 9 (0.6) 
2.1 (0.8) 
156.3(44.3) 
9.7(7.0) 
1.4(0.4) 
1 8 (0.8) 
142 3(31.4) 
10 3(7.0) 
ACQ = Agoraphobic Cognitions Questionnaire, BDI = Beck 1 
Cohen's d 
Completers 
0.5 
0.6 
0.8 
0.7 
0.4 
0 7 
0.6 
0.4 
Depression Inventory, 
LOCF 
0.5 
0 5 
0.6 
0.5 
0.4 
0.8 
0.6 
0.3 
LOCF = Last 
Observation Carried Forward, Ml-A = Mobility Inventory Avoidance scale, SCL-90 = Symptom 
Checklist. 
F = 4.86, df = 133,1, ρ = .029; LOCF: F = (166,1), df = 166,1, ρ = .006). 
For the other primary outcome parameter, ACQ agoraphobic cognitions, time 
effects achieved significance in the completers analyses, but not in the LOCF analyses 
(Completers: F = 4.33, df = 132,1, ρ = .039; LOCF: F = 3.54; df = 165,1, ρ = .062). Similar 
results were found for the secondary outcome measures BDI depressive symptoms 
(Completers: F = 4.86, df = 132,1, ρ = .03; LOCF: F = 2.78, df = 167,1, ρ = .10) and SCL-90 
general psychopathology (Completers: F = 6.51; df = 126,1; ρ = 012; LOCF' F = 3.32, df 
= 167,1, ρ = .07). In none of these analyses significant interactions with age were found 
(range p-values .15 through .78) Taken together, the results demonstrate that CBT had 
significantly improved all outcomes in both age groups with a larger improvement in 
agoraphobic avoidance in the 60-plus group compared to the younger patients. 
The post-treatment panic-free ratio for the completers was 69% for both age groups 
(< 60s: n = 96; a 60s: η = 20), with the LOCF yielding ratios of 62% (n = 87) and 71% 
(n = 22), respectively. 
6.7 Discussion 
Main findings 
Although originally developed for and extensively tested in younger to middle-aged 
adults with panic disorder, the protocolized CBT we delivered in our study was effective 
in improving avoidance behaviour and anxiety cognitions in both the younger and the 
older participants with PDA. The intervention even resulted in a significantly stronger 
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reduction of avoidance behaviour in the 60-plus group. In contrast to what has frequently 
been suggested in the literature, we found our protocol to be as feasible in older patients 
as it was in younger patients, with a trend towards superior feasibility in the older 
patients 
Comparison with the literature 
Baseline differences - Agoraphobic cognitions were significantly less severe and panic 
attacks in the week before treatment less frequent in our 60-plus patients than they were 
in their younger counterparts. Agoraphobic avoidance, the most important measure 
of disease severity, however, did not differ between the two age groups In contrast to 
our expectations, the duration of illness also failed to show any age-related differences. 
In line with previous empirical findings the prevalence of benzodiazepine usage did 
not differ between the under- and the over-60s patients (Benitez, Smith, Vasile, Rende, 
Edelen & Keller, 2008). 
Treatmenf effects - An important finding was the remarkably low dropout rate in the 
over-60s group: 6% versus 22% in the younger adults. Although the difference was 
statistically not significant, the ratio is indicative of how well our elderly patients 
tolerated the demanding and challenging aspects of the targeted CBT (e.g. the daily 
homework assignments and exposure exercises). We had decided not to make age-
specific adaptations to the treatment protocol because this could have affected the 
comparability of the treatment results of our two age groups. Although some small-scale 
studies did indicate that such modifications enhanced the efficacy of CBT for late-life 
generalized anxiety disorder (GAD) (Mohlman et al., 2003; Stanley et al., 2003b) these 
findings are preliminary. The comprehensive and methodologically more sophisticated 
study by Stanley et al. (2003a) showed comparable effect sizes as in CBT for younger 
adults with GAD. 
The effect sizes of the primary outcome measures ranged between 0.4 and 0.8, 
indicating moderate to large effects in both age groups, which is comparable to the effect 
sizes reported in recent meta-analytic reviews of PD-specific CBT for adult patients 
(Haby et al., 2006) and for CBT for GAD in older people (Pinquart & Duberstein, 2007). 
Major risk factors of later life anxiety disorders are increasing social deprivation and 
isolation, which are key determinants of the quality of life in elderly people (Beekman et 
al., 2000) The large effect size (0.8) found for avoidance behaviour in our 60-plus group 
indicates that targeted CBT helps secure a better quality of life for this older patient 
group by substantially lowering these risks. 
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Strengths and limitations 
For a proper interpretation of the current results some limitations should be taken into 
account. First, the size of our 60-plus sample was relatively small, although this was 
to be expected as PD(A) in later life tends to go largely un(der)diagnosed and un(der) 
treated (De Beurs et al., 1999). The average age in our over-60s group was 68 years, but, 
although not statistically significant, post-hoc analyses were suggestive of even better 
effects in the patients aged over 70 years. 
Secondly, we used self-report instruments to evaluate treatment outcome. Although 
studies validating self-report anxiety inventories originally developed for younger adults 
(18-65 yrs) in our age group are scarce, the available studies found no major objections for 
their use in older populations (Fuentes & Cox, 2000; Goldberg et al., 2003; Mohlman, de 
Jesus, Gorenstein, Kleber, Gorman & Papp, 2004; Crittendon & Hopko, 2006). The only 
study directly comparing the ACQ between older and younger PD patients found, similar 
to our results, lower scores for the older patients (Sheikh et al., 2004a). Furthermore, 
earlier findings of self-assessed anxiety cognitions in younger adults were inconsistent. 
The ACQ may thus not be the most suitable instrument to establish the scope of anxiety 
cognitions in PD(A) (Khawaja, 2003). The use of observer-rated instruments like the 
Panic Disorder Severity Scale (PDSS; Shear et al., 2001) or the Panic Agoraphobia Scale 
(PAS; Bandelow et al., 2000), might have been more suitable but neither were available in 
Dutch translation nor psychometrically tested at the launch of our project. 
6.8 Final conclusion 
Given the 2% prevalence of late-life (agoraphobic) panic disorder and its underdiagnosis 
and undertreatment, we need to educate both general practitioners and the elderly 
themselves in recognizing anxiety symptoms. Acknowledging the preference of older 
people for CBT over drug therapy (Wetherell et al., 2004b), the associated side effects of 
drug therapies (Ensrud et al., 2002; Ensrud et al., 2003; French et al., 2006; Hartikainen et 
al.; 2007) and the similar effect sizes that have been obtained for CBT and antidepressants 
for anxiety disorders in general in this age group (Pinquart & Duberstein, 2007), CBT 
is a good treatment alternative and should be made more widely available for elderly 
patients suffering from panic disorder. Future studies should then expand our knowledge 
of existing CBT approaches and the potential of age-related modifications. 
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Chapter 7 
Old age is not a determinant 
of cognitive-behavioural 
therapy outcome in panic 
disorder with agoraphobia 
' * * 
This chapter has been submitted for publication: 
Hendriks, GJ., Keijsers, G.P.J., Kampman, M., Broekman, T.G., Oude Voshaar, R.C. & 
Hoogduin, CA L. Old age is not a determinant of cognitive-behavioural therapy outcome 
in panic disorder with agoraphobia. 
Cogniiive-behavioural therapy oulcome 
7.1 Introduction 
A systematic review and meta-analysis showed that in the acute-phase treatment of 
panic disorder with agoraphobia (PDA) cognitive behavioural therapy (CBT) is more 
effective compared to antidepressants, whereas the combination of both treatments is 
most efficacious in the short term. Since CBT alone and the combined treatments are 
equally effective in the long term, both are considered first-line treatments for PDA 
(Furukawa et al., 2006). 
In elderly patients suffering from anxiety disorders it is suggested that drug treatment 
might be preferable over CBT (Pinquart & Duberstein, 2007) However, the empirical 
ground for the preference of drug treatment over psychological treatment for elderly 
patients with PD(A) is small. One randomized controlled trial (n = 25) showed superiority 
of alprazolam and Imipramine over placebo treatment in late-life PD(A) (Sheikh & Swales, 
1999). Furthermore, two case series have suggested efficacy for both CBT (N = 20) and 
sertraline (N = 10) in the treatment of late-life PD(A) (Sheikh et al., 2004a; Swales et al., 
1996). There was only one study directly comparing CBT and drug therapy in elderly 
patients in mixed population of anxiety disorders. This study showed superiority of drug 
treatment over CBT (Schuurmans et al., 2006). However, it is questionable wether the 
findings of this study pertain to panic disorder patients. Only 45% of the patients suffered 
from PD, and 32% of the patients dropped out prematurely from the study. 
Recently, we concluded a RCT (N = 49) in which both paroxetine and CBT were superior 
to a waiting-list control condition in late-life PD(A). No differences in outcome were 
observed between CBT and paroxetine treated patients (Hendriks et al., submitted). 
As substantial evidence support CBT for PD(A) as a first-line treatment in adult life, 
it is relevant to study age-related variables in the outcome of CBT in a sample including 
a sufficiently large number of elderly patients. 
Research into predictors of outcome in PD(A) in young and middle-aged adults 
showed only initial severity of symptoms as a consistent predictor of outcome (Kampman, 
Keijsers, Hoogduin & Hendriks, 2008). A number of studies found a negative effect of 
older age, earlier age at onset and longer duration of illness on outcome (DOI) of CBT for 
PD(A) (Basoglu et al., 1994b; De Beurs et al., 1995; Dow, Kenardy, Johnston, Newman, 
Taylor & Thomson, 2007a; Dow, Kenardy, Johnston, Newman, Taylor & Thomson, 
2007b). However, these findings were limited to young and middle-aged patients and 
their findings cannot readily be generalized to elderly patients. Studies in outcome 
prediction in elderly patients with anxiety disorders are lacking. In fact, only Welherell 
and colleagues (2005b) studied predictors of outcome in late-life anxiety. They found 
in an elderly population with generalized anxiety disorder, as was shown in young and 
middle-aged adults with PD(A) also (Kampman et al., 2008), that initial severity of 
symptoms was related to outcome. 
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The current study was set up to examine a widespread view among general practitioners 
and mental health professionals that old age and a long DOI is negatively associated with 
outcome in the treatment of anxiety disorders in later life (Stanley &r Avenll, 1999) We 
were especially interested in PDA as epidemiological evidence showed PDA as clinically 
more severe and more in need for treatment compared to PD without agoraphobia (Grant 
et al, 2006) The specific effect of (very) late-onset of PDA remains unknown, although 
it has been suggested that an onset at older age results in less severe symptoms (Segui et 
al , 2000, Sheikh et al, 2004a) as compared to an onset earlier in life, and from previous 
prediction studies it can be concluded that lower symptom severity is related to better 
treatment outcomes (Kampman et al , 2008) 
The effect of age, age at onset and DOl on CBT outcome for PDA with respect to both 
agoraphobic cognitions and agoraphobic avoidance over a broad age span is examined 
We hypothesize that after correction for initial symptom seventy 1) age is not related 
to outcome and 2) a longer DOl predicts a less favourable outcome Due to the lack of 
empirical data, we do not have an a priori hypothesis on the effect of age at onset of the 
PDA 
7.2 Method 
Design and patients 
A naturalistic treatment study of patients suffering from PDA who were referred 
to a specialized outpatient anxiety clinic was conducted from January 1997 through 
December 2005 As the treatment program was opened for the elderly since January 
1999, older patients suffering from anxiety disorders were also referred All patients who 
were diagnosed with a PDA during intake and did not meet the exclusion criteria, were 
asked to participate in the study and were invited for a baseline assessment Exclusion 
criteria were 1) a severe somatic illness interfering with appropriate application of CBT, 
2) current use of an antidepressant in an adequate dosage, 3) current and adequate 
psychological treatment, and finally 4) presence of a primary psychiatric diagnosis of 
a psychotic disorder, bipolar disorder, substance use disorder or dementia A comorbid 
diagnosis of other anxiety disorders, depression or dysthymia was allowed as long as 
PD(A) was the primary and targeted diagnosis 
Those patients who consented to the present study received a baseline assessment in 
which a primary diagnosis of a PDA had to be confirmed by the Dutch version (Bouman, 
et al , 1997) of the Anxiety Disorders Interview Schedule-Revised (AD1S-1V, DiNardo 
et al , 1994) The ADIS-IV was administered by independent and trained assessors who 
were not involved with treatment delivery Subsequently, several self-report instruments 
had to be completed (see below) After the baseline assessment, patients directly started 
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the 14-week treatment programme. After concluding this programme, an outcome 
assessment was conducted (week 15) using similar questionnaires. 
Treatment protocol 
The cognitive-behavioural treatment programme (CBT) was delivered individually 
and consisted of 14 weekly sessions of fifty minutes each. The CBT was manual-based, 
followed the Dutch version (Kampman <Sr Keijsers, 1997) of the manual of Craske and 
Barlow (1993), and comprised the five following components: 1) provision of psycho-
education about panic, anxiety and agoraphobic avoidance, including the treatment 
rationale, 2) teaching relaxation techniques (applied relaxation), 3) interoceptive 
exposure, 4) cognitive therapy, and 5) exposure in vivo. 
The treatment was delivered by psychologists (MSc level) experienced and extensively 
trained in the manuals. Throughout the study period therapists were weekly supervised 
by cognitive-behavioural therapists certified as supervisors for the Dutch Association 
for Behavioural and Cognitive Therapy to safeguard adequate application of the CBT 
techniques and adherence to the manual For this purpose, therapists had to record 
which CBT components had been addressed within each session, which was discussed 
with the supervisor. Deviations from the treatment manual were discussed. Adaptations 
to the intervention to meet a patient's specific circumstances were allowed if they were 
not in conflict with the manual. 
Patients using benzodiazepines were tapered off before the start of the study under 
medical supervision or had to adhere to a fixed daily dose during CBT. The use of 
benzodiazepines as needed was not allowed. 
Dependent variables 
The primary outcome measure was panic disorder severity, defined as the severity of 
agoraphobic avoidance and the severity of agoraphobic cognitions after treatment. 
Agoraphobic avoidance was measured by the Mobility Inventory Avoidance scale 
(Ml-A) (Chambless et al., 1985) The MI-A contains 3 subscales: avoidance when alone 
(MI-AAL), avoidance when accompanied (MI-AAC), and frequency of panic attacks (MI-
PF). The MI-PF offers a definition of panic attacks as formulated in the DSM-IV, after 
which the respondent is asked to indicate the number of actual panic attacks during 
the past 7 days. As the panic attack frequency is largely dependent on the level of the 
agoraphobic avoidance and agoraphobic avoidance is a better predictor of treatment 
effects than the panic attack frequency (Basoglu et al., 1993; De Beurs et al., 1994), the 
total mean scores on the MI-Α at end of treatment will be used in the analyses (Kampman 
et al., 2002). 
The severity of agoraphobic cognitions was measured by the Agoraphobic Cognitions 
Questionnaire (ACQ) (Chambless et al., 1984; De Beurs, 1993) The ACQ is a self-report 
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questionnaire containing 14 items that had to be rated on a 5-point rating scale. The sum 
score at end of treatment will be used in the analyses. 
The ACQ, the MI-Α, and their Dutch adaptations are frequently used instruments 
in panic disorder treatment outcome studies and have good test-retest reliability, high 
internal consistencies and reasonable concurrent validity (Chambless et al., 1984; 
Chambless et al., 1985; De Beurs, 1993). 
Independent variables 
The independent variables under study were age of the participants, age of onset of 
the panic disorder (defined as the self-report age of the first panic attack based on the 
ADIS-IV interview) and DOI (defined as the actual age minus the age of onset). 
Late-onset panic disorder was defined as an age of onset after the age of 60 years, 
similar to Segui and colleagues (2000) and similar to the definition of late-onset mood 
disorders (Alexopoulos, Young & Meyers, 1993; Reynolds III, Dew, Frank, Begley, Miller, 
Cornes et al., 1998). 
Covariates 
Some covariates may be important in comparing outcome in CBT between younger and 
older adults First, sociodemographic variables are different between younger and older 
adults, e.g marital status or educational level, and may be related to outcome in both 
the pharmacological and psychological treatment of affective disorders (Schoevers &r 
Dekker, 2008). Furthermore, although depression in young and middle-aged adults is 
inconsistently related to outcome in CBT for PD(A) (Kampman et al., 2008), in elderly with 
anxiety disorders and comorbid depression treatment outcome may be poorer (Lenze, 
Mulsant, Shear, Alexopoulos, Frank 61 Reynolds, 2001). Additonally, insomnia is a relevant 
stressor in elderly and is associated with anxiety disorders in later life (Hidalgo, Gras, 
Garcia, Lapeira, del Campo & Verdejo, 2007). Therefore, sociodemographic variables, 
severity of depressive symptoms and sleeping problems were considered potential 
confounders. All sociodemographic variables were entered as dichotomous variables: 
currently married (yes/no), living alone versus with others, and higher eduction, i.e. 
a minimal educational level at a bachelors degree (yes/no). The seventy of depressive 
symptoms at baseline was assessed with the Beck Depression Inventory (BDI); a 20-item, 
self-reported questionnaire (Beck, 1988; Bouman et al., 1985). The BDI has a sufficient 
and reasonable internal consistency and test-retest reliability and a good construct and 
discriminative validity. The severity of sleeping complaints was assessed with a subscale 
of the Symptom Checklist (SCL-90), a 90-item self-report questionnaire containing 8 
subscales (Arrmdell & Ettema, 1986; Derogatis et al., 1976). Both scales, the BDI and 
the SCL-90, do have Dutch versions with good psychometric properties (Arrmdell & 
Ettema, 1986; Beck, 1988; Bouman et al., 1985; Derogatis et al., 1976). 
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Statistical analyses 
Multiple linear regression analyses were applied separately for each of the dependent 
variables, i.e. agoraphobic avoidance and agoraphobic cognitions. Each independent 
variable of interest (age, age of onset, DOl) was separately tested after having been corrected 
for the baseline level of agoraphobic avoidance and agoraphobic cognitions, respectively. 
A similar procedure was conducted for each of the covanates of interest. When a covariate 
was related to the primary outcome of interest at ρ < .15, the covariate was added as 
predictor to the regression model to check for potential confounding effects. 
The DOl had a skewed distribution, which normalized after log transformation. For 
the sake of interpretation, the non-transformed values will be mentioned in the text, but 
all statistics will be based on the log-transformed values. All other variables were either 
normally distributed or dichotomous. 
The SPSS 16.0 statistical analysis package was used (SPSS ine, 2008). Effects were 
tested two-sided and are reported as significant at a level of ρ < .05. 
7.3 Results 
Patient recruitment 
A total of 208 patients received a diagnosis of a panic disorder, of which 189 gave 
informed consent. A further total of 17 patients were excluded as the diagnosis of PDA 
was not confirmed using the ADIS-IV (panic disorder without agoraphobia, Ν = 15; social 
phobia, Ν = 1; specific phobia, Ν = 1). The final study sample comprised 172 patients: 141 
patients were aged between 18 and 60 years and 31 patients were aged over 60 years 
The age of onset differed significantly between elderly and younger patients: 56 (SD 
15) versus 27 (SD 10) years (p < .001). The DOl was not significantly different between 
adult and elderly patients: 7.8 (SD 9.4) versus 12.0 (SD 14.7) years (p = .68). Among 
elderly patients (> 60 years), those with a late-onset panic disorder had a significantly 
shorter DOl: 3.2 (SD = 3.2) versus 24.1 (SD = 15.9) years (p < .001). 
Agoraphobic avoidance 
Table of 7-1 presents analyses of agoraphobic avoidance. As expected, the best predictor 
agoraphobic avoidance severity at end of treatment was baseline severity of agoraphobic 
avoidance. As a continuous variable, age was not significantly related to treatment 
outcome. However, when split up in adult and elderly patients, elderly patients had 
significantly better results. Furthermore, within the subgroup of elderly patients, a 
higher age turned out to be associated not with less favourable outcome but with more 
favourable outcomes. Similarly, a higher age of onset and shorter DOl were related to a 
better outcome in the elderly patient group. 
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Table 7-1. Regression of each variable of interest on agoraphobic avoidance at end of treatment in 
a separate model 
Variables 
Agoraphobic avoidance at baseline 
Age (continuous)·" 
Age dichotomized at 60a 
Age of onset (continuous)3 
Late-onset panic disorder" 
Duration of illness (log-transformed) 
Whole sample 
<n = 
R2 
.50 
.51 
.52 
.52 
.56 
.51 
148) 
β 
.71 
- 0 9 
- 1 3 
-.13 
-.23 
.09 
Ρ 
<.001 
.15 
032 
030 
<.001 
.14 
Under 60 
(n = 
R2 
.54 
.56 
-
.56 
-
.54 
119) 
ß 
.73 
07 
-
.08 
-
.02 
Ρ 
<.001 
.33 
-
21 
-
73 
Over 60 
(n = 
R2 
.44 
.53 
-
.60 
.62 
.53 
29) 
β 
.67 
-.30 
-
-.40 
-.43 
.30 
Ρ 
<.001 
.037 
-
.003 
.002 
.038 
a Univariate analyses, adjusted for level of avoidance at baseline. 
In elderly patients, both, age and DOI, were independently associated with treatment 
outcome in one overall regression model (effect of age, β = -.30, ρ = .024; effect of DOI, β 
= .31, ρ = .025) (Model R 2= .62). 
Late-onset panic disorder and DOI cannot be included in one regression analysis as 
both variables are intrinsically related or, in other words, a late-onset implies a short 
duration. For this reason, we repeated the analysis with a restriction to those patients 
with a DOI of less than 5 years. This analysis revealed significantly better outcomes for 
patients with a late-onset panic disorder: whole sample (β = -.22, ρ = .015, model R2 = 
.46), elderly subgroup (β = -.61, ρ = .044; model R2 = .39). Restricting our sample to those 
with a DOI of less than 2 years, still yielded a significant superior effect for late-onset 
panic disorder (whole sample, β = -.34, ρ = .005, model R2 = .46; elderly patients, β = -.84, 
ρ = .003, model R2 = 74). 
Sleeping problems as assessed with the SCL-90 was the only covanate associated 
with outcome in the whole sample and younger age sample. Adding this variable to the 
final regression models did not change outcome (data not shown). 
Anxiety cognitions 
Table 7-2 presents similar analyses for anxiety cognitions. In this case, we found no 
effect of age on therapy outcome Again, a shorter DOI was related to a better outcome, 
whereas a higher age of onset was only related to a better outcome among the elderly 
patients. Repeating the analyses for late-onset panic disorder with a restriction to those 
patients with a short DOI, however, did not yield significant better effects for late-onset 
panic disorder anymore (data not shown). 
Marital status was the only covanate associated with outcome in the whole sample. 
Adding this variable to the final regression models did not change outcome (data not 
shown). 
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Table 7-2. Regression of each variable of interest on anxiety cognitions at end of treatment in a 
separate model 
Variables 
Anxiety cognitions at baseline 
Age (continuous)b 
Age dichotomized at 60b 
Age of onset (continuous)11 
Age of onset (< > 60 years)b 
Duration of illness (log-transformed)b 
Whole sample 
(" = 
R2 
.39 
41 
.39 
.41 
41 
.41 
148) 
Ρ 
.63 
.04 
-.03 
-.04 
-.07 
.14 
Ρ 
<.001 
.55 
.69 
.59 
.33 
.039 
Under 60 
(n = 
R2 
.33 
35 
-
.34 
-
.34 
119) 
ß 
.57 
.10 
-
.05 
-
.10 
Ρ 
<.001 
.22 
-
.58 
-
.19 
Over 60 
(n = 
R2 
.48 
.48 
.62 
.54 
.60 
29) 
β 
.69 
.03 
-.41 
-.25 
34 
Ρ 
<.001 
.86 
.006 
.085 
.012 
b Univariate analyses, adjusted for level of anxiety cognitions at baseline. 
7.4 Discussion 
Confirming the results of previous studies by demonstrating a worse treatment effect 
in the most severely ill patients, the main finding of our study is that a higher age and a 
higher age of onset were not associated with a negative treatment outcome. In contrast, 
both, a higher age and a higher age of onset, predicted even better treatment effects 
with respect to the level of agoraphobic avoidance, whereas these variables were only 
marginally related to treatment effects on the level of anxiety cognitions. 
Effect of age 
Conform our hypothesis, age was not a predictor for CBT outcome. However, in the 
subsample of elderly patienls, higher age was associated with a larger reduction of 
agoraphobic avoidance (but not anxiety cognitions). These findings contrast with 
several previous studies showing a lower than expected effect size of protocohzed CBT 
in elderly patients with anxiety disorders compared to effect sizes of CBT in younger 
adults (Schuurmans et al., 2006). The difference may be contributed to the variability 
in underlying psychiatric diseases in the Schuurmans study (2006), which included 
patients with generalized anxiety disorder, panic disorder and agoraphobia without 
panic disorder. If true, our findings suggest that disorder-specific treatment protocols 
should also be preferred in elderly patients similar to the application of CBT in younger 
and middle-aged adults. 
Effect of age of onset 
With respect to the improvement of agoraphobic avoidance, a higher age of onset was 
associated with a better outcome, which was most pronounced in the elderly subgroup. 
The effect of age of onset was not related to improvement of anxiety cognitions in the whole 
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sample, but in the elderly subgroup it was still associated with a stronger improvement 
of anxiety cognitions. The more favourable prognosis of late-onset PDA is in line with 
findings that the late-onset type of PDA is a milder form (Segui et al., 2000; Sheikh et al., 
2004a). Large epidemiological projects showed that only 5% of the patients with panic 
disorder had an age of onset after the age of 56 years and 1% after the age of 63 years 
(Kessler et al., 2005a). This low incidence rate might be explained by methodological 
limitation of epidemiological studies as well as a referral bias for treatment in clinical 
practice. Irrespective of the explanation, in old age psychiatry patients with late-onset 
PDA constitute approximately half of the patients with PDA under treatment as found 
in our study (18/31, 68%) and those of others (Segui et al., 2000), which justifies special 
attention to this specific group of patients. 
Effect of duration of illness 
A longer DOI was associated with a negative treatment outcome, which is in line with 
most previous studies (Basoglu et al., 1994b; De Beurs et al., 1995). For clinicians, 
such findings may lead to the conclusion that elderly patients do have a worse 
prognosis when entering treatment. In our study, however, even after correction 
for DOI, a higher age of the participants remained associated with a significantly 
better treatment outcome with respect to the severity of agoraphobic avoidance. 
Strengths and weaknesses 
For a good interpretation of the present findings, some limitations should be 
acknowledged. First, considerable debate exists on the definition of late-onset panic 
disorder with a range between 30 and 50 years (Katerndahl & Talamantes, 2000; Sheikh 
et al., 2004a). The median age of onset of panic disorder in large epidemiological projects 
is 25 years (Kessler et al., 2005a). These definitions, however, largely neglect the effects 
of ageing on the symptomatology and severity of the panic disorder. It has been shown 
that the symptom severity of panic disorder as measured with self-report questionnaires 
decreases with age (Sheikh et al., 2004a), as well as physiological arousal in panic 
challenge studies (Flint et al., 1998; Griez et al., 2007). It is unknown to what extent 
these findings can be translated to a lower severity of the panic disorder in later life per 
se. In our study only 2 patients aged above 60 years had an onset before the age of 25 
years. For this reason, it was not possible to examine this definition of a late-onset in 
our sample and we have chosen a clinical definition of late-onset at 60 years, in line with 
Segui and colleagues (2000). Secondly, although the age of onset and DOI are based upon 
data gathered within a well-validated structured interview (ADIS-IV), these data are 
retrospectively collected. However, it was found that within a time period of four years 
test-retest reliability of the recall of age at onset for panic disorder was good (Prusoff, 
Menkangas & Weissman, 1988). Thirdly, we used self-report instruments to evaluate 
94 
Cognitive behavioural therapy outcome 
treatment outcome and did not use a clinical global impression scale or the AD1S-1V 
interview at outcome Although validation studies of self-report anxiety questionnaires 
in older patients are scarce, the available studies did not find major objections for their 
use in older populations (Critlendon & Hopko, 2006, Fuentes &r Cox, 2000, Goldberg 
et al, 2003) 
Clinical implications / final conclusion 
Our results clearly show that high age should not be an exclusion criterion for CBT 
and even in the older age groups (> 60 years) shows better results compared to younger 
patients 
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8.1 Introduction 
Old age is often seen as a negative predictor of treatment outcome in panic disorder with 
or without agoraphobia (PD(A)), just as it is in late-life anxiety and depression (Mitchell 
& Subramamam, 2005). Empirical studies, however, only point to the severity of the 
initial symptoms as a consistent predictor of therapy outcome in PD(A) (Kampman 
et al., 2008), although the findings are exclusively based on younger and middle-aged 
populations, which limits their generalization to later life. Furthermore, interpretation 
of the results of late(r)-life studies can be complicated due to the sample heterogeneity 
caused by large differences in the age of disease onset Epidemiological surveys show 
that with a median age of onset of 25 years, most patients with late-life PD(A) have been 
suffering from the effects of their condition for quite some time (Kessler el al., 2005a). 
Nevertheless, a substantial number of elderly patients is referred on account of a (very) 
late-onset type of PD(A), having had their first symptoms as late as in their sixties (Segui 
et al., 2000). One may hypothesize that especially this late-onset type is more susceptible 
to CBT than the early-onset type with its consequential lengthy illness duration. 
The current study evaluated whether age, age at onset, and duration of illness (DOI) 
have any differential effects on the outcome of pharmacological and psychological 
treatment approaches for agoraphobic PD in elderly patients. 
8.2 Methods 
A total of 49 patients aged 60 years and over diagnosed with PDA, as confirmed by the Dutch 
version (Bouman et al., 1997) of the Anxiety Disorders Interview Schedule for DSM-1V 
(ADIS-1V, DiNardo, 1994), were randomly allocated to three study conditions: 40 mg/d 
paroxetine (n = 17), cognitive-behavioural therapy (CBT; η = 20), or a standard waiting-list 
control condition (n = 12). A detailed description of the interventions and the baseline and 
end-of-treatment interview assessments is given elsewhere (Chapter 4, this thesis). 
In this brief report we describe the results of multiple regression analyses predicting 
post-treatment effects on agoraphobic avoidance and agoraphobic cognitions in the 
paroxetine and the CBT condition separately in terms of the total scores on the Mobility 
Inventory Avoidance scale (MI-Α; Chambless et al., 1985) and the total scores on the 
Agoraphobic Cognitions Questionnaire (ACQ; Chambless et al., 1984), respectively. Both 
questionnaires are frequently used in PD(A) treatment outcome studies and for both Dutch 
versions are available with proven good psychometric properties (De Beurs, 1993). 
Participants' age, age at PDA onset, defined as the participant's age at the time of 
the first panic attack as reported during the ADIS-IV interview, and DOI defined as the 
actual age minus the age at onset, were regressed on the MI-Α and ACQ sum scores, 
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respectively. The treatment conditions were examined separately by multiple regression 
analyses after controlling for baseline symptom severity. When the treatment arms 
yielded different predictors, the modalities were examined in one model. 
8.3 Results 
Outcome data were available for 14/17 (82%) patients assigned to the paroxetine condition 
and for 18/20 (90%) in the CBT condition The patients' baseline characteristics did not 
differ across conditions: they were on average 69 2 (SD = 4.7) years old and 57% were 
women; the mean baseline MI-Α score was 2.4 (SD = 0.9) and the mean baseline ACQ 
score 1.7 (SD = 0.5). Post-treatment mean Ml-A and ACQ scores were respectively 1.8 
(SD = 0 9) and 1.4 (SD = 0.4) (see Chapter 4, this thesis). 
The results of the multiple regression analyses are reported in Table 8-1. Late-onset type 
and a shorter DOl predicted significantly better outcome with respect to both agoraphobic 
cognitions and avoidance behaviour in the CBT condition. However, when both treatment 
conditions were entered into one regression model, only the late-onset PDA (Late-onset 
type by Condition: R2 = .50, β = -1.80, ρ = 009) yielded a significant interaction term with 
treatment condition in favour of CBT, whereas interaction of treatment condition with 
DOI did not reach significance (DOl by Condition: R2= .49, β = .54, ρ = .10). With respect 
to avoidance behaviour, neither DOI nor late-onset type yielded a significant interaction 
term with treatment condition (DOI by Condition: R2 = .55, β = -.56, ρ = .22; Late-onset 
type by Condition: R2= .62, β = .06, ρ = .07). 
Table 8-1. Results of the multiple regression analyses testing the predictive values of three variables 
of interest on treatment outcome after conlrolhng for baseline symptom seventy 
Age* 
Late-onset PDA (yes/no)* 
Duration of illness* " 
Paroxetine 
Ml-A 
R2 
.68 
.68 
68 
Ρ 
.13 
-.11 
.11 
condition (n = 
Ρ 
.53 
.54 
.53 
ACQ 
R2 
.22 
.26 
.14 
17) 
Ρ 
.29 
-.48 
.08 
Ρ 
.30 
11 
.78 
CBT condition (n = 20) 
Ml-A 
R2 
41 
.60 
.50 
Ρ 
-.25 
-.51 
.39 
ACQ 
Ρ R2 
.24 .47 
.007 .61 
.052 .68 
Ρ 
.13 
.40 
48 
Ρ 
.49 
.025 
.005 
* Regression analyses with post-treatment Ml-A and ACQ total scores as the dependent variables corrected for 
baseline Ml-A and ACQ scores, respectively 
# Due to a skewed distribution the analyses are based on the log-transformed values. 
Abbreviations ACQ = Agoraphobic Cognitions Questionnaire, Ml-A = Mobility Inventory Avoidance scale, 
CBT = Cognitive-Behavioural Therapy, PDA = Panic Disorder with Agoraphobia 
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8.4 Discussion 
Although preliminary because of the small sample size, this first randomized controlled 
treatment study of agoraphobic panic disorder in later life revealed some interesting 
findings. In contrast to what is generally assumed in clinical practice, with our study we 
showed that age is not related to treatment outcome. Interestingly, we did find differential 
effects for paroxetine and CBT for the other predictors tested, those patients with late-onset 
PDA and shorter illness duration had a more favourable outcome following CBT. No such 
effects were observed in the paroxetine condition. These findings suggest that CBT may be 
treatment of choice for the late-onset type of PDA. For elderly patients with the early-onset 
type (with an onset before the age of 60 years) and a prolonged illness duration both CBT 
and pharmacological strategies may be the preferred modality. Again, our findings have to 
be considered with caution due to small number of patients and not all our overall analyses 
comparing the effects of the two treatment conditions together yielded significant results 
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9.1 Introduction 
Anxiety disorders are the most prevalent mental disorders (Kessler et al., 2005a). Highly 
efficacious pharmacological and psychological treatments have been developed for panic 
disorder with or without agoraphobia (PD(A)), social phobia, obsessive-compulsive 
disorder, posttraumatic stress disorder and generalized anxiety disorder (GAD). The 
effectiveness of both treatment modes has been substantiated in numerous meta-
analytic reviews (Abramowitz, 1997; Bakker et al., 2002; Van Balkom et al., 1997; Bisson 
&r Andrew, 2007; Bradley et al., 2005; Fedoroff «Sr Taylor, 2001, Van der Linden et al., 
2000; Mitte, 2005a; Mitte, 2005b; Norton & Price, 2007; Seidler & Wagner, 2006; Stein 
et al., 2000; Taylor, 1996). The development of international guidelines has, accordingly, 
been based upon these findings1. However, and regrettably, these guidelines are almost 
exclusively founded on randomized controlled trials (RCTs) in adults aged between 18 
and 65 years, with an average age of about 35 years. Studies into the treatment of late-
life anxiety are scarce, even though anxiety disorders are the most prevalent mental 
disorders in the elderly (Beekman et al., 1998; Kessler et al., 2005a). Furthermore, less 
than 10% of all elderly patients suffering from anxiety disorders is offered adequate 
treatment with cognitive-behavioural therapy (CBT) or antidepressants (De Beurs 
et al., 1999). In contrast to our elderly, young and middle-aged people suffering from 
complaints are treated adequately five times more often (Wang el al., 2005b). On the 
other hand, although not recommended in the guidelines as first-line agents in the 
management of late-life anxiety disorders, 25 to 43% of all elderly patients are prescribed 
benzodiazepines (De Beurs et al., 1999; Schuurmans et al., 2005). Frequent use of 
prescription benzodiazepines is, however, associated with serious drug-related hazards 
such as an increased risk of falls and fractures, and a possible aggravation of cognitive 
difficulties (Paterniti et al., 2002; Wang et al., 2001a; Wang et al, 2001b). Furthermore, 
a critical consideration of the adverse events of SSRIs, the recommended first-line agents 
for late-life anxiety disorders, showed that the risk of falls and fractures were comparable 
to those found for both benzodiazepines and antidepressants (Ensrud et al., 2002; 
Ensrud et al., 2003; Hartikainen et al., 2007; Liu et al., 1998). Given the adverse effects of 
all major pharmacological agents, CBT should perhaps be more seriously considered as 
the preferred first-line treatment in late-life anxiety disorders. 
But what explains the undertreatment of late-life anxiety disorders? Plausibly, because 
of their being retired and because they often receive support in and around the home, 
elderly people may increasingly and successfully avoid anxiety-provoking situations 
1 http//www nice org uk/gmdance/indexjsp 
hup //www psych org/MainMenu/PsychiatricPractice/PracUceGuidelmes_l aspx 
hup //www ggznchllijnen nl/ 
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(Lindesay, 1991). In addition, proper diagnostic procedures may be complicated by a) a 
higher prevalence of somatic disorders and overlapping physical symptoms (e.g. pulmonary 
or cardiovascular diseases; Seung Kim et al, 2001), b) comorbid depression (Beekman et 
al., 2000), c) the elderly being less open in sharing their psychological problems (Weijnen 
et al., 2006), d) their attributing psychological symptoms to somatic diseases (Sheehan et 
al., 2002), and e) a different phenotypical expression (Brenes, 2006; Crittendon & Hopko, 
2006; Goldberg et al., 2003, Hunt et al, 2003; Klapow et al, 2002; Lau et al., 2001). 
Although it is assumed that age-related differences between younger and older adults 
suffering from anxiety disorders affect the outcome of targeted treatment (Stanley & 
Averill, 1999), this has, so far, not been empirically established. In addition, the few 
findings from RCTs focusing exclusively on elderly patients (60-plus and 65-plus) also 
tentatively indicate that both CBT and antidepressants are likely optimal options for the 
management of late-life anxiety disorders (Pinquart & Duberstein, 2007), albeit that the 
evidence is predominantly limited to GAD or mixed anxiety disorders (Hendriks et al., 
2008a; Pinquart & Duberstein, 2007). Inspired by the positive outcomes we obtained 
with CBT and SSRIs in 60-plus patients suffering from late-life anxiety disorders as 
reported in two case studies (Hendriks et al., 1999; Hendriks et al., 2008b), and prompted 
by all the conflicting evidence and the considerable gaps in our knowledge, the work 
presented in this thesis was aimed at expanding the empirical data on the efficacy of CBT 
and antidepressants in older adults, in our case patients over 60 years of age diagnosed 
with anxiety disorders in general, as well as gathering the first empirical evidence for 
these treatments in elderly patients with confirmed PD(A). Although RCTs and meta-
analyses have amply confirmed the effectiveness of both treatments in younger adults, 
RCTs directly comparing the two approaches in elderly patients suffering from anxiety in 
general are scarce, while trials evaluating late-life PD(A) are absent, leaving the question 
whether CBT is to be preferred over specific pharmacological or other psychological 
treatments unanswered. In the case of PD(A), it has never been tested whether the 
guideline-recommended treatments with antidepressants or CBT are effective or even 
feasible in elderly populations. Accordingly, the main research questions posed were-
1. Are CBT and antidepressants similarly effective in the treatment of late-life anxiety 
disorders? 
2 Is CBT more effective than an active control comparison in the management of late-
life anxiety disorders? 
3. Are both paroxetine and CBT effective and well-tolerated treatments for PD(A) in 
older adults? 
4. Does the content of agoraphobic cognitions differ between younger and older adults 
suffering from PDA? 
5. Is CBT as effective and as well-tolerated in older adults diagnosed with PDA as it 
has been found to be in younger adults? 
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6. Are age, age at onset and duration of illness related to outcome in CBT for PDA? 
7 Are age and duration of illness related to paroxetine and CBT outcome in late-life 
PDA? 
9.2 Review of the literature and meta-analysis 
In Chapters 2 and 3 a systematic overview was given of outcome studies evaluating both 
psychological and pharmacological treatments for older adults (> 55 years) with anxiety 
disorders. Although still modest in volume, since the end of the 1990s systematic research 
into the treatment of late-life anxiety has intensified. To guarantee the methodological 
quality of the studies, only RCTs in which use was made of valid instruments specifically 
designed to diagnose anxiety disorders and monitoring outcome were considered. 
Both reviews served to summarize the evidence on the effectiveness of CBT and 
pharmacotherapy for late-life anxiety disorders and to establish the efficacy of CBT over 
other non-pharmacological treatments. Of the 56 potential studies only eight CBTs and 
three pharmacotherapy trials met the inclusion criteria. All eight studies focused on 
patients with GAD, or on mixed groups of patients with GAD, PD(A) or social phobia 
In Chapter 2 the effect sizes for both the anxiety and depression outcomes were 
calculated using Cohen's d. With large effect sizes (> 0.8) in nine of the ten studies testing 
CBT and pharmacotherapy relative to a waiting list or treatment as usual, we found 
convincing evidence of superior treatment effects for CBT and medical interventions for 
late-life anxiety disorders. The effect sizes for CBT were generally also larger than those 
for supportive psychotherapy or discussion groups, especially at follow-up. Interestingly, 
for anxiety CBT efficacy at follow-up had even improved in seven of the eight CBT studies. 
Moreover, CBT showed a superior effect on accompanying depressive symptoms. It is, 
moreover, important to bear in mind that, whereas pharmacotherapy was continued 
during follow-up in all studies, CBT was not. 
The results of the meta-analysis presented in Chapter 3 subsequently provided 
evidence for the effectiveness of CBT in the treatment of anxiety disorders (as based on 
DSM-IV criteria) occurring later in life Its efficacy was demonstrated in various samples 
of patients over 60 years of age and not only relative to a waiting-list condition but also 
relative to an active control condition. 
In sum, the empirical data reported thus far showed CBT and antidepressants to 
be most effective in the treatment of late-life anxiety disorders. The only study that 
directly compared antidepressant treatment and CBT found a superior effect for the 
antidepressant. This result should, however, be interpreted with caution, since the effect 
size of CBT in this study was considerably smaller than those reported in the other 
studies we reviewed 
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Our systematic reviews confirmed the lack of RCTs testing the effects of treatment 
approaches targeting specific late-life anxiety disorders, with the exception of GAD (Mitte, 
2005b; Pinquart & Duberstein, 2007) Given that in these latter studies the outcomes 
obtained in the younger and older adults were comparably favourable, we deemed it 
relevant to establish whether the other anxiety disorders could also be successfully 
treated in later life. As the life-time prevalence of PD(A) in this age group is relatively 
high (2%; Kessler et al, 2005a)), we chose to focus our research reported in this thesis on 
this specific disorder. Moreover, because in younger adults the agoraphobic type is the 
most serious and sufferers of this type are most frequently referred to specialized clinics, 
we were particularly interested in the treatment effects in older patients diagnosed with 
agoraphobic PD. 
9.3 The treatment of late-life panic disorder with and without 
agoraphobia 
The study in Chapter 4 examined the effectiveness of paroxetine and CBT in 49 patients 
aged on average 70 years (SD = 5) all diagnosed with PD(A) who were randomly assigned 
to 40 mg paroxetine (n = 17), individual CBT (n = 20), or a 14-week waiting list (n = 
12). Outcomes, with avoidance behaviour and agoraphobic cognitions being the primary 
measures, were assessed at baseline, and in weeks 8, 14 (end CBT/waiting list), and 
26 (treated patients only), and analyzed using mixed models. All outcome measures 
showed that both the patients having received CBT and those treated with paroxetine 
had improved significantly more than the patients in the waiting-list condition, with 
effect sizes being moderate to large (Cohen's d ranged from 0.6 to 0.9) No differences 
were found between CBT and paroxetine With one patient (1/20, 5%) dropping out in 
the CBT and three (3/14, 17.6%) in the paroxetine and one (1/12, 8%) in the waiting-list 
condition, attrition rates were low. We accordingly concluded that elderly patients with 
PD(A) responded well to both types of treatment. 
One of the study's strong points was that both treatments were well tolerated. With 
a total attrition rate of 10% (5/49), the loss of patients during this trial was remarkably 
low compared to other RCTs in elderly people with anxiety disorders, with dropout rates 
varying between 25 and 30% (Hendriks et al, 2008a; Pinquart & Duberstein, 2007). 
Our favourable results may be due to the fact that both treatments were delivered at our 
specialized outpatient clinic, which has a long tradition in the protocolized management 
of anxiety disorders. 
A major concern, on the other hand, is that between 1999 and 2006 we were only able to 
recruit 49 PD(A) patients over the age of 60 years. This was far less than we had expected 
based on the prevalence rates reported in epidemiological studies. Other outcome studies 
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of late-life anxiety disorders also appeared to have had difficulty recruiting participants 
(e.g. Schuurmans et al, 2006). Besides the explanatory and prohibitive factors mentioned 
earlier in the introduction of this chapter, and although speculative, two other aspects 
may have played a role here. Both menial health professionals and patients, as well 
their relatives, may have low expectations regarding the outcome of interventions at 
this late stage in life, with the prolonged course of the disorder having caused the loss 
of confidence in recovery (Klap el al , 2003). Alternatively or additionally, referral to a 
mental health facility may trigger a fear of stigmatization (Sirey, Bruce, Alexopoulos, 
Perlick, Raue, Friedman et al., 2001). 
Finally, we were somewhat surprised by the relatively low total baseline scores for 
agoraphobic cognitions we obtained in our sample, even though an earlier study also 
recorded lower scores for their older PD(A) patients than for their younger patients (Sheikh et 
al, 2004). This raised two questions: do older people with PD(A) have different agoraphobic 
cognitions than their younger counterparts, or do these cognitions decline with increasing 
age7 To try and resolve these issues, we conducted the study reported in Chapter 5. 
9.4 Agoraphobic cognitions in younger and older patients with 
panic disorder with agoraphobia 
In Chapter 5 we reported on our comparative study of the frequency and intensity of 
agoraphobic cognitions in 48 older (a 60 years, range 60 to 85 years) and 157 younger adults 
(< 60 years) with PDA. The 60-plus patients had a significantly lower mean Agoraphobic 
Cognitions Questionnaire (ACQ) total score than their younger counterparts: their 
scores on the items fear of going crazy, acting foolishly, losing control, passing out, and 
having a brain tumour were significantly lower. This differential effect at the ACQ-item 
level suggests that some cognitions appear less relevant for agoraphobic PD in later life. 
Future research should establish whether and which age-related cognitions are missing 
in the currently widely used self-report instruments. In our study we did not verify 
whether late-life PDA is characterized by different agoraphobic cognitions than it is in 
younger and middle-aged patients. Although preliminary, we concluded that the ACQ 
is not the most suitable self-report tool to assess patients with late-life PDA. However, 
to date there is no alternative inventory for agoraphobic cognitions. As the total mean 
scores for the frequency and intensity of avoidance behaviour did not differ between the 
two age-groups, we made the recommendation to base the severity of late-life PDA on the 
severity of agoraphobic avoidance. 
In clinical practice many therapists consider manual-based CBT inappropriate, being 
convinced that patients need personalized treatment plans adapted to their individual 
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needs, with which stance they prevent CBT from being offered to specific target groups 
like elderly PD patients. Empirical evidence for these assumptions is, however, hardly 
available (Wilson, 1996). In addition, some authors recommend age-specific modifications 
in the CBT manual and delivery in a group format (Stanley & Avenll, 1999). Yet, the 
evidence to substantiate these assumptions is again scarce. Until now, only Mohlman and 
colleagues (2003) have compared both standard and age-specific CBT to a waiting-list 
control condition. Although the modified CBT showed better results than the standard 
programme, the study was limited by its small sample size (n = 42) and the lack of a 
direct comparison of the standard and modified interventions. 
As no studies were available that directly compared the outcomes of protocolized CBT 
in younger and older adults with PD(A) without age-specific modifications, we decided 
to do so ourselves and the results of this comparison are described in the following 
section. 
9.5 Cognitive-behavioural therapy for panic disorder with agora-
phobia in older people: A comparison with younger patients 
Chapter 6 describes the results of our comparison of the outcomes obtained with the 
same, protocol-based CBT programme in 141 younger and middle-aged patients diagnosed 
with PDA (average age 35 years; SD = 10) and 31 older patients (average age 68 years; 
SD = 5). The older patients improved significantly more with respect to agoraphobic 
avoidance than their younger counterparts. No between-group differences were found 
for post-treatment agoraphobic cognitions and the secondary outcomes, general level of 
psychopathology and depressive symptoms. Although not significant (p = .06), with 2/31 
(6%) and 31/141 (22%) attrition rates were numerically lower for the 60-plus group than 
they were for the younger adults. The results thus showed the standard, protocolized 
CBT for PDA to be feasible for patients over the age of 60 years, yielding even better 
outcomes than obtained in younger adults. The need to adapt the existing CBT protocols 
for PDA to elderly patients hence does not appear to be urgent or warranted although it 
cannot altogether be ruled out that modifications may produce even better outcomes. 
PD(A) onset usually occurs at a relatively young age: in 75% of all patients the complaints 
manifest themselves before their 40'h year, while only 1% have an onset at age 63 or later 
(Kessler et al., 2005a). As PD(A) is relatively prevalent in older people, the symptoms have 
run a chronic course in most elderly patients. However, epidemiological surveys show 
there is a small population that first develops symptoms after the age of 60. Proportionally, 
with rates ranging from 3 to 6%, this group is relatively frequently represented in clinical 
populations (Raj, Corvea & Dagon, 1993; Segui et al, 2000, Sheikh et al, 1991). It is widely 
109 
C hapter 9 
assumed that the effectiveness of CBT for anxiety disorders decreases with age, but the 
empirical grounds for this presumption are, however, weak. Therefore, in Chapters 7 
and 8 we put these assumptions to the test. 
9.6 The relationship between age-related variables and treat-
ment outcome in late-life PDA 
In Chapter 7 we examined the effects of age, age at onset, and duration of illness (DOI) 
on CBT outcomes in 172 PDA patients stratified at age 60 years. As expected, the seventy 
of both agoraphobic avoidance and agoraphobic cognitions were the most important 
predictors of outcome in the overall sample. Age was not related to outcome, with the 
exception of a superior reduction of agoraphobic avoidance in the elderly subgroup. 
In this latter subgroup, a higher age, a later onset, and a short DOI resulted in less 
agoraphobic avoidance at outcome. We felt the results merited the conclusion that in 
PDA old(er) age does not reduce the effectiveness of protocohzed CBT. 
The differential predictive values of age and DOI on the outcomes of paroxetine and 
cognitive-behavioural therapy (CBT) in late-life PDA were evaluated in Chapter 8. 
Forty-nine patients aged 60* years with a confirmed diagnosis of PDA were randomly 
assigned to 40 mg/d paroxetine (n = 17), individual CBT (n = 20), or a waiting-list 
control condition (n = 12). The main finding was that age had no impact on treatment 
modality outcome. Furthermore, a higher age at onset and a shorter illness duration were 
predictors of superior outcomes following CBT, while the variables did not influence the 
treatment effects of paroxetine. These findings suggest that CBT may be the treatment 
of choice for the late-onset type of PDA. For elderly patients with the early-onset type, 
i.e. an onset before the age of 60 years, and a prolonged illness duration, both CBT and 
pharmacological strategies may be the preferred modalities. Our findings have to be 
considered with caution, however, due to small number of patients and because not 
all our overall analyses comparing the effects of the two treatment modalities together 
yielded significant results. 
9.7 Methodological considerations 
Our review of the literature on pharmacological and psychological treatments of late-life 
anxiety disorders (Chapter 2) was restricted due to the quality criteria we set. We limited 
our search to controlled studies and this yielded only a small number whose methodological 
quality merited evaluation. In addition, the sample sizes used in the studies we reviewed 
were relatively small and attrition rates often exceeded 20%, which is the percentage the 
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Cochrane Study Group uses as the upper limit for attrition. Moreover, most studies only 
included patients with GAD, and, with ages between 61 and 72 years, the patients treated 
were still relatively young The small number (n = 3) of pharmacological RCTs prevented 
a quantitative analysis, which is why we, in our meta-analytic review (Chapter 3) only 
discussed the results on the psychological interventions for late-life anxiety disorders. 
Yet again, the meta-analysis suffered the same limitations as our literature review and its 
results can thus only be generalized to 'relatively younger' older patients with GAD. 
Our RCT of paroxetine and CBT for the treatment of late-life PD(A) using a waiting-
hst control condition (Chapter 4) was the first to directly compare two guideline-
recommended treatments. However, its statistical power was limited by its relatively 
small sample size (n = 49) Our conclusions should therefore be interpreted with caution 
We also omitted to use a placebo condition for both treatment modalities. However, both 
treatments yielded effect sizes comparable to those reported in meta-analytic reviews 
for young and middle-aged adults with PD(A) (Mitte, 2005), which argues against a 
discernible placebo effect in our study Furthermore, the self-report instruments we used 
to evaluate treatment effects in our 60-plus cohort have, so far, only been validated in 
younger PD(A) populations (18-65 yrs), which may imply that the scales are less valid for 
patients over the age of 65 years. Yet, and although few in number, this is countered by 
the available validation studies in 60-plus samples that found no objections for their use 
in this age range (Fuentes et al., 2000; Crittendon et al, 2006). Finally, as our findings 
were limited to relatively young (average age: 70 years) and relatively healthy elderly 
patients, the results cannot be generalized to their older and frailer peers 
The aforementioned reservations against the use of self-report questionnaires and the 
problems associated with the specificity of the demographic characteristics of our study 
population also apply to the subsequent studies we conducted. 
The main limitation of the study we conducted into the potential differences in the 
content of agoraphobic cognitions in older and younger adults with PDA (Chapter 5) was 
that we failed to perform a quantitative analysis on agoraphobic cognitions that were not 
included in the Agoraphobic Cognitions Questionnaire (ACQ). 
The relatively small size of the 60-plus group (n = 31) in our comparison of PDA-
specific CBT for younger and older adults (Chapter 6) reduced its statistical power, which 
is why our conclusions warrant cautious interpretation. Furthermore, we cannot rule 
out a selection bias in the 60-plus group. In contrast to younger adults, elderly people 
with PDA are far more often underdiagnosed and undertreated (De Beurs et al., 1999; 
Kessler et al., 2005b), which may imply that, perhaps, the ability of the elderly patients 
in our study to express their complaints adequately and make clear that they wished to 
be referred for specialized treatment was above average. 
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The study reported in Chapter 7 examined the relationship between age, age at onset, 
and duration of illness (DOl) and the outcome of PDA treatment. However, defining 
early and late age of onset in PD(A) is rather complex. In epidemiological and clinical 
studies, a PD(A) onset between the ages of 30 and 50 years is defined as late age of 
onset (Katerndahl & Talamantes, 2000; Sheikh et al , 2004). Yet, such a definition largely 
ignores the influence of the ageing process on the symptoms and severity of the PD(A). 
Therefore, in line with the generally accepted cut-off age between 55 and 65 years, and 
similar to what other researchers (Alexopoulos et al., 1993, Reynolds et al., 1998; Segui 
et al, 2000) did before us, we chose 60 years as the lower limit for the definition of late 
age of onset. Furthermore, as age of onset and hence DOl are, by definition, based on 
retrospectively collected data, their reliability is, of course, limited. Finally, in Chapter 
8 we showed that CBT and paroxetine yielded differential outcomes in late-life PD(A) 
and hence tentatively concluded that CBT was the preferred modality for older patients 
with a late age of onset and shorter DOl and paroxetine the treatment of choice for older 
patients with an early age of onset and long-standing DOl Nevertheless, it should be 
borne in mind that sample sizes were small and that the findings were not consistently 
statistically significant when both treatments were compared and analyzed in one 
model. 
This critical reflection on the research reported in this thesis is not complete without 
returning to a vital issue in this type of investigation. Worldwide, the recruitment and 
(extended) participation of elderly people in RCTs evaluating outcomes of treatments 
for late-life anxiety remains particularly difficult. Although prior to our studies the 
management of GAD in later life had been frequently evaluated, for the other anxiety 
disorders, most notably panic disorder, empirical findings were still scarce or even absent, 
the underlying factors for which have been discussed above. It is therefore unique that 
the effectiveness of both CBT and SSR1 treatment in the management of late-life PD(A) 
have now been investigated in a randomized and controlled design for the first time and 
that the outcome of non-adapted manuahzed CBT for PDA has been directly compared 
in older (> 60 years) and younger (18-59 years) patients. 
9.8 Conclusions and clinical implications 
At the highest level of empirical evidence, i.e. the meta-analy tical level, the results of our 
studies only provide sufficient proof for the efficacy of CBT in the psychological treatment 
of late-life anxiety disorders, prompting the inference that in later life CBT is to be 
preferred over other psychological interventions Moreover, although recommendations 
have been made to adapt protocolized CBT for anxiety disorders to the specific needs 
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of the elderly to enhance outcome (Schuurmans, 2005), the empirical grounds for such 
age-specific modifications are weak. To date, only one pilot study (n = 42; Mohlman 
et al., 2004) comparing age-adapted and standard CBT showed better results for the 
adapted protocol The other available and methodologically sounder studies using larger 
samples showed no differences between two such treatment versions (Stanley et al, 
2003a, Wetherell et al, 2003). Furthermore, comparing the effect sizes obtained with 
CBT in elderly adults with anxiety disorders to those reported for younger and middle-
aged patients, only one study found a lower effect size for CBT in the elderly group 
(Schuurmans et al., 2006), while the other studies reported results for their older patients 
that were similar to those obtained in relatively younger adults (this thesis Chapter 2 
and Pinquart & Duberstein, 2007). In short, it is too precipitate to argue for age-specific 
adaptations to be introduced in the available and evidence-based CBT protocols for 
the treatment of anxiety disorders. Also the suggestion that antidepressants should be 
preferred in the treatment of late-life anxiety disorders (Pinquart & Duberstein, 2007) 
is preliminary considering the fact that empirical data of direct comparisons of CBT 
and antidepressants are lacking. Moreover, the relative risks of fractures and slip-and-
fall accidents in elderly patients treated with antidepressants or benzodiazepines are 
similarly high (see e.g. Hartikainen et al., 2007). 
Our PD(A) studies showed both CBT and paroxetine to be effective in elderly patients, 
with slightly better outcomes for CBT in patients with PDA onset at an older age. Both 
treatments were well tolerated and attrition was low Although unsubstantiated, we 
attribute the low attrition rates to the fact that the treatment was provided in our dedicated 
outpatient clinic where therapists are specialized in protocohzed CBT for anxiety 
disorders, which may not always have been the case in the other studies. Additionally, in 
such specialized settings like ours, systematic attention is paid to adherence-enhancing 
interventions, which may also have contributed to the low dropout 
Finally, and perhaps most saliently, age was never significantly negatively associated 
with outcome in our studies evaluating treatments of late-life PDA delivered according to 
the existing guidelines, and neither were age of onset and duration of illness. 
9.9 Recommendations for clinical practice and future research 
It is important to mention again that our samples, as in other trials of late-life anxiety 
disorders, were relatively small. This, obviously, warrants replication of our findings in 
larger cohorts. Additionally, as the prevalence of these disorders is high (Kessler et al., 
2005) and quality of life is impaired similarly to that in depression (Wetherell el al., 2004), 
more research into the treatment of late-life anxiety disorders is truly indispensable We, 
therefore, propose the following recommendations: 
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1. Education of patients and general practitioners (GPs) needs to be stepped up. Despite 
various efforts to boost the recruitment of elderly patients with PD(A) for our 
studies, among which coverage of the topic and our research in local newspapers, 
the referral rate remained low, drawing out our study accordingly. Arguably, the 
lack of knowledge about the symptoms and available treatments in primary care 
settings that prevent an adequate and timely identification and targeted treatment 
of late-life anxiety disorders remains a major concern. Providing elderly people 
as well as referrers (mostly GPs) with (more) targeted information about anxiety 
disorders in later life may contribute to a better recognition and treatment of these 
prevalent disorders. 
2. Offering dedicated consulting hours or setting up counselling clinics in local health 
centres or GP (group) practices should be considered. Many older people are rather 
averse to being referred to a mental health facility, which is probably caused by a 
fear of stigmatization. Especially in elderly patients with anxiety disorders offering 
targeted screening and treatment by specialized mental health professionals at the 
familiar local health centre or GP's office may reduce such reservations. 
3. RCTs should be conducted in accordance with the existing guidelines for the 
treatment of specific anxiety disorders to answer the following three main 
questions: 
a Can elderly people with specific anxiety disorders be treated as effectively as 
younger and middle-aged adults when applying the existing guidelines? 
b If not, which variables negatively affect outcome (most)? 
c Can these variables be neutralized by adapting the existing treatment protocols 
to the target group7 
4. Prospective studies need to examine the effects of ageing on the phenomenology of 
late-life anxiety disorders to help improve diagnostic and screening procedures. 
Prompted by the findings reported in this thesis and to help convey the current 
knowledge of the management of anxiety disorders in elderly patients with as much 
transparency as possible, we have prepared two protocols on the psychological and 
pharmacological treatments of late-life anxiety disorders for the Cochrane Database of 
Systematic Reviews. In these protocols we provide a summary of the available evidence 
and present the evidence gathered in this thesis, to which we aim to periodically add 
new empirical data on the topic (see Appendices A and B). 
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Samenvauing en discussie 
Angststoornissen zijn de meest voorkomende psychiatrische stoornissen (Kessler et al., 
2005a). Voor specifieke angststoornissen zoals paniekstoornis met/zonder agorafobie, 
sociale fobie, obsessief-compulsieve stoornis, posttraumatische stressstoornis en 
gegeneraliseerde angststoornis zijn effectieve farmacologische en psychologische 
behandelingen ontwikkeld. Hiervan is de werkzaamheid definitief vastgesteld in een 
groot aantal gepubliceerde meta-analyses (Abramowitz, 1997; Bakker et al., 2002; Van 
Balkom et al., 1997; Bisson & Andrew, 2007, Bradley et al., 2005; Fedoroff & Taylor, 
2001; Van der Linden et al , 2000; Mitte, 2005a; Mitte, 2005b; Norton & Price, 2007; 
Seidler &r Wagner, 2006; Stein et al., 2000; Taylor, 1996) Op basis daarvan zijn zowel 
nationale als internationale richtlijnen voor behandeling opgesteld1. Een belangrijke 
omissie is dat deze behandelrichtlijnen gebaseerd zijn op wetenschappelijk onderzoek 
bij volwassen van 18 lot 65 jaar met een gemiddelde leeftijd van ongeveer 35 jaar. Hoewel 
angststoornissen ook bij ouderen tot de meest voorkomende psychiatrische stoornissen 
behoren (Beekman et al, 1998; Kessler et al., 2005a), is onderzoek naar de behandeling 
hiervan in deze leeftijdsgroep uiterst beperkt. Bovendien blijkt uit bevolkingsonderzoek, 
dat minder dan 10% van de ouderen met een angststoornis hiervoor een adequate 
behandeling krijgt (De Beurs et al., 1999) in tegenstelling lot 50% bij jongere volwassenen 
(Wang et al., 2005b). Opvallend is dat ouderen met angststoornissen relatief vaak 
benzodiazepinen gebruiken (25-43%) (De Beurs et al., 1999; Schuurmans et al., 2005), 
terwijl deze juist op oudere leeftijd gepaard gaan met belangrijke bijwerkingen (verhoogd 
risico op (onge)vallen, amnesie en afhankelijkheid) en voor geen enkele angststoornis 
eerste keus zijn. Wanneer kritisch naar de eerste keus stappen gekeken wordt (SSRI of 
cognitieve gedragstherapie (CGT)), zou gezien de bijwerkingen van SSR's (vergelijkbaar 
valnsico als benzodiazepinen (Ensrud et al., 2002; Ensrud et al., 2003; Hartikainen et 
al., 2007; Liu et al., 1998)), voor ouderen misschien wel een voorkeur voor CGT moeten 
worden uitgesproken. 
Verschillende factoren liggen ten grondslag aan de onderbehandeling van angststoor-
nissen bij ouderen. Ten eerste is vermijdingsgedrag moeilijk op te sporen bij ouderen 
omdat het sociaal-maatschappelijk appel minder is, er dus minder externe druk is om op 
zoek te gaan naar een gerichte behandeling en er meer ondersteuning vanuit de sociale 
omgeving wordt aangeboden (Lindesay, 1991). Ten tweede is bij ouderen de diagnostiek 
complexer door a) een hogere prevalentie van somatische aandoeningen die symptomen 
geven die overlappen met somatische angstequivalenten (o.a. Seung Kim et al., 2001), b) 
overlap met depressieve stoornissen (hoewel die bij slechts 25% van de angststoornissen 
op hogere leeftijd speelt (Beekman et al., 2000)), c) terughoudendheid bij de huidige 
generatie ouderen om psychische problemen bespreekbaar te maken (Weijnen et al., 
1 htlp //www nice org uk/guidance/index jsp 
htlp //www psych org/MainMenu/PsychiatricPracticc/PracticeGuidelines_l aspx 
htlp //wwwggznchtlijnen nl/ 
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2006) of de neiging deze toe te schrijven aan somatische problemen (Sheehan et al., 2002) 
en tot slot d) een mogelijk andere, soms mildere fenotypische expressie (Brenes, 2006; 
Cnttendon & Hopko, 2006; Goldberg et al., 2003; Hunt et al., 2003; Klapow et al., 2002, 
Lau et al., 2001). Hoewel verondersteld wordt dat verschillen tussen angststoornissen op 
jongere en oudere leeftijd het effect van gerichte behandeling beïnvloeden (Stanley & 
Avenll, 1999), is dat nooit empirisch vastgesteld. Daarentegen wijzen gerandomiseerde, 
gecontroleerde behandelstudies juist op vergelijkbare effecten van psychologische en 
farmacologische behandeling bij (jong)volwassenen en ouderen met angststoornissen 
(Pinquart & Duberstein, 2007). 
Een belangrijke beperking bij het onderzoek onder ouderen is dat tot nu toe de focus 
vooral lag op de behandeling van gegeneraliseerde angststoornis of angststoornissen 
in algemene zin (Pinquart & Duberstein, 2007). Behandelstudies naar specifieke 
angststoornissen bij ouderen, zoals paniekstoornis met/zonder agorafobie, zijn niet 
voorhanden. Geïnspireerd door succesvolle praktijkervaringen met het behandelen 
van angststoornissen op oudere leeftijd en vanwege de schaarse empirische gegevens 
bij de oudere leeftijdscategorie is het doel van dit proefschrift een bijdrage te leveren 
aan het vergaren van meer empirische gegevens over de effectiviteit van cognitieve 
gedragstherapie bij angststoornissen op oudere leeftijd in algemene zin, en de 
farmacologische en cognitief-gedragstherapeutische behandeling van paniekstoornis 
met/zonder agorafobie op oudere leeftijd in het bijzonder. Gezien de vooroordelen ten 
aanzien van de behandelmogelijkheden bij ouderen, werd specifiek onderzoek gedaan 
naar het effect van leeftijd, de ontstaansleeftijd van de paniekstoornis en de ziekteduur 
op het behandelresultaat. De onderzoeksvragen luidden als volgt 
1. Zijn zowel CGT als antidepressiva vergelijkbaar effectief in de behandeling van 
ouderen met angststoornissen? 
2. Is CGT effectiever dan andere niet-farmacologische interventies bij de behandeling 
van ouderen met angststoornissen? 
3. Zijn zowel paroxetine als CGT effectief bij de behandeling van ouderen met een 
paniekstoornis met/zonder agorafobie en worden beide behandelingen goed 
verdragen? 
4. Is de inhoud van de agorafobische cognities bij (jong)volwassenen en ouderen met 
een paniekstoornis met agorafobie verschillend? 
5. Is CGT voor paniekstoornis met agorafobie bij ouderen even effectief en wordt deze 
behandeling net zo goed verdragen als bij (jong)volwassenen? 
6. Zijn leeftijd, ontstaansleeftijd en ziekteduur geassocieerd met het behandelresultaat 
van CGT voor paniekstoornis met agorafobie? 
7. Zijn bij ouderen met een paniekstoornis met agorafobie leeftijd en ziekteduur 
geassocieerd met het behandelresultaat van paroxetine en/of CGT? 
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Literatuuroverzicht en meta-analyse 
In hoofdstuk 2 en 3 wordt een systematische literatuurstudie gepresenteerd van de tot 
nu toe verschenen behandelstudies bij ouderen (> 55 jaar) met angststoornissen. Sinds 
hel einde van de jaren '90 van de vorige eeuw wordt er, hoewel bescheiden in volume, 
systematisch onderzoek verricht naar de behandeling van angststoornissen op oudere 
leeftijd. Om te voorkomen dat de geincludeerde studies van onvoldoende methodologische 
kwaliteit zouden zijn en onvoldoende vergelijkbaar, werden alleen gerandomiseerde, 
gecontroleerde studies opgenomen waarin gebruikt werd gemaakt van valide instrumenten 
voor diagnostiek en monitoring van het behandelresultaat. Het doel was na te gaan of 
angststoornissen ook bij ouderen effectief te behandelen zijn met zowel farmacotherapie als 
CGT en of er bewijs was dal CGT effectiever was dan andere psychologische interventies. 
Van de 56 potentiële studies naar behandeling van angststoornissen bij ouderen, voldeden 
slechts acht CGT- en drie farmacotherapiestudies aan de inclusiecriteria Alle studies 
hadden betrekking op patiënten met een gegeneraliseerde angststoornis of een gemengde 
groep patiënten met een gegeneraliseerde angststoornis, paniekstoornis of sociale fobie. 
In hoofdstuk 2 werden de effect sizes volgens Cohens d berekend voor de gemeen-
schappelijke angst- en depressieschalen. De effect sizes met betrekking tot de voor- en 
nameting/follow-up binnen behandelgroepen met farmacotherapie en CGT waren groot 
(> 0.8) in zeven van de acht CGT-studies en in alle farmacotherapiesludies. In vergelijking 
met de controlecondities, werden matig tot grote effect sizes gevonden (Cohens d = 0.3 
tot 0.8), waarbij farmacotherapie superieur bleek aan CGT (1 studie). 
In hoofdstuk 3 werd een meta-analyse uitgevoerd naar het effect van CGT. Behandeling 
met CGT bleek zowel superieur aan een wachthjstcontroleconditie als aan een actieve 
controleconditie waarin patiënten (met-specifieke) aandacht of ondersteunende psycho-
logische interventies kregen aangeboden. 
De conclusie van beide overzichten is dat zowel CGT als antidepressiva effectief zijn 
voor de behandeling van angststoornissen op oudere leeftijd en dal CGT effectiever is 
dan andere niet-farmacologische interventies. De enige studie waarin farmacotherapie 
en CGT direct vergeleken werden liet een superieur effect voor farmacotherapie zien. Dit 
resultaat moet echter met enige voorzichtigheid geïnterpreteerd worden, aangezien het 
effect van CGT in deze studie duidelijk kleiner was dan het effect van CGT in de andere 
CGT-studies. 
Deze systematische literatuurstudies bevestigden de afwezigheid van gecontroleerde 
behandelstudies naar angststoornissen bij ouderen anders dan de gegeneraliseerde 
angststoornis. Aangezien bij de behandeling van de gegeneraliseerde angststoornis 
vergelijkbare effecten werden gevonden als in jongere populaties (Mitte, 2005b; Pinquart 
& Duberstein, 2007), is het belangrijk na te gaan of de andere angststoornissen op 
oudere leeftijd evenzeer succesvol behandeld kunnen worden. In dit proefschrift werd 
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ervoor gekozen de behandelmogelijkheden van ouderen met een paniekstoornis nader te 
onderzoeken omdat de prevalentie daarvan gedurende het leven bij deze leeftijdsgroep 
relatief hoog is, namelijk 2% (Kessler et al , 2005a). Aangezien bij jongere volwassenen 
met een paniekstoornis met/zonder agorafobie de agorafobische variant als de meest 
ernstige variant wordt beschouwd en deze relatief frequent voor behandeling naar 
gespecialiseerde poliklinieken worden doorverwezen waren wij vooral geïnteresseerd in 
oudere patiënten met deze variant 
Behandeling van ouderen met een paniekstoornis met/zonder agorafobie 
De studie in hoofdstuk 4 was gericht op het vaststellen van de effectiviteit van CGT 
en paroxetine voor ouderen met een paniekstoornis In totaal werden 49 patiënten 
geincludeerd met een gemiddelde leeftijd van 70 (SD = 5) jaar. Hiervan werden 20 
patiënten toegewezen aan de behandelconditie met CGT (14 sessies, protocollair), 17 
aan de medicatieconditie (paroxetine 40 mg per dag) en 12 patiënten aan de wachtlijst-
conditie. De uitval was 5% (1/20) in de CGT-conditie, 18% (3/17) in de paroxetineconditie 
en 8% (1/12) in de wachtlijstconditie. Beide behandelingen waren significant beter dan 
de controleconditie op primaire uitkomstmaten (agorafobisch vermijdingsgedrag en 
agorafobische cognities) en de secundaire uitkomstmaat algemene psychopathologie met 
middelmatige tot grote effectgroottes (Cohens d varieerde van 0.6 tot 0.9). Er was geen 
verschil tussen behandeling met CGT of paroxetine. 
Een belangrijk aandachtspunt is dal zowel de farmacologische als de psychologische 
behandeling goed werd verdragen. Met een totale uitval van 5 van de 49 patiënten (10%) 
is deze opvallend gering in vergelijking met andere behandelstudies bij ouderen met 
angststoornissen (meestal tussen de 25 en 30% (Hendriks et al., 2008a; Pinquart & 
Duberslein, 2007). Een mogelijke verklaring is hel feit dat beide behandelingen werden 
uitgevoerd op een gespecialiseerde polikliniek met een lange traditie in de uitvoering 
van geprotocolleerde behandeling van angststoornissen. 
Een tweede belangrijk aandachtspunt is dat tussen 1999 en 2006 slechts 49 patiënten van 
60 jaar of ouder met een paniekstoornis met/zonder agorafobie werden geincludeerd. Dit is 
fors minder dan verwacht mag worden op basis van prevalentiecijfers in bevolkingsstudies 
en in het verzorgingsgebied van onze polikliniek. Eerdere studies naar oudere patiënten 
met angststoornissen blijken eveneens moeite te hebben gehad met de recrutering (o.a. 
Schuurmans et al., 2006). Hoewel men enkel kan speculeren naar een verklaring hiervoor, 
zijn de volgende aspecten, naast de eerdergenoemde factoren (zie de inleiding van deze 
samenvatting), mogelijk van belang. Zowel hulpverleners, patiënten zelf als hun omgeving 
kunnen lage verwachtingen hebben van de behandelmogelijkheden op oudere leeftijd 
voor vaak al lang bestaande klachten waardoor het vertrouwen in herstel gering zal zijn 
(Klap et al., 2003). Daarnaast zou er sprake kunnen zijn van angst voor stigmatisering bij 
doorverwijzing naar een instelling voor geestelijke gezondheidzorg (Sirey el al., 2001). 
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Een opvallende bevinding ten slotte was de relatief lage totaalscore op de vragenlijst voor 
agorafobische cognities. Een eerdere studie vond eveneens lagere scores voor agorafobische 
cognities bij oudere patiënten met een paniekstoornis in vergelijking met jongere patiënten 
(Sheikh et al., 2004). Dit roept de vraag op of ouderen met een paniekstoornis andere 
angstcognities hebben of dat specifieke cognities afnemen met hel ouder worden en dit 
een aanwijzing zou kunnen zijn voor een leeftijdsgerelateerde afname in ernst van de 
paniekstoornis. Om dit te onderzoeken werd de volgende studie verricht. 
Agorafobische cognities bij ouderen en (jong)volwassenen met een paniekstoornis 
met agorafobie 
In hoofdstuk 5 werden de agorafobische cognities van 48 oudere (Ä 60 jaar, range 60 - 85 
jaar) patiënten met een paniekstoornis met agorafobie vergeleken met die van 157 jongere 
patiënten (< 60 jaar) De oudere patiënten hadden een significant lagere totaalscore op de 
Agoraphobic Cognitions Questionnaire (ACQ). Ouderen hadden op elke item gemiddeld 
een lagere score, waarbij significant lagere scores gevonden werden voor de angstgedachte 
om gek te worden, om zich belachelijk te gedragen, om de controle te verliezen, om 
flauw te vallen en de angstgedachte een hersentumor te hebben. Geconcludeerd werd 
dat het differentiële effect op itemniveau aangeeft dat bepaalde agorafobische cognities 
bij paniekstoornis met agorafobie op oudere leeftijd mogelijk minder relevant zijn dan 
bij jongere volwassenen met een paniekstoornis. Een beperking van de studie is dat 
niet is nagegaan of ouderen met paniekstoornis met agorafobie wellicht andere agora-
fobische cognities hebben. Deze bevindingen zetten dus twijfels bij het gebruik van de 
ACQ bij ouderen. Vooralsnog is er echter geen geschikt onderzoeksinstrument voor 
het beoordelen van de agorafobische cognities bij ouderen met een paniekstoornis 
met agorafobie. Omdat er geen verschil was in agorafobische vermijding tussen beide 
leeftijdsgroepen is het advies om bij het beoordelen van de ernst van de paniekstoornis 
met agorafobie bij ouderen vooral af te gaan op ernst van de agorafobische vermijding. 
In de literatuur over psychotherapie bij ouderen wordt vaak gesproken over leeftijd-
specifieke aanpassingen in de behandeling. In het kader van de behandeling van 
angststoornissen bij ouderen, is slechts 1 studie bekend waarbinnen een gerandomiseerde 
studieopzet een standaard- versus een aangepaste vorm van CGT bij ouderen werd 
toegepast (Mohlman et al., 2003). Hoewel de aangepaste vorm betere resultaten het zien, 
kunnen hier gezien de beperkte omvang van de studie (n = 42) geen harde conclusies 
aan verbonden worden. Tevens zijn eerdere behandelstudies naar angststoornissen 
bij ouderen vaak in groepsvorm uitgevoerd vanuit het idee dat dit juist voor ouderen 
prettig is (Stanley et al., 1996). Bevindingen bij jongere patiënten met angststoornissen 
wijzen echter uit dat de effecten van groepsbehandeling geringer zijn in vergelijking met 
individuele behandeling. 
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Omdat een vergelijking tussen de behandeling van ouderen en jongeren met een bestaand 
behandelprotocol zonder aanpassing aan de oudere leeftijdsgroep nooit is uitgevoerd, 
werd dit door ons nader onderzocht. 
CGT voor paniekstoornis met agorafobie: een vergelijking tussen ouderen en (jong) 
volwassenen 
In hoofdstuk 6 werd de effectiviteit van een niet aan de oudere leeftijd aangepaste, 
geprotocolleerde CGT voor paniekstoornis met agorafobie bij 31 oudere patiënten 
(Ä60 jaar, gemiddelde leeftijd 68) vergeleken met 141 jongere patiënten. Opvallend 
was de significant grotere verbetering op agorafobisch vermijdingsgedrag in de oudere 
leeftijdsgroep in vergelijking met de jongere patiënten. Er werden geen significante 
verschillen in behandeleffect gevonden tussen de twee leeftijdsgroepen op de andere 
primaire uitkomstmaat (agorafobische cognities) en de secundaire uitkomstmaten 
(algemeen niveau psychopathologie en depressieve symptomen). De uitval in de jongere 
leeftijdsgroep (31/141, 22%) was numeriek hoger dan in de oudere leeftijdsgroep (2/31, 
6%), maar dit verschil bleek niet significant (p = 0.06). 
Geconcludeerd werd dat geprotocolleerde CGT even goed verdragen werd door de 
oudere patiënten en dat zij zelfs in vergelijking met de jongere patiënten meer profiteerden 
van het CGT-protocol met betrekking tot afname van de agorafobische vermijding. 
Het aanpassen van de bestaande CGT-behandelprotocollen aan oudere patiënten lijkt 
vooralsnog niet nodig. 
Vanwege onderdiagnostiek en daarmee samenhangende onderbehandeling bestaat de 
paniekstoornis, die veelal op jongere leeftijd onstaat, bij oudere patiënten al vele jaren. 
Daarnaast blijkt uit bevolkingsonderzoek dat er een kleine groep ouderen is die voor 
het eerst na het 60e levensjaar een paniekstoornis ontwikkelt (Kessler et al., 2005a). 
Deze groep blijkt in klinische populaties relatief frequent vertegenwoordigd te zijn met 
percentages variërend van 3-6% (Segui et al., 2000, Sheikh et al., 1991; Raj, Corvea &r 
Dagon, 1993). Omdat in de praktijk veel behandelaren een hogere leeftijd en/of langere 
ziekteduur associëren met een slechter behandelresultaat, werd dit in de studies in 
hoofdstuk 5 gericht onderzocht. 
Het verband tussen leef tij dsgerela teerde variabelen en het behandelresultaat 
De studie in hoofdstuk 7 betrof dezelfde populatie als in hoofdstuk 6. Onderzocht werd 
de relatie tussen leeftijd, de ontstaansleeftijd van de stoornis en de ziekteduur met het 
behandelresultaat. Het bleek dat leeftijd geen invloed had op het behandelresultaat 
Echter, oudere leeftijd en het ontstaan van de paniekstoornis op een leeftijd van 
boven de 60 jaar voorspelde een sterkere verbetering van de agorafobische vermijding. 
Geconcludeerd werd dat het hebben van een oudere leeftijd zeker niet geassocieerd mag 
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worden met een afgenomen effectiviteit van geprotocolleerde CGT voor paniekstoornis 
met agorafobie. 
De studie in hoofdstuk 7 was gericht op het onderzoeken van leeftijdsgerelateerde 
variabelen en ziekteduur met betrekking tot de effecten van paroxetine 40 mg per dag 
(n = 17) of geprotocolleerde CGT (n = 20) bij patiënten van 60 jaar of ouder met een 
paniekstoornis met agorafobie. Gevonden werd dat een hogere leeftijd en een korte 
ziekteduur een beter behandeleffect voorspelden bij geprotocolleerde CGT, maar 
niet voor behandeling met paroxetine. De conclusie was dat onafhankelijk van de 
behandelmodaliteit leeftijd niet van invloed is op de uitkomst voor behandeling van 
paniekstoornis met agorafobie op oudere leeftijd. Tevens kwam naar voren dat een hoge 
ontstaansleeftijd in combinatie met een kortere ziekteduur een relatief gunstig effect van 
de CGT voorspelde, terwijl ontstaansleeftijd en ziekteduur niet van invloed waren op het 
effect van paroxetine. Hieruit zou voorzichtig afgeleid kunnen worden dat bij een vroege 
ontstaansleeftijd en dus ook een lang ziektebeloop ouderen met een paniekstoornis 
mogelijk beter met paroxetine behandeld kunnen worden dan met CGT. Een belangrijke 
beperking van beide studies is echter de geringe groepsgrootte van de groep oudere 
patiënten. Du betekent dat het slechts voorlopige bevindingen betreft en dat replicatie in 
grotere onderzoekspopulaties nodig is om de betekenis van leeftijd, ontstaansleeftijd en 
duur van de klachten verder te ontrafelen bij oudere patiënten. 
Methodologische overwegingen 
De belangrijkste beperking van het literatuuroverzicht (hoofdstuk 2) is in de eerste 
plaats het bescheiden aantal gecontroleerde studies van goede methodologische kwaliteit 
betreffende de farmacologische en psychologische behandeling van angststoornissen bij 
ouderen. Daarnaast zijn de steekproefgroottes relatief geringen is het uitvalpercentage vaak 
meer dan 20% wat als belangrijke bovengrens wordt gehanteerd door de Cochrane Study 
Group. Bovendien hebben de meeste studies alleen patiënten met een gegeneraliseerde 
angststoornis onderzocht en is bij alle studies de gemiddelde leeftijd relatief laag, 
namelijk 61 tot 72 jaar. Het aantal behandelstudies met farmacologische interventies 
was zo gering dat een goede kwantitatieve analyse niet mogelijk was. Daarom betreft de 
meta-analyse (hoofdstuk 3) enkel een kwantitatieve analyse van behandelstudies met 
psychologische interventies bij ouderen met angststoornissen Ook voor de meta-analyse 
gelden bovengenoemde beperkingen, waardoor de resultaten enkel generaliseerbaar zijn 
naar relatief jongere ouderen met een gegeneraliseerde angststoornis. 
De studie (hoofdstuk 4) naar de effecten van paroxetine en CGT bij ouderen met 
een paniekstoornis in vergelijking met een wachtlijstconditie is de eerste studie ter 
wereld. Helaas is de statistische power enigszins beperkt door de steekproefgrootte 
(n = 49), waardoor de conclusies met enige voorzichtigheid geïnterpreteerd moeten 
worden. Een belangrijke tweede beperking is het ontbreken van een placebo-conditie 
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voor de paroxetineconditie en een steunende, structurerende interventiearm voor de 
CGT-conditie. Het feit dat beide actieve behandelingen vergelijkbare effect sizes lieten 
zien als die in eerder gepubliceerde meta-analyses bij (jong)volwassenen (Mitte, 2005), 
pleit tegen een grote invloed van een placebo-effect. Het gebruik van klachtenspecifieke 
zelfrapportagevragenlijsten die niet gevalideerd zijn bij ouderen met een paniekstoornis, 
is een volgende beperking. Hier kan overigens tegenin worden gebracht dat de beperkte 
empirische gegevens over het valideren van bestaande, voor (jong)volwassenen 
ontwikkelde klachtenspecifieke zelfrapportagevragenlijsten bij ouderen met een angst-
stoornis niet tot bezwaren hebben geleid om zulke vragenlijsten ook bij ouderen te 
gebruiken (Crittendon et al., 2006, Fuentes et al., 2000). Tot slot hebben de bevindingen 
betrekking op een relatief jonge, relatief gezonde en mobiele groep ouderen (gemiddelde 
leeftijd is 69.6 jaar) Hierdoor zijn onze bevindingen niet generaliseerbaar naar meer 
kwetsbare en oudere ouderen. 
De eerdergenoemde beperkingen die samenhangen met het gebruik van zelf-
rapportagevragenlijsten en de demografische kenmerken van de groep ouderen gelden 
ook voor de navolgende studies. 
De studie naar verschillen in agora fobische cognities bij ouderen en (jong) volwassenen 
met een paniekstoornis met agorafobie (hoofdstuk 5) wordt vooral beperkt vanwege het 
feit dat er geen kwantitatieve analyse heeft plaatsgevonden naar agorafobische cognities 
die niet in de Agoraphobic Cognitions Questionnaire (ACQ) waren opgenomen. 
Bij de vergelijking van CGT voor paniekstoornis met agorafobie bij ouderen en (jong) 
volwassenen (hoofdstuk 6) beïnvloedt eveneens de beperkte omvang van de 60-plus 
steekproef (n = 31) de statistische power en dienen de conclusies met enige voorzichtigheid 
geïnterpreteerd te worden. Daarnaast is niet uitgesloten dat er, in vergelijking met de 
groep (jong)volwassenen juist bij de groep ouderen sprake is van selectiebias, aangezien 
juist bij ouderen in grotere mate sprake is van onderdiagnostiek en onderbehandeling. 
Dit zou kunnen betekenen dat juist de ouderen met paniekstoornis die het best in staat 
zijn hun angst- en paniekklachten te verwoorden en te vertalen naar een duidelijke 
hulpvraag zijn verwezen naar onze gespecialiseerde polikliniek. 
In hoofdstuk 7 wordt de relatie bestudeerd tussen leeftijd, ontstaansleeftijd en 
ziekteduur en het uiteindelijke behandelresultaat. Het operationaliseren van een vroege en 
late ontstaansleeftijd van de paniekstoornis is echter complex. Data uit epidemiologische en 
klinische studies definieren late ontstaansleeftijd meestal als het ontstaan boven het 30' tot 
50c levensjaar (Katerndahl & Talamantes, 2000; Sheikh et al., 2004). Nadeel van zo'n lage 
leeftijdsgrens is het voorbijgaan aan de invloed van veroudering op de Symptomatologie 
en ernst van de paniekstoornis. Aansluitend bij de algemeen geaccepteerde leeftijdsgrens 
van 55 tot 65 jaar en in navolging van andere onderzoekers (Segui et al., 2000) is besloten 
een klinische definitie te hanteren van 60 jaar en ouder voor een late ontstaansleeftijd. 
Daarnaast wordt het betrouwbaar vaststellen van de ontstaansleeftijd en de daarmee 
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samenhangende ziekteduur ongunstig beïnvloed omdat dit is gebaseerd op retrospectieve 
data. Het is mogelijk dat er sprake is van een differentieel effect van CGT en paroxetine bij 
ouderen met een paniekstoornis met agorafobie (hoofdstuk 8), waarbij CGT de voorkeur 
heeft bij ouderen met een late onstaansleeftijd en korte ziekteduur en farmacotherapie de 
voorkeursbehandeling zou kunnen zijn bij een jonge ontstaansleeftijd en een langdurig 
chronisch ziektebeloop. Omdat de bevindingen niet consistent significant zijn wanneer 
beide behandelingen in één analyse rechtstreeks met elkaar vergeleken worden en de 
onderzochte steekproef gering van omvang is, dient men de nodige terughoudendheid te 
betrachten bij deze conclusie. 
Deze kritische reflectie op onze studies dient echter ook in de volgende context te worden 
geplaatst. Het rekruteren en includeren van ouderen voor wetenschappelijk onderzoek 
naar de behandeling van angststoornissen is wereldwijd nog steeds een moeizaam proces. 
Van de angststoornissen is alleen de behandeling van de gegeneraliseerde angststoornis 
bij ouderen relatief frequent onderzocht. Voor de andere angststoornissen zijn de 
empirische gegevens summier of ontbreken. De tot nu toe bekende factoren die hieraan 
ten grondslag liggen zijn eerder besproken. Binnen deze context is het een unicum 
dat voor de eerste maal CGT en SSRI-behandeling bij ouderen met een panieksloornis 
gecontroleerd zijn onderzocht op effectiviteit, en dat voor de eerste maal de CGT voor 
paniekstoornis op effectiviteit is vergeleken binnen twee leeftijdsgroepen, namelijk een 
groep van 18-59 jaar en een groep van 60 jaar en ouder. 
Conclusies en klinische betekenis 
Samenvattend kan worden vastgesteld dat uit onze studies is gebleken dat enkel voor 
CGT voldoende empirisch bewijs in de hoogste bewijsklasse (meta-analyses) bestaat 
voor de behandeling van angststoornissen op hogere leeftijd. Dit betekent dat CGT de 
voorkeur verdient boven andere psychologische behandelvormen bij de behandeling 
van angststoornissen op oudere leeftijd. Hoewel eerder onderzoek suggereerde dat het 
bij ouderen met angststoornissen van belang is het CGT-protocol aan te passen om 
het resultaat van de behandeling te vergroten (Schuurmans, 2005) is het empirische 
fundament hiervoor bescheiden. Tot nu toe is er slechts één pilotstudie (n = 42; Mohlman 
et al., 2004) waaruit is gebleken dat een specifiek voor ouderen met gegeneraliseerde 
angststoornis (GAS) ontwikkeld CGT-protocol een beter resultaat heeft dan het standaard 
CGT-protocol voor GAS. Andere studies, groter van omvang en methodologisch van 
hogere kwaliteit, lieten geen verschil zien tussen een aan ouderen aangepast CGT-protocol 
en het standaard CGT-protocol voor GAS (Stanley et al., 2003a, Wetherell et al., 2003). 
Slechts één studie vond, in vergelijking met (jong)volwassenen, een lagere effect size 
voor CGT bij ouderen met angststoornissen (Schuurmans et al., 2006), terwijl de overige 
behandelresultaten van CGT voor ouderen met angststoornissen vergelijkbaar waren met 
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die bij (jong)volwassenen (hoofdstuk 2, dit proefschrift; Pinquart & Duberstein, 2007). 
Het is daarom nog te vroeg om te stellen dat bij ouderen met angststoornissen de CGT 
specifiek dient te worden aangepast aan de hogere leeftijd. Ook de suggestie dal ouderen 
met angststoornissen bij voorkeur met farmacotherapie dienen te worden behandeld 
(Pinquart & Duberstein, 2007) dient met enige terughoudendheid te worden betracht. 
Empirische gegevens over rechtstreekse vergelijkingen van CGT en farmacotherapie bij 
angststoornissen zijn er nauwelijks en voorts blijken de antidepressiva een vergelijkbaar 
risico te hebben op valongevallen en fracturen als de benzodiazepinen (o.a. Hartikainen 
et al., 2007). 
De bevindingen van onze studies wezen vervolgens uit dat bij oudere patiënten met 
een paniekstoornis met/zonder agorafobie zowel CGT als paroxetine effectief waren. 
Tevens was er een lichte voorkeur voor geprotocolleerde CGT wanneer de paniekstoornis 
was ontstaan op latere leeftijd. Beide behandelvormen werden goed verdragen op oudere 
leeftijd met slechts geringe uitval. Het is mogelijk dat het gegeven dat deze patiënten 
verwezen waren naar een gespecialiseerde polikliniek een rol heeft gespeeld bij de 
geringe uitval (in vergelijking met andere studies op dit gebied) vanwege de aanwezige 
expertise betreffende de behandeling van angststoornissen. Omdat in deze setting ook 
systematisch veel aandacht werd besteed aan therapietrouwbevorderende interventies 
zou dit ook een aanvullende verklaring kunnen zijn voor de geringe uitval. 
Tot slot was een belangrijke bevinding van onze studies dat leeftijd geen rol van 
betekenis speelde met betrekking tot het te behalen effect van de behandeling van 
paniekstoornis conform de bestaande richtlijnen. Eveneens waren de ontstaansleeftijd 
en ziekteduur geen voorspellers van een negatief behandelresultaat. 
Aanbevelingen voor de klinische praktijk en toekomstig onderzoek 
Van belang om nogmaals te noemen is dat ook onze steekproef relatief klein was en dat 
replicatie met een grotere steekproef, evenals onderzoek naar de overige angststoornissen 
op hogere leeftijd zeker nodig is vanwege de hoge prevalentie van deze aandoeningen 
in de oudere leeftijdscategorie (Kessler et al., 2005) en de hiermee gepaard gaande 
ziektelast (Wetherell et al., 2004). Op grond hiervan zouden wij de volgende, allerminst 
uitputtende, aanbevelingen willen doen: 
1. Voorlichting aan verwijzers en patiënten. Ondanks diverse inspanningen (o.a. 
berichtgeving in lokale dagbladen) om voldoende ouderen met angststoornissen 
verwezen te krijgen, was de instroom traag en het beloop van onze studie daardoor 
lang Het onderkennen van angststoornissen in de eerste lijn en hel vervolgens 
gericht gaan behandelen blijft een belangrijk aandachtspunt. Gerichte voorlichting 
over angststoornissen bij ouderen voor zowel patiënten zelf als verwijzers (meestal 
huisartsen) zou kunnen bijdragen tot verbetering van de herkenning en de 
behandeling van angststoornissen bij ouderen. 
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2. Het aanbieden van gespecialiseerde consultatiemogehjkheden in de huisartsen-
praktijk. Veel ouderen ervaren, vanuit angst voor stigmatisering, een hoge drempel 
om doorverwezen te worden naar een GGZ-instelling. Gerichte screening door 
gespecialiseerde professionals binnen de voor ouderen veelal bekende en vertrouwde 
setting van de huisarts zou mogelijk deze drempel kunnen verlagen waardoor de 
mogelijkheden voor het aanbieden van gerichte behandeling zou kunnen worden 
vergroot. 
3. Het opzetten van RCT's conform de bestaande richtlijnen voor de behandeling van 
specifieke angststoornissen met een drieledig doel: 
a Zijn ouderen met specifieke angststoornissen net zo effectief te behandelen 
conform de bestaande richtlijnen als (jong)volwassenen? 
b Indien dit niet het geval blijkt, welke zijn dan de variabelen die dit ongunstig 
beïnvloeden? 
c Zijn deze belemmerende variabelen met aanpassingen in de bestaande behandel-
protocollen weg te nemen? 
4. Het opzetten van prospectieve studies om na te gaan wat de effecten zijn van 
veroudering op de fenomenologie van de angststoornissen met als doel de diagnos-
tiek en screening van angststoornissen bij ouderen te verbeteren. 
Teneinde de kennis over de behandeling van angststoornissen bij deze specifieke doel-
groep zo goed mogelijk naar voren te brengen, hebben wij naar aanleiding van ons 
onderzoek twee protocollen met betrekking tot de psychologische en farmacologische 
behandeling van angststoornissen op oudere leeftijd opgesteld voor de Cochrane 
Database of Systematic Reviews. Het doel is de huidige, beschikbare evidentie samen 
te vatten en periodiek aan te vullen met toekomstige empirische gegevens betreffende 
behandeling van angststoornissen op oudere leeftijd (zie bijlage A en B). 
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Background 
Description of the condition 
Patients with anxiety complain of tension or restlessness, or they exhibit jitteriness, 
autonomic hyperactivity, vigilance, insomnia, distractibihty, shortness of breath, 
numbness, apprehension, worry or rumination. Although most people experience such 
symptoms, an anxiety disorder is suspected when symptoms become disproportionately 
severe compared to their problems. According to the criteria of the Diagnostic and 
Statistical Manual of Mental Disorders (DSM), anxiety disorders in later life are classified 
similarly to those in adult life and include panic disorder with and without agoraphobia, 
generalized anxiety disorder, social phobia, specific phobia, obsessive-compulsive 
disorder, and posttraumatic and acute stress disorder (APA 1980, APA 1987, APA 1994). 
Pure anxiety disorders in later life are rare, as most patients have a comorbid second 
anxiety disorder or depressive disorder (Flint,2005b; Kessler et al. 2005a; Lenze et al. 
2005a; Van Balkom et al., 2000). 
The prevalence rate of anxiety disorders among older adults living in the community 
has been estimated between 10 and 15%, with generalized anxiety disorder, panic 
disorder and specific phobias being the most common (Beekman et al., 1998; Kessler 
et al., 2005a). In later life, anxiety disorders impair quality of life by having a negative 
impact on functioning, well-being, and medical consumption (De Beurs et al., 1999; Van 
Zeist, De Beurs, Beekman, Van Dyck & Deeg, 2006; Wetherell et al, 2004a). Moreover, 
patients suffering from anxiety disorders have an increased risk of becoming depressed 
(Beekman et al., 2000), and left untreated, anxiety disorders tend to become chronic 
(Larkin, Copeland, Dewey, Davidson, Saunders, Sharma et al., 1992). In two large cohort 
studies, anxiety disorders in later life were prospectively associated with an increased 
mortality rate (Brenes et al., 2007; Van Hout et al., 2004). 
Description of the intervention 
First line treatment for anxiety disorders consists, of psychological treatment or 
antidepressant drugs (Trimbos-instituut, 2003; NICE, 2007) Community studies show 
that only 5.1% of older adults suffering from anxiety disorders receive psychological 
treatment and only 3.8% are prescribed an antidepressant drug (De Beurs et al., 1999). 
Both patient and physician characteristics may contribute to this phenomenon. Many 
older adults resist the use of antidepressants based on fear of dependence, prior negative 
experiences, resistance to viewing their symptoms as a medical illness, and concern that 
antidepressants will prevent natural feelings (Givens et al., 2006). The average duration 
between anxiety symptom onset and first treatment contact has been shown to be between 
9 and 23 years, suggesting general practitioners do not easily recognize anxiety disorders 
(Kroenke, Spitzer, Williams, Monahan &r Lowe, 2007; Wang et al., 2005a) The referral 
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rate from primary care to a mental health specialist is three times lower for older adults 
suffering from anxiety disorders (17%) compared to those suffering from depression 
(55%) (Ettner & Hermann, 1997). Furthermore, general practitioners themselves may 
be reluctant to prescribe drugs for anxiety symptoms being afraid for increased side 
effects in later life, for example the increased risk of falling and traffic accidents, memory 
impairment, and dependency associated with the use of benzodiazepines (Gorgels, Oude 
Voshaar, Mol, Breteler, Van de Lisdonk & Zitman, 2001) and hyponatraemia with the 
use of serotonin reuptake inhibitors (Wright & Schroeter, 2008). Also of concern are 
the adverse effects of drug interactions, such as gastrointestinal bleeding resulting from 
the concurrent use of serotonin reuptake inhibitors and non steroidal anti-inflammatory 
drugs in this age group known for polypharmacy use (Weinneb et al., 2005; Yuan et al., 
2006). As effective management of anxiety disorders in later life may improve outcome, 
it is important that guidelines for treatment become available. 
Cognitive-behavioural therapy (CBT) combines principles of both behavioural and 
cognitive therapy. Cognitive therapy (CT) assumes that a patient's symptoms (e.g., 
anxiety) arise from misperceptions and attitudes about the world and themselves (Beck, 
1995). Behavioural therapy (BT) is a directive, active approach involving principles of 
learning to help the patient develop new and adaptive ways of behaving (Bandura, 1969; 
Yates, 1970). As a psychotherapy, CBT is characterized as a structured, goal-oriented, 
problem-focused, time-limited intervention (Korrelboom & ten Broeke, 2004). In order 
to deal with age-associated cognitive impairment, some authors argue for inclusion of 
learning and memory aids like homework reminders, troubleshooting calls or weekly 
review of all concepts and techniques (Mohlman et al., 2003). Recent RCTs on older adults, 
however, remain inconclusive on whether age-related adaptations of psychotherapeutic 
techniques are necessary to remain efficacious for anxiety disorders in later life (Stanley 
et al, 2003a; Stanley et al., 2003b; Wetherell, Lenze & Stanley, 2005c). 
How the intervention might work 
CBT identifies habitual ways in which patients distort information (e.g., automatic 
thoughts) and teaches patients to identify and respond to their dysfunctional thoughts 
and beliefs, using a variety of techniques to change thinking, mood, and behaviour. 
Behavioural interventions help the patient develop new and adaptive ways of behaving. 
Exposure-based treatment utilizes gradual, systematic, repeated exposure to the feared 
object or situation to desensitize patients with anxiety disorders to the feared stimulus. 
The controlled exposures are predictable and the patient is taught a variety of adaptive 
coping strategies. 
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Why it is important to do this review? 
CBT is generally considered the most effective psychotherapy for anxiety disorders 
(Trimbos-instituut, 2003) The efficacy of CBT for anxiety disorders in young and middle-
aged adults is supported by a variety of meta-analyses (Bakker, Van Balkom, Spinhoven, 
Blaauw & Van Dyck, 1998, Furukawa et al, 2006, Mitte, 2005a, Mitte, 2005b, Westen 
& Morrison, 2001) However, whether these results also apply to older adults remains 
unclear since most trials exclude participants over the age of 65 years (Wetherell et al , 
2003) Generalization of meta-analytic studies in young and middle-aged adults to older 
adults is limited, as older adults often have more chronic disorders, which are presumed 
to be more treatment resistant (Katz et al , 2002) Therefore, the current review aims 
to provide a comprehensive and up to date summary of the available evidence on CBT 
as a treatment for older adults Many of the earlier studies regarding the psychological 
treatment of anxiety disorders in later life suggest efficacy for CBT, but have been limited 
to subclinical anxiety and lack rigorous inclusion criteria, like the presence of an anxiety 
disorder according to diagnostic guidelines (Nordhus & Pallesen, 2003) Recent reviews 
generally conclude psychological treatment is effective for anxiety disorders in later life, 
but also conclude that there is a need for large, rigorous controlled trials for the different 
anxiety disorders (Ayers et al , 2007, Nordhus & Pallesen, 2003, Pinquart & Duberstein, 
2007) 
However, in later life, pure anxiety disorders are rare, as most patients have a comorbid 
second anxiety disorder or depressive disorder For the purposes of conducting the 
current review, therefore, generalized anxiety disorder, panic disorder with and without 
agoraphobia and social phobia, conditions that often overlap, will be combined into 
one single diagnostic category called anxiety disorders Obsessive-compulsive disorder 
and the stress disorders, acute and posttraumatic stress disorder, will be considered as 
separate diagnostic categories 
Objectives 
1 To assess the efficacy and feasibility of CBT (CT, BT, CBT and third wave CBT 
interventions) for different anxiety disorders in older adults aged 55 years or over 
compared with minimal management 
2 To assess the efficacy and feasibility of CBT (CT, BT, CBT and third wave CBT 
interventions) for different anxiety disorders in older adults aged 55 years or over 
compared with other psychological therapies 
3 To conduct a narrative review to additionally describe trials omitted from the 
quantitative analysis due to missing data 
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Methods 
Criteria for considering studies for this review 
Types of studies 
All randomized controlled trials (RCTs) will be included. In the case of cross-over trials 
(a rare feature within this field of research), only the first randomization period will 
be included in the review. Studies using a quasi-randomized design will be excluded. 
Cluster RCTs, in which centres or therapists were randomized to intervention or control 
groups will be included, provided that the specific aim of the study was to examine the 
effect of the intervention. 
Types of participants 
All RCTs of older people (55 years or older) with a primary diagnosis of an anxiety 
disorder according to DSM-I11 (APA, 1980), DSM-IIl-R (APA, 1987), DSM-IV (APA, 1994), 
ICD-9 (ICD-9, 1979), ICD-10 (ICD-10, 1999) diagnostic criteria will be considered for 
inclusion, irrespective of culture and setting. The review will combine generalized anxiety 
disorder, panic disorder with and without agoraphobia and social phobia, conditions that 
often overlap, into one single category called anxiety disorders. Obsessive-compulsive 
disorder (OCD) and the stress disorders, acute and posttraumatic stress disorder, will be 
considered separately. 
OCD is often hypothesized to be part of an obsessive-compulsive symptom spectrum, 
including body dysmorphic disorder, hypochondriasis, eating disorders, lie disorders 
and autism (Bartz & Hollander, 2006). Moreover, OCD is more treatment resistant 
compared to other anxiety disorders, and pharmacological treatments may be different 
from the other anxiety disorders, since they include the use of antipsychotics where there 
is treatment resistance and benzodiazepines are not effective agents (Bandelow, 2008; 
Trimbos-instituut, 2003). Posttraumatic stress disorder and acute stress disorder are 
reviewed and analyzed separately due to their causal relationship with psycho-traumatic 
events prior to the onset of the disorder. A similar distinction is made by the International 
Classification of Diseases (ICD-9, 1979; ICD-10, 1999), acknowledging four categories of 
anxiety disorders, namely 1) phobic anxiety disorders, 2) other anxiety disorders (together 
comparable to our category 'anxiety disorders'), 3) obsessive-compulsive disorders and 
4) reaction to severe stress and adjustment disorders. For the purposes of this review, the 
three anxiety disorder categories (anxiety disorders, OCD and PTSD) will be stratified 
in analyses. Of studies that include both the target population and younger participants, 
the relevant data will be included on the condition that randomized age blocks have 
been used and data are reported in age blocks. Studies concerning anxiety symptoms 
that are part of the clinical presentation of another primary diagnosis (e.g. substance 
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use disorders, major depression) will be excluded, as well as studies involving patients 
with a comorbid psychiatric diagnosis of substance-related disorder, schizophrenia or 
psychotic disorder. However, studies involving participants with comorbid physical 
illnesses will be eligible for inclusion to increase generalizability, as most older people 
suffer from physical illnesses. 
Types of interventions 
Experimental inter\enüon 
Cognitive therapy (CT) is defined as cognitive restructuring of irrational and maladaptive 
anxiety beliefs. Behavioural therapy (BT) is defined as some form of exposure and/or 
relaxation exercises. Cognitive-behavioural therapy (CBT) is defined as delivering a 
combination of both CT and BT In studies where behavioural experiments are included, 
the therapy will be considered to be CBT, because behavioural experiments are exercises 
of new behaviour (BT) designed to challenge irrational or maladaptive beliefs (CT). 
Studies including third wave CBT interventions (e.g. mindfulness, acceptance and 
commitment therapy) will also be included. A minimum number of six therapy sessions 
has to be delivered, either in an individual or group format. 
Comparator interveniions 
Non-CBT psychological therapies and minimal management will be included as 
control interventions. Non-CBT psychological therapies include non-directive 
(supportive) therapies, psychodynamic therapy and interpersonal psychotherapy. 
Minimal management (also sometimes described in trials as standard care, treatment 
as usual or waiting list), is defined as being elements of clinic attendance, investigation, 
reassurance, and simple advice, without explicit psychological therapy, and also may 
include naturalistic prescribing of medication and/or other interventions 
Combination therapy 
CBT in combination with pharmacological treatment will be excluded, as its superior 
effects over the monotherapies (Bakker et al., 1998; Van Balkom et al., 1997) have been 
challenged by recent meta-analyses (Furukawa et al., 2006; Mitte, 2005a; Mitte, 2005b). 
Main comparisons 
1. CBT, stratified as CBT, BT, CT and third wave CBT interventions versus minimal 
management. 
2. CBT, stratified as CBT, BT, CT and third wave CBT interventions versus all non-
CBT psychological therapies. 
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Types of outcome measures 
Primary outcomes 
The principal outcome used in this review will be anxiety, measured as follows: 
1. Reduction in anxiety severity (continuous), measured by a well-validated, observer-
rated instrument like the Hamilton Rating Scale for Anxiety (Hamilton, 1959), or if 
not available, a well-validated self-report instrument measuring general anxiety like 
the Beck Anxiety Inventory (Beck, 1988a). Validated disorder-specific instruments 
for obsessive-compulsive disorder or posttraumatic stress disorder will be used. 
2. Clinical recovery or improvement (dichotomous), based on diagnostic interview or 
defined cut-off on validated scales, as specified by trial authors. In case the Clinical 
Global Impression scale [change item] (CGI-C) is used, responders are defined as 
having a change score of 1 = very much or 2 = much improved (Guy, 1976). 
Secondary outcomes 
The following secondary outcome measures will be included in the review. 
1. Worrying, assessed continuously by well-validated, self-report questionnaires, like 
the Penn State Worrying Questionnaire (Meyer et al., 1990; Van Rijsoort, 1999). 
2. Depression, assessed continuously by well-validated, self-report questionnaires, 
like the Beck Depression Inventory (Beck, 1988b). 
3. Anxiety, assessed continuously by well-validated observer-rated or self-report 
questionnaires, in studies of obsessive-compulsive disorder or posttraumatic stress 
disorder. 
4 Dropout rate will be included as a surrogate measure of feasibility of cognitive-
behavioural therapy, in lieu of other more direct indicators of feasibility 
5. Occurrence of adverse events. 
6. Quality of life, assessed continuously by well-validated, self-report questionnaires, 
like the SF-36 (Ware & Sherbourne, 1992). 
Search methods for identification of studies 
A number of sources will be used to identify studies for possible inclusion in this review 
(see below). Studies will not be limited to any particular language 
Electronic searches 
The Cochrane Collaboration Depression, Anxiety and Neurosis Controlled Trials 
Register (CCDANCTR) will be searched using the following terms: 
CCDANCTR-Studies 
Diagnosis = Anxiety or Anxious or Phobi* or Panic or Obsess* or Compulsi* or Post-
traumatic and Age-Group = Aged and Intervention = *Therapy 
CCDANCTR-Re/erences 
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Keyword = Anxiety or Anxious or *phobi* or 'Panic Disorder' or Obsessive Compulsive 
Disorder' or 'Post-Traumatic Stress Disorders and Free-text = Elder* or Geriatri* or Senil* 
or Older or 'Old Age' or 'Late Life' or 'Aged, 80-And-Over' 
A search of PubMed and of PsycINFO (which includes Dissertation Abstracts 
Internal, a database of unpublished dissertations) will also be conducted. The following 
keywords will be used: late-life, Elderly, Aged, Aged, 80 years and over, Old Age, Anxiety 
disorder, Anxiety, Panic, Agoraphobia, Phobia, Obsessive-compulsive, Posttraumatic, 
psychotherapy, cognitive therapy, behavior therapy, cognitive behavior therapy . 
See Appendix 1 for the exact search strings that will be used in the different 
databases. 
Searching other resources 
Correspondence 
Experts in this field and principal authors who have published controlled trials in the 
field of late-life anxiety will be asked if they know of any study which meets the inclusion 
criteria of this review. 
Reference lists 
Citation lists of potentially relevant papers obtained by these methods will be searched 
for further relevant trials, as will be the reference lists of those further relevant trials. In 
addition, the citation lists of relevant and recent systematic reviews were perused. 
Data collection and analysis 
Selection of studies 
RCTs that have been identified will be independently assessed for inclusion by two review 
authors (RCOV & GJH), based on information included in the abstract and/or main 
body of the trial report. RCTs that both raters regard as satisfying the inclusion criteria 
specified in the 'Criteria for selecting studies' section will be collated by the raters (see 
above). If the raters disagree, the final rating will be made by consensus, if necessary with 
the involvement of another member of the review group (AJLMvB). Non-congruence in 
selection of trials will be reported as percentage disagreement. Considerable care will be 
taken to exclude duplicate publications. 
Data extraction and management 
Spreadsheet forms will be designed for the purpose of recording descriptive information, 
summary statistics of the outcome measures, the quality scale ratings, and associated 
commentary. These data will then be exported to RevMan. Where information is missing, 
the reviewers will contact investigators by letter or e-mail in an attempt to obtain it. 
The following data will be extracted from each trial by two review authors 
independently (RCOV & GJH): 
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1. Description of the trials, including primary researcher and year of publication 
2. Characteristics of the interventions, including the number of participants rando-
mized to CBT-condition and control groups, therapycharactenstics, including the 
number of sessions provided, groups versus individual therapy, and components of 
the therapy (psycho-education, relaxation training, anxiety management, type(s) 
of exposure, cognitive techniques, and behavioural experiments), and finally the 
classification in CT, BT, CBT or third wave CBT interventions. 
3. Characteristics of trial methodology, including the diagnostic and exclusion criteria 
employed, the screening instrument used, the inclusion of comorbidity, a minimal 
severity criterion, and the number of centres involved. 
4. Characteristics of participants, including their gender distribution, mean age, and 
the duration of primary symptoms. 
5. Outcome measures employed, and summary continuous (means and standard 
deviations) and dichotomous (number of responders) data. Additional information 
will be included, such as whether the data reflected the intenl-lo-lreat (ITT) with 
either last observation carried forward (LOCF), or completer/observed cases (OC) 
sample, and the dropout rates of participants randomized to the experimental and 
control groups. 
Assessment of risk of bias in included studies 
Risk of bias will be assessed for each included study using the Cochrane Collaboration 
'risk of bias' tool. The following six domains will be considered: 
1. Sequence generation: Was the allocation sequence adequately generated? 
2. Allocation concealment: Was allocation adequately concealed? 
3. Blinding of participants, personnel and outcome assessors for each main outcome 
or class of outcomes: Was knowledge of the allocated intervention adequately 
prevented during the study? 
4. Incomplete outcome data for each main outcome or class of outcomes: Were 
incomplete outcome data adequately addressed? 
5. Selective outcome reporting: Are reports of the study free of suggestion of selective 
outcome reporting? 
6. Other sources of bias: Was the study apparently free of other problems that could 
put it at a high risk of bias? 
A description of what was reported to have happened in each study will be provided, and 
a judgement on the risk of bias will be made for each domain within and across studies, 
based on the following three categories: 
A. Yes (low risk of bias). 
B. Unclear. 
C. No (high risk of bias). 
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Two independent review authors (RCOV δι GJH) will assess the risk of bias in selected 
studies. Any disagreement will be discussed with a third review author (AJLMvB). Where 
necessary, the authors of the studies will be contacted for further information. 
Measures of treatment effect 
Dichotomous outcomes 
These outcomes will be analyzed by calculating a pooled relative risk (RR) for each 
comparison, with 95% confidence intervals. Where overall results are significant, the 
number-needed-to-treat (NNT) to produce one outcome will be calculated. 
Continuous outcomes 
Anticipating different measures across studies, data will be pooled by calculating the 
standardized mean difference (SMD), using 95% confidence intervals. 
Unit of analysis issues 
Where studies have two relevant experimental conditions to be compared against a 
control condition, data will be managed as follows: 
Continuous data - means, SDs and number of participants for each experimental 
condition will be pooled across the two conditions as a function of the number of 
participants in each condition (Law, Garrett & Nye; 2003) to be compared against the 
control condition. 
Dichotomous data - active treatment groups will be collapsed into a single arm for 
comparison against the control group, or the control group will be split equally into two. 
A similar approach will be used where studies have two relevant control conditions 
(e.g psychodynamic psychotherapy and a waiting-list control condition) to be compared 
against one experimental condition. 
Dealing with missing data 
Missing dichotomous data will be managed through intention to treat (ITT) analysis, 
in which it will be assumed that patients who dropped out after randomization had 
a negative outcome. Best / worse case scenarios will also be calculated for the clinical 
response outcome, in which it will be assumed that dropouts in the active treatment 
group had positive outcomes and those in the control group had negative outcomes (best 
case scenario), and that dropouts in the active treatment group had negative outcomes and 
those in the control group had positive outcomes (worst case scenario), thus providing 
boundaries for the observed treatment effect. 
Missing continuous data will either be analyzed on an endpoint basis, including 
only participants with a final assessment, or analyzed using last observation carried 
forward to the final assessment (LOCF) if LOCF data were reported by the trial authors. 
Where SDs are missing, attempts will be made to obtain these data through contacting 
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trial authors Where SDs are not available from trial authors, they will be calculated 
from (-values, confidence intervals or standard errors, where reported in articles (Deeks, 
1997a, Deeks, 1997b) If these additional figures are not available or obtainable, the study 
data will not be included in the comparison of interest 
Assessment of heterogeneity 
Statistical heterogeneity will be formally tested using the natural approximate chi-
square test, which provides evidence of variation in effect estimates beyond that of 
chance Since the chi-square test has low power to assess heterogeneity where a small 
number of participants or trials are included, the p-value will be conservatively set at 0 1 
Heterogeneity will also be tested using the 12 statistic, which calculates the percentage of 
variability due to heterogeneity rather than chance, with 12 values over 50% indicating 
strong heterogeneity (Higgins & Green, 2008) 
Assessment of reporting biases 
Where sufficient numbers of trials allow a meaningful presentation, funnel plots will be 
constructed to establish the potential influence of publication bias 
Data synthesis 
Data will be entered into RevMan 5 0 software by two review authors (double data entry) 
A fixed effect model will be used in the first instance to combine data If there is evidence 
of statistical heterogeneity, results will be recalculated using a random effects model, in 
order to obtain a more conservative estimate 
Subgroup analysis and investigation of heterogeneity 
Multiple subgroup analyses will be performed, but interpreted with caution, due to the 
risk of false positive conclusions If possible, the following subgroup analyses will be 
performed 
1 Separate anxiety disorders (category 1), stratified as generalized anxiety disorder, 
panic disorder and social phobia 
2 Minimal management control condition (waiting list versus other minimal 
management control conditions) 
3 Other psychological therapy control conditions, stratified as psychodynamic, 
interpersonal and supportive therapies 
4 CBT versus third wave CBT interventions 
5 Group versus individual treatment delivery 
6 The age classification of participants (55-79 years versus 80 years and over) 
Where there are sufficient studies, these subgroup analyses will also be used to examine 
potential sources of clinical heterogeneity 
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Sensitivity analysis 
Sensitivity analyses will also be undertaken to assess the degree to which the effect sizes 
depend on the assumptions made by the reviewers. Studies will be limited to those of 
higher quality as determined by risk of bias domains, including: 
1. Allocation concealment. 
2. Dropout rate lower than 20%. 
3. Use of formal testing of fidelity to psychological therapy manual. 
4. Use of blinded outcome assessors. 
These sensitivity analyses will also be used to examine potential sources of methodological 
heterogeneity. 
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Search strategies 
The following search strings will be used: 
For the CCDANCTR-Studies database: Keyword = late-life OR Elderly OR Aged OR 
Old Age AND Keyword = Anxiety OR Panic OR Agoraphobia OR Phobia OR Obsessive-
compulsive OR Posttraumatic AND Keyword = psychological therapy OR psychotherapy 
OR cognitive therapy OR behavio(u)r(al) therapy OR cognitive-behavio(u)r(al) therapy 
ORCBT 
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For PubMed: Keyword = Aged [MESH] OR Aged, 80 years and over [MESH] AND keyword 
= Anxiety disorder [MESH] AND Keyword = behaviour therapy [MESH] 
For PsyclNFO: Keyword = late-life OR Elderly OR Aged OR Old Age AND Keyword 
= Anxiety disorder [Thesaurus] AND Keyword = cognitive therapy [Thesaurus] or 
psychotherapy [thesaurus] OR cognitive behavior therapy [Thesaurus] OR behavior 
therapy [Thesaurus] 
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Text of review 
Background: 
Description of the condition 
Patients with anxiety complain of tension or restlessness, or they exhibit jitteriness, 
autonomic hyperactivity, vigilance, insomnia, distractibihty, shortness of breath, 
numbness, apprehension, worry or rumination. Although most people experience such 
symptoms, an anxiety disorder is suspected when symptoms become disproportionately 
severe compared to their problems. According to the criteria of the Diagnostic and 
Statistical Manual of Mental Disorders (DSM), anxiety disorders in later life are classified 
similarly to those in adult life and include panic disorder with and without agoraphobia, 
generalized anxiety disorder, social phobia, specific phobia, obsessive-compulsive 
disorder, and posttraumatic and acute stress disorder (APA, 1980; APA, 1987; APA, 
1994). Pure anxiety disorders in later life are rare, as most patients have a comorbid 
second anxiety disorder or depressive disorder (Flint, 2005b; Kessler et al., 2005a; Lenze 
et al., 2005a; Van Balkom et al., 2000). 
The prevalence rate of anxiety disorders among older adults living in the community has 
been estimated between 10 and 15% (Beekman et al., 1998; Kessler et al., 2005a), with 
specific point prevalence for the distinct anxiety disorders of 7.3% for generalized anxiety 
disorder, 3.1% for social phobia, 1.0% for panic disorder with or without agoraphobia, 
0.9% for posttraumatic stress disorder and 0.6% for obsessive-compulsive disorder 
(Beekman et al., 1998). In later life, anxiety disorders impair quality of life by having 
a negative impact on functioning and well-being and are associated with an increased 
health-care utilisation (De Beurs et al., 1999; Van Zeist et al , 2006; Wetherell et al., 
2004a). Moreover, patients suffering from anxiety disorders have an increased risk of 
becoming depressed (Beekman et al., 2000), and left untreated, anxiety disorders tend 
to become chronic (Larkin et al., 1992). In two large cohort studies, anxiety disorders in 
later life were prospectively associated with an increased mortality rate (Van Hout et al., 
2004; Brenes et al, 2007). 
Description of the intervention 
First line treatment for anxiety disorders consists of antidepressant drugs or psychological 
treatment (Trimbos-instituut, 2003; NICE, 2007). The place of benzodiazepines within 
the treatment of anxiety disorders differs between guidelines: some guidelines advise to 
never use benzodiazepines long-term (NICE, 2007), in some guideline benzodiazepines 
are a final treatment option when alternative strategies have failed (Trimbos-instituut, 
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2003) and some guidelines do not restrict the use of benzodiazepine but also do not give 
them a clear place (ΑΡΑ-guidelines). In the late nineties, community studies showed 
that only 3.8% of adults aged 55 years or over and suffering from anxiety disorders were 
prescribed an antidepressant, 25.8% were prescribed a benzodiazepine and 5.1% received 
psychological treatment (De Beurs et al, 1999). As no recent studies are available, it is 
unknown whether these figures have improved in the past decade. Both, patients and 
physician characteristics, may contribute to this phenomenon of undertreatment. Many 
older adults resist the use of antidepressants based on fear of dependence, prior negative 
experiences, resistance to viewing their symptoms as a medical illness, and concern 
that antidepressants will prevent natural feelings (Givens et al., 2006). The average 
duration between anxiety symptom onset and first treatment contact has been shown 
to be between 9 and 23 years, suggesting general practitioners do not easily recognize 
anxiety disorders (Wang et al., 2005; Kroenke et al., 2007). The referral rate from 
primary care to a mental health specialist is three times lower for older adults suffering 
from anxiety disorders (17%) compared to those suffering from depression (55%) (Ettner 
& Hermann, 1997). Furthermore, general practitioners themselves may be reluctant 
to prescribe drugs for anxiety symptoms in later life due to associated sideeffects that 
may become more pronounced in the elderly, for example the increased risk of falling 
and traffic accidents, memory impairment, and dependency associated with the use of 
benzodiazepines (Gorgels et al., 2001) and hyponatraemia with the use of serotonin 
reuptake inhibitors (Wright & Schroeter, 2008). Also of concern are the adverse effects 
of drug interactions, such as gastrointestinal bleeding resulting from the concurrent use 
of serotonin reuptake inhibitors and non steroidal anti-inflammatory drugs in this age 
group known for polypharmacy use (Yuan et al., 2006; Weinrieb et al, 2005). 
How the interventions might work 
Anxiety and fear symptoms are regulated by an amygdale-centered circuit. Worry, on 
the other hand, is regulated by a cortico-striatal-thalamic-cortical (CSTC) loop. These 
circuits may be involved in all anxiety disorders, with the different phenotypes reflecting 
not uniquely circuitry but rather divergent malfunctioning within those circuits. GABA 
is one of the key neurotransmitters involved in anxiety and in the anxiolytic action 
of many drugs used to treat anxiety disorders. Benzodiazepines act by enhancing the 
inhibitory actions of GABA at the level of the amygdala and the prefrontal cortex within 
the CSTC loops to relieve anxiety. 
As the amygdala receives input from serotonergic neurons, which can have an 
inhibitory effect on some of Us output, serotonergic agents may alleviate anxiety and fear 
by enhancing serotonin input to the amygdala Antidepressants that increase serotonin 
output by blocking the serotonin transporter are also effective in reducing symptoms 
of anxiety and fear. Such agents include selective serotonin reuptake inhibitors (SSRIs), 
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serotonin norepinephrine reuptake inhibitors (SNRIs) as well as tricyclic antidepressants 
(TCAs) A serotonin 1A partial agonist, buspirone, is recognized as a generalized 
anxiolytic In contrast to the direct action of benzodiazepines, the delayed onset of 
serotonergic agents suggest that these agents exert their therapeutic effects by virtue of 
adaptive neuronal events and receptor events rather than simply by the acute occupancy 
of associated receptors 
Why it is important to do this review7 
Meta-analyses of pharmacotherapy for anxiety disorders in young and middle-aged adults 
support the efficacy of pharmacotherapy (Abramowitz, 1997, Bakker et al, 2002, Fedoroff 
& Taylor, 2001, Mitte, 2005a, Mitte, 2005b, Stein et al, 2000, Van Balkom et al , 1997, 
Van der Linden et al, 2000) However, whether these results also apply to older adults 
remain unclear since most trials exclude participants over the age of 65 years (Wetherell 
et al , 2003) Generalization of these meta-analytic studies to older patients is limited as 
older adults often have more chronic disorders, which are presumed to be more treatment 
resistant (Katz et al, 2002), and have increased risk for adverse side effects due to age-
associated changes in organ function and multimorbidity (Krasucki, Howard &r Mann, 
1999) Therefore, the current review aims to provide a comprehensive and up to date 
summary of the available evidence on pharmacotherapy as a treatment for older adults 
Most of the earlier studies regarding the treatment of anxiety disorders in older people 
suggest efficacy for pharmacotherapy, but have been limited to uncontrolled comparisons 
and lack rigorous inclusion criteria, like the presence of an anxiety disorder according to 
diagnostic guidelines (e g Majercsik, Haller, Leveleki, Baranyi, Halsz & Rodgers, 2003, 
Small & Bystntsky, 1997, Wyhe, Miller, Shear, Little, Mulsant, Pollock et al, 2000) 
A recent review concluded that SSRls are efficacious for late-life anxiety disorders, 
whereas the effect of benzodiazepines and tricyclic agents did not reach significance, 
which might be explained by a lack of statistical power The authors concluded that 
there is a need for large, rigorous controlled trials for the different anxiety disorders 
(Pinquart & Duberstein, 2007), which was probably the reason that they included also 
uncontrolled trials and studies that failed to apply adequate psychiatric diagnoses by 
including patients with (only) subjective anxiety complaints 
A final difficulty is the fact that in later life pure anxiety disorders are rare, as most 
patients have a comorbid second anxiety disorder or depressive disorder (Flint, 2005b, 
Lenze et al, 2001, Lenze et al , 2005a) For the purposes of conducting the current review, 
therefore, generalized anxiety disorder, panic disorder with or without agoraphobia and 
social phobia, conditions that often overlap, will be combined into one single diagnostic 
category called anxiety disorders Obsessive-compulsive disorder and the stress disorders, 
acute and posttraumatic disorder, will be considered as separate diagnostic categories 
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Objectives: 
1. To assess the short- and long-term efficacy of different medication classes 
(benzodiazepines, selective serotonin reuptake inhibitors (SSRIs), serotonin 
norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), 
other medications) for different anxiety disorders in older adults aged 55 years or 
over compared with placebo. 
2. To assess the relative efficacy of different medication classes for anxiety disorders 
in older adults aged 55 years or over 
3. To assess adverse events associated with the use of each medication class, as well 
as comparing differences in the incidence of adverse events between different 
medication classes. 
4. To conduct a narrative review to additionally describe trials omitted from the 
quantitative analysis due to missing data. 
Criteria for selecting studies for this review: 
Types of studies 
All randomized controlled trials (RCTs) will be included. In the case of cross-over trials, 
only the first randomization period will be included in the review. Studies using a quasi-
randomized design will be excluded. Cluster RCTs, in which centres were randomized 
to intervention or control groups will be included, provided that the specific aim of the 
study was to examine the effect of the intervention. 
Types of participants 
All RCTs of older people (55 years or older) with a primary diagnosis of an anxiety 
disorders according to DSM-III (ΑΡΑ, 1980), DSM-III-R (ΑΡΑ, 1987), DSM-IV (ΑΡΑ, 
1994), 1CD-9 (ICD-9, 1979), 1CD-10 (ICD-10, 1999) diagnostic criteria will be considered 
for inclusion, irrespective of culture and setting. 
The review will combine generalized anxiety disorder, panic disorder with and without 
agoraphobia and social phobia, conditions that often overlap, into one single category 
called anxiety disorders. Obsessive-compulsive disorder (OCD) and the stress disorders, 
acute and posttraumatic stress disorder, will be considered separately. OCD is often 
hypothesised to be part of an obsessive-compulsive symptom spectrum, including body 
dysmorphic disorder, hypochondriasis, eating disorders, tic disorders and autism (Bartz 
et al., 2006). Moreover, OCD is more treatment resistant compared to other anxiety 
disorders, and pharmacological treatments may be different from the other anxiety 
disorders, since they include the use of antipsychotics where there is treatment resistance 
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and benzodiazepines are not effective agents (Bandelow, 2008, Trimbos-instituut, 2003) 
Posttraumatic stress disorder and acute stress disorder are reviewed and analyzed 
separately due to their causal relationship with psycho-traumatic events prior to the 
onset of the disorder A similar distinction is made by the International Classification of 
Diseases (ICD-9,1979,1CD-10,1999), acknowledging four categories of anxiety disorders, 
namely 1) phobic anxiety disorders, 2) other anxiety disorders (together comparable to 
our category 'anxiety disorders'), 3) obsessive-compulsive disorders and 4) reaction to 
severe stress and adjustment disorders For the purposes of this review, the three anxiety 
disorder categories (anxiety disorders, OCD and PTSD) will be stratified in analyses 
Of studies that include both the target population and younger participants, the relevant 
data will be included on the condition that randomized age blocks have been used and 
data are reported in age blocks 
Studies concerning anxiety symptoms that are part of the clinical presentation of another 
primary diagnosis (e g substance use disorders, major depression) will be excluded, as 
well as studies involving patients with a comorbid psychiatric diagnosis of substance-
related disorder, schizophrenia or psychotic disorder However, studies involving 
participants with comorbid physical illnesses will be eligible for inclusion to increase 
generahzabihty, as most older people suffer from physical illnesses 
Types of interventions 
Experimental and comparator interventions 
All trials in which one or more medication classes are compared with a placebo 
Trials which include medications which do not fall within one of the 4 major classes 
(benzodiazepines, SSRIs, SNRIs, TCAs), such as buspirone and tranylcypromine, will 
also be included Where available, placebo-controlled dose comparison trials will also 
be included In this latter case, the different active intervention arms will be combined 
to one 
Mam comparisons 
Each medication class (benzodiazepines, SSRIs, SNRIs, TCAs, other drugs) versus 
placebo (5 comparisons) 
Each medication class against each of the other classes (10 comparisons) 
The main comparisons will be evaluated for the end of treatment scores, or in case of 
repeated measures over a longer time-period, 12 weeks after the start of the intervention 
Follow-up results will be evaluated separately and are defined as outcome results between 
6 and 12 months 
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Types of outcome measures 
Primary outcomes 
The principal outcome used in this review will be anxiety, measured as follows: 
1. Clinical recovery or improvement (dichotomous), based on diagnostic interview or 
defined cut-off on validated scales, as specified by trial authors. In case the Clinical 
Global Impression scale [change item] (CGI-C) is used, responders are defined as 
having a change score of 1 = very much or 2 = much improved (Guy, 1976). 
2. Reduction in anxiety severity (continuous), measured by a well-validated, observer-
rated instrument like the Hamilton Rating Scale for Anxiety (Hamilton, 1959), or 
if not available, a well-validated self-report instrument measuring general anxiety 
like the Beck Anxiety Inventory (Beck, 1988a). These scales are potentially able 
to determine whether the core features of late-life anxiety disorders respond to 
medication (rather than simply the comorbid symptoms). Validated disorder-
specific instruments for obsessive-compulsive disorder or posttraumatic stress 
disorder will be used. 
3. Occurrence and number of adverse events as reported by the trial authors. 
Secondary outcomes 
The following secondary outcome measures will be included in the review 
1. Worrying, assessed continuously by well-validated, self-report questionnaires, like 
the Penn State Worrying Questionnaire (Meyer et al., 1990; Van Rijsoort, 1999). 
2. Depression, assessed continuously by well-validated, self-report questionnaires, 
like the Beck Depression Inventory (Beck, 1988b). 
3. Anxiety, assessed continuously by well-validated observer-rated or self-report 
questionnaires, in studies of obsessive-compulsive disorder or posttraumatic stress 
disorder. 
4. Dropout rate will be included as a surrogate measure of tolerance of the different 
medication classes. 
5. Quality of life, assessed continuously by well-validated, self-report questionnaires, 
like the SF-36 (Ware & Sherbourne, 1992). 
Search methods for identification of studies 
A number of sources will be used to identify studies for possible inclusion in this review 
(see below). Studies will not be limited to any particular language. 
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Electronic searches 
A search of the Cochrane Collaboration Depression, Anxiety and Neurosis Controlled 
Trials Register (CCDANCTR), PubMed and PsycINFO (which includes Dissertation 
Abstracts Internal, a database of unpublished dissertations) will be conducted We 
will use detailed search strategies for each database searched, which will be adapted 
for each database to take account of differences in controlled vocabulary and syntax 
rules (see appendix 1). The used search terms are: Anxiety, Anxiety disorder, Anxious, 
Phobia, Panic disorder, Obsessive Compulsive Disorder, Post-traumatic Stress Disorders, 
Aged, Aged, 80-years-And-Over, Old Age, Elderly, Geriatric, Senil, Older, Late Life, 
Antidepressive Agents, Monoamine Oxidase Inhibitors, Selective Serotonin Reuptake 
Inhibitors, Tricyclic Drugs, Anti-Anxiety Agents, Benzodiazepines. The searches will be 
extended with the names of individual drugs. 
Searching other resources 
Correspondence 
Pharmaceutical companies and experts in this field (including all authors who have 
published controlled trials in the field of late-life anxiety) will be asked if they know of 
any study that examines the efficacy of pharmacological strategies for the treatment of 
anxiety disorders in later life. Furthermore, clinical trials registries, as the WHO portal 
and controlled-trials.com, will be consulted. 
Reference lists 
Citation lists of potentially relevant papers obtained by these methods will be searched 
for further relevant trials, as will be the reference lists of those further relevant trials. In 
addition, the citation lists of relevant and recent systematic reviews were perused 
Data collection and analysis 
Selection of studies 
RCTs that have been identified will be independently assessed for inclusion by 2 review 
authors (GJH & GK), based on information included in the abstract and/or main body of 
the trial report. RCTs that both raters regard as satisfying the inclusion criteria specified 
in the 'Criteria for selecting studies' section will be collated by the raters (see above). 
If the raters disagree, the final rating will be made by consensus, if necessary with 
the involvement of another member of the review group (RCOV). Non-congruence in 
selection of trials will be reported as percentage disagreement. Considerable care will be 
taken to exclude duplicate publications. 
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Data extraction and management 
Spreadsheet forms will be designed for the purpose of recording descriptive information, 
summary statistics of the outcome measures, the quality scale ratings, and associated 
commentary. This data will then be exported to RevMan. Where information is missing, 
the reviewers will contact investigators by e-mail in an attempt to obtain it. 
The following data will be extracted from each trial by two review authors independently 
(GJH & GK): 
1. Description of the trials, including primary researcher and year of publication 
2. Setting in which the trial is conducted (primary care, secondary care, academic/ 
specialized anxiety clinic). 
3. Characteristics of the interventions, including the number of participants 
randomized to the medication and control groups, the name of the medication, 
the class to which it belongs (benzodiazepines, SSRIs, SNRIs, TCAs, other), the 
dosages used and the duration of medication usage. 
4. Characteristics of trial methodology, including the diagnostic and exclusion criteria 
employed, the screening instrument used, the inclusion of comorbidity (especially 
the allowance of a comorbid diagnosis of major depression), the use of a placebo 
run-in, a minimal severity criterion, the number of centres involved, duration of 
follow-up. 
5. Characteristics of participants, including their gender distribution, mean age, and 
the duration of primary symptoms. 
6. Outcome measures employed, and summary of dichotomous (number of responders) 
and continuous (means and standard deviations) data at end of treatment (6 
through 16 weeks) and at follow-up (6 through 12 months). Additional information 
will be included, such as whether the data reflected the intent-to-treat (ITT) with 
either last observation carried forward (LOCF), or completer/observed cases (OC) 
sample, the number of participants experiencing serious adverse events (SAEs), 
and the dropout rates of participants randomized to the medication and control 
groups. 
Assessment of risk of bias in included studies 
Risk of bias will be assessed for each included study using the Cochrane Collaboration 
'risk of bias' tool. The following six domains will be considered: 
1. Sequence generation: Was the allocation sequence adequately generated? 
2. Allocation concealment: Was allocation adequately concealed? 
3. Blinding of participants, personnel and outcome assessors for each main outcome 
or class of outcomes: Was knowledge of the allocated intervention adequately 
prevented during the study? 
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4. Incomplete outcome data for each main outcome or class of outcomes: Were 
incomplete outcome data adequately addressed? 
5. Selective outcome reporting: Are reports of the study free of suggestion of selective 
outcome reporting? 
6. Other sources of bias: Was the study apparently free of other problems that could 
put it at a high risk of bias? 
A description of what was reported to have happened in each study will be provided, and 
a judgement on the risk of bias will be made for each domain within and across studies, 
based on the following three categories: 
A. Yes (low risk of bias). 
Β Unclear. 
C. No (high risk of bias). 
Two independent review authors (GJH &r GK) will assess the risk of bias in selected 
studies. Any disagreement will be discussed with a third review author (RCOV). Where 
necessary, the authors of the studies will be contacted for further information. 
Measures of treatment effect 
Dichoiomous outcomes 
These outcomes will be analyzed by calculating a pooled relative risk (RR) for each 
comparison, with 95% confidence intervals. Where overall results are significant, the 
number-needed-to-treat (NNT) to produce one outcome will be calculated. 
Continuous outcomes 
Anticipating different measures across studies, data will be pooled by calculating the 
standardized mean difference (SMD), using 95% confidence intervals. 
Unit of analysis issues 
Studies comparing two experimental conditions consisting of the same drug in different 
dosages or consisting of two drugs from the same class to a control condition, data will 
be managed as follows: 
• Dichotomous data - active treatment groups will be collapsed into a single arm for 
comparison against the control group, or the control group will be split equally 
into two. 
• Continuous data - means, SDs and number of participants for each experimental 
condition will be pooled across the two conditions as a function of the number of 
participants in each condition (Law et al., 2003) to be compared against the control 
condition. 
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In case of two different experimental conditions being evaluated against placebo, both 
experimental conditions will be included in (different) meta-analyses against the same 
placebo condition 
Dealing with missing data 
Missing dichotomous data will be managed through intention to treat (ITT) analysis, 
in which it will be assumed that patients who dropped out after randomization had 
a negative outcome. Best/worst case scenarios will also be calculated for the clinical 
response outcome, in which it will be assumed that dropouts in the active treatment 
group had positive outcomes and those in the control group had negative outcomes (best 
case scenario), and that dropouts in the active treatment group had negative outcomes and 
those in the control group had positive outcomes (worst case scenario), thus providing 
boundaries for the observed treatment effect. 
Missing continuous data will either be analyzed on an endpoint basis, including only 
participants with a final assessment, or analyzed using last observation carried forward 
to the final assessment (LOCF) if LOCF data were reported by the trial authors. Where 
SDs are missing, attempts will be made to obtain these data through contacting trial 
authors. Where SDs are not available from trial authors, they will be calculated from 
t-values, confidence intervals or standard errors, where reported in articles (Decks, 
1997a; Decks, 1997b). If these additional figures are not available or obtainable, the study 
data will not be included in the comparison of interest. 
Assessment of heterogeneity 
Statistical heterogeneity will be formally tested using the natural approximate chi-
square test, which provides evidence of variation in effect estimates beyond that of 
chance Since the chi-square lest has low power to assess heterogeneity where a small 
number of participants or trials are included, the p-value will be conservatively set at 0 1. 
Heterogeneity will also be tested using the 12 statistic, which calculates the percentage of 
variability due to heterogeneity rather than chance, with 12 values over 50% indicating 
strong heterogeneity (Higgins & Green, 2008). 
Assessment of reporting bias 
Where sufficient numbers of trials allow a meaningful presentation, funnel plots will be 
constructed to establish the potential influence of publication bias. 
Data synthesis 
Data will be entered into RevMan 5.0 software by two review authors (double data entry 
by GJH & RCOV). A fixed effect model will be used in the first instance to combine 
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data. If there is evidence of statistical heterogeneity, results will be recalculated using a 
random effects model, in order to obtain a more conservative estimate. 
Subgroup analysis and investigation of heterogeneity 
Multiple subgroup analyses will be performed, but interpreted with caution, due to the 
risk of false positive conclusions. If possible, the following subgroup analyses will be 
performed: 
1. Separate anxiety disorders (category 1), stratified as generalized anxiety disorder, 
panic disorder and social phobia. 
2. The age classification of participants (55-79 years versus 80 years and over). 
3. Duration of treatment (less than 12 weeks versus 12 weeks and over). 
4. Presence or absence of major depression. 
Where there are sufficient studies, these subgroup analyses will also be used to examine 
potential sources of clinical heterogeneity. 
Sensitivity analysis 
Sensitivity analyses will also be undertaken to assess the degree to which the effect sizes 
depend on the assumptions made by the reviewers. Studies will be limited to those of 
higher quality as determined by risk of bias domains, including: 
1. Allocation concealment. 
2. Dropout rate lower than 20%. 
3. Use of clinician rated scales. 
4. Use of blinded outcome assessors. 
These sensitivity analyses will also be used to examine potential sources of methodological 
heterogeneity. 
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Search strategy 
The following search strings will be used: 
For studies included in the Cochrane Collaboration Depression, Anxiety and Neurosis 
Controlled Trials Register (CCDANCTR): 
Diagnosis = Anxiety or Anxious or Phobi* or Panic or Obsess* or Compulsi* or Post-
Traumatic 
AND 
Age-Group = Aged 
AND 
Intervention = Antidepressive Agents or 'Monoamine Oxidase Inhibitors' or 'Selective 
Serotonin Reuptake Inhibitors' or Tricyclic Drugs' or 'Benzodiazepines' (extended with 
the names of individual drugs) 
For studies included in the CCDANCTR-References : 
Keyword = Anxiety or Anxious or *phobi* or 'Panic Disorder' or 'Obsessive Compulsive 
Disorder' or 'Post-Traumatic Stress Disorders 
AND 
Free-text = Elder* or Geriatri* or Semi* or Older or 'Old Age' or 'Late Life' or 'Aged, 
80-And-Over' 
For the CCDANCTR-Studies database: 
Keyword = late-life OR Elderly OR Aged OR Old Age 
AND 
Keyword = Anxiety OR Anxious OR Panic OR Phobi* OR Obses* OR Compulsi* OR Post-
Traumatic 
AND 
Keyword = Antidepressant Agents OR Anti-Anxiety Agents. 
For PubMed: 
Keyword = Aged [MESHl OR Aged, 80 years and over [MESH] 
AND 
keyword = Anxiety disorder [MESH] 
AND 
Keyword = Antidepressant agents [MESH] OR Anti-anxiety agents [MESH]. 
For PsycINFO: 
Keyword = late-life OR Elderly OR Aged OR Old Age 
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AND 
Keyword = Anxiety disorder [Thesaurus] 
AND 
Keyword = antidepressant agents [thesaurus] OR anti-anxiety agents [Thesaurus] 
These search strings will be extended with the names of the individual drugs: 
Acetylcarnitine or Alaproclate or Amersergide or Amiflamine or Amineptine or 
Amitripiyline or Amoxapine or Befloxatone or Benactyzine or Brofaromine or Bupropion 
or Butriptylme or Caroxazone or Chlorpoxiten or Cilosamine or Cimoxatone or 
Citalopram or Clomipramine or Clorgyline or Clorimipramine or Clovoxamine or 
Deanol or Demexiptiline or Deprenyl or Desipramine or Dibenzipin or Diclofensine or 
Dothiepin or Doxepin or Duloxetine or Etopendone or Femoxetine or Fluotracen or 
Fluoxetine or Fluparoxan or Fluvoxamine or Idazoxan or Imipramine or Iprindole or 
Iproniazid or isocarboxazid or Litoxetine or Lofepramine or Maprotiline or Medifoxamine 
or Mehtracen or Metapramine or Mianserin or Milnacipran or Minaprine or Mirtazapine 
or Moclobemide or Nefazodone or Nialamide or Nomifensine or Nortriptyline or 
Noxiptilme or Opipramol or Oxaflozane or Oxaprotiline or Pargyline or Paroxetine or 
Phenelzine or Piribedil or Pirlmdole or Pivagabine or Prosulpride or Protriptylme or 
Quinupramine or Reboxetine or Rolipram or Sertraline or Setiptiline or Temloxine or 
Tetrindole or Thiazesim or Thozalinone or Tianeptine or Toloxatone or Tomoxetine 
or Tranylcypromine or Trazodone or Trimipramine or Venlafaxine or Viloxazine or 
Viqualine or Zimeldine or benzodiazepine* or Adinazolam or Alprazolam or Bentazepam 
or Bromazepam or Brotizolam or Camazepam or Chlordiazepoxide or Cinolazepam or 
Clobazam or Clonazepam or Clorazepate or Clotiazepam or Cloxazolam or Delorazepam 
or Diazepam or Estazolam or Etizolam or Fludiazepam or Flunitrazepam or Flurazepam 
or Flutoprazepam or Halazepam or Haloxazolam or Ketazolam or Loprazolam or 
Lorazepam or Lormetazepam or Medazepam or Metaclazepam or Mexazolam or 
Midazolam or Nimetazepam or Nitrazepam or Nordazepam or Oxazepam or Oxazolam 
or Pinazepam or Prazepam or Quazepam or Temazepam or Tetrazepam or Tofisopam or 
Triazolam or Zolazepam or Zaleplon or Zolpidem or Zopiclone. 
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Dankwoord 
Eindelijk is het dan zover. Mijn proefschrift is geschreven, waarmee ik, althans volgens 
de definities, heb laten zien in staat te zijn zelfstandig onderzoek te doen en dit fatsoenlijk 
en leesbaar te beschrijven. Dat zelfstandig onderzoek een rekbaar en relatief begrip is, 
zult u hierna kunnen lezen. 
Dit proefschrift was nooit tot stand gekomen als ik daarbij niet de ondersteuning had 
gehad van velen die ik hierbij wil bedanken. 
Kees Hoogduin wil ik bedanken voor het gestelde vertrouwen toen hij in 1998 zonder 
meer instemde om als promotor betrokken te zijn bij mijn onderzoek. Kees, zonder jouw 
bijdrage was dit project niet van de grond gekomen. Van tijd tot tijd beteugelde je mijn 
optimistische inslag. Het heeft me geholpen om door te kunnen blijven zetten en het 
heeft me een passende wetenschappelijke bescheidenheid bijgebracht. In de eindfase, 
toen het schrijven van dit proefschrift stagneerde, heb je me daar op orthodox gedrags-
therapeutische wijze doorheen geloodst met stevige 'sancerre'-sancties als ik deadlines 
zou overschrijden Hoe het vak van psychiater beoefend dient te worden in praktiserend, 
onderwijskundig en wetenschappelijk opzicht heb ik van jou geleerd. Het was, en is nog 
steeds, voor mij een genoegen dat ik de kunst af heb mogen kijken en dat we nog steeds 
samenwerken in het 'angstpoh-team' met een aantal van je promovendi. 
Mijn copromotores, Ger Keijsers en Richard Oude Voshaar, waren mijn vaste 
begeleiders. Ger, samen hebben we aan de wieg gestaan van dit project en je bent er vanaf 
de voorbereiding in 1998 non-stop bij betrokken geweest. Ik wil je bedanken voor je 
inzet in de afgelopen jaren en vooral ook datje nooit getwijfeld hebt aan de 'goede afloop' 
Je kritische, gedetailleerde en zorgvuldige becommentariëring van de stukken die ik 
aanleverde, was zeer leerzaam en heb ik altijd bijzonder gewaardeerd. De manuscripten 
werden er beduidend beter van. Heel plezierig was dat je ook in de eindfase van mijn 
schrijfproces, toen er de nodige tijdsdruk lag, scherp en snel commentaar leverde. Het 
werk is gedaan, maar het begeleiden is overgegaan naar samenwerken in het Nijmegen 
Centre for Anxiety Research and Expertise (Nij-CARE), met van tijd tot tijd gezellige 
etentjes. Ik verheug me op het voortzetten daarvan! Richard, voor mij ben je op het juiste 
moment ingestapt bij dit project. Je specifieke kennis van de ouderenpsychiatrie gaf me 
de gelegenheid om met je te debatteren over de verschillende thema's en vraagstellingen 
van dit project. Het is heel waardevol geweest bij het analyseproces en het aanscherpen 
van de manuscripten. Ik heb met verbazing en enige afgunst aanschouwd met welk een 
energie en tempo je hierin opereerde. Veel dank hiervoor, en niet in de laatste plaats 
voor de tijd die je ook privé hebt genomen om aan het door mij gewenste tempo tegemoet 
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